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Abstract 
Bone development and repair involve complex processes that include interaction between 
cells and their surrounding matrix.  In the body, bone sialoprotein (BSP) expression is up-
regulated at the onset of mineralization.  BSP is a multifunctional acidic phosphoprotein with 
collagen-binding, hydroxyapatite nucleating, and integrin recognition (RGD sequence, which 
is important for cell-attachment and signaling) regions.  Mice lacking BSP expression (Bsp
-/-
), exhibit a bone phenotype with reductions in bone mineral density, bone length, osteoclast 
activation, and impaired bone healing.  This thesis examined the role of BSP in tooth 
development and also its potential use as a therapeutic reagent for bone repair.  MicroCT and 
histological analysis of Bsp
-/- 
mice revealed significant periodontal tissue breakdown marked 
by defective acellular cementum formation leading to periodontal ligament detachment, 
extensive alveolar bone and tooth root resorption, and tooth malocclusion.  Substituting hard 
to soft diet, which minimized applied stress during mastication, did not reduce extent of 
periodontal tissue breakdown.  However, soft diets eliminated the incidence of severe incisor 
malocclusion and the Bsp
-/-
 mice featured normal body weight, long-bone length, and serum 
alkaline phosphatase activity, suggesting that tooth dysfunction and malnutrition contribute 
to growth and skeletal defects previously reported. 
In the bone repair studies, the effectiveness of BSP-treated nano-hydroxyapatite/poly(ester-
urethane) (nHA/PU) scaffolds in promoting bone regeneration was determined using a rat 
calvarial defect model.  Recombinant human bone morphogenetic protein (rhBMP-2), which 
is a potent growth factor was used as the positive control for repair.  Addition of BSP to 
nHA/PU scaffolds improved cell attachment and differentiation, and the consequent 
osteogenic mineralization in vitro.  In vivo, at 6 weeks, microCT and histological analysis 
indicated that the rhBMP-2 treated nHA/PU scaffolds promoted significant new bone repair, 
in which approximately 70% of the defect, based on bone volume to total defect volume,  
was filled with new bone.  In contrast, both BSP-treated nHA/PU scaffolds and non-treated 
scaffolds resulted in approximately 20% new bone formed.  These findings suggest that BSP 
plays a non-redundant role in cementum formation, likely involved in initiating 
mineralization on the root surface.  The effectiveness of nHA/PU scaffold as a carrier for 
 iii 
 
rhBMP-2 and BSP was verified.  However, in our system, BSP by itself was not a potent 
promoter of bone regeneration in vivo.   
 
Key words: Bone sialoprotein, cementum, periodontal ligament, bone resorption, 
malocclusion, hydroxyapatite, poly(ester-urethane), bone morphogenetic protein 2, bone 
repair 
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CHAPTER 1  
 
 
 
1 Literature Review 
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1.1 INTRODUCTION 
Bone is a complex tissue that undergoes a remodeling process involving resorption and 
formation of bone.  Cell interactions with various hormones and growth factors and the 
surrounding extracellular matrix are crucial for bone development and bone regeneration.  
The bioactive protein of interest for this study is bone sialoprotein (BSP), whose 
expression has been shown to be up-regulated at the onset of mineralization.  Various 
studies have indicated that BSP plays a role in promoting biomineralization during bone 
development.  However, the role of BSP in other mineralized tissues such as those 
associated with the periodontal tissues is still not fully understood.  Furthermore, it has 
been suggested that BSP may promote bone repair, however there have only been limited 
studies in this area. 
This thesis has two main objectives: 1) to determine the role of BSP in periodontal tissue 
development and 2) to determine the potential use of BSP as therapeutic agent to enhance 
bone repair.  The literature review that follows covers these two topics.    
 
1.2 SKELETAL TISSUE DEVELOPMENT 
Mineralized tissue formation is an essential development of the human body.  All 
mammalian skeletal tissues are comprised of inorganic mineral (mainly hydroxyapatite) 
that are embedded in an extracellular organic matrix.  There are two developmental 
processes responsible for bone development and growth: endochondral and 
intramembranous ossification (Cohen, 2000; Olsen et al., 2000; Provot and Schipani, 
2005).  The main difference between the two is that endochondral ossification has the 
presence of a cartilaginous intermediate, whereas intramembranous ossification does not.  
For both developmental processes, cells such as osteoblasts and osteoclasts are important 
in maintaining balance in order to have normal skeletal tissue development.   
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1.2.1 Skeletal cell: Osteoblasts 
Osteoblasts are cells derived from osteoprogenitor cells within the bone marrow and the 
periosteum (Olsen et al., 2000; Wagner and Karsenty, 2001).  Osteoblastic differentiation 
is regulated by the transcription factors Runx2 and Osterix (Osx) (Aubin, 2001; Chau et 
al., 2009).  In addition, it can also be induced by various growth factors such as bone 
morphogenetic proteins (BMPs) (Long, 2012).  Osteoblasts are responsible for the 
production of the osteoid matrix, the non-mineralized matrix, and its subsequent 
mineralization.  During bone formation, osteoblasts have been shown to express a variety 
of proteins and enzymes including Type I collagen, alkaline phosphatase (ALP), and non-
collagenous proteins such as bone sialoprotein (BSP), osteopontin (OPN), osteonectin, 
and osteocalcin.  As the osteoblasts mature, they will either become osteocytes, bone 
lining cells or undergo apoptosis (Crockett et al., 2011).   
Osteocytes are mature osteoblasts trapped within the mineralized bone tissue.  These cells 
are connected with each other through microscopic canals called canaliculi, which 
function as conduits for transport of nutrients and signaling molecules to maintain proper 
bone homeostasis.  In addition, studies also have shown that the osteocyte network acts as 
a mechanosensor that is crucial for the bone-remodeling process (Bonewald, 2006; You 
et al., 2008).  In contrast, the bone-lining cells are inert reserve cells at the bone surface 
that are thought to have a role as osteoprogenitors or involved in coupling of bone 
resorption and bone formation (Everts et al., 2002).  
 
1.2.2 Skeletal cell: Osteoclasts 
Osteoclasts are cells derived from monocytes (Quinn et al., 1998) or macrophages 
(Udagawa et al., 1990) and are usually found in pits on the bone surface called Howship's 
lacunae.  The differentiation of osteoclasts from hematopoetic lineage cells is regulated 
by receptor activator of nuclear factor kappa-B ligand (RANKL) and tumor necrosis 
factor (TNF) (Boyle et al., 2003).  These multinucleated cells are responsible for the 
degradation of both mineral and organic matrix (Blair et al., 1986) in bone during 
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development, maintenance and repair.  Normal healthy bone requires ongoing bone 
resorption and formation.  For resorption, osteoclasts bind to mineralized surfaces in bone 
where they form a tight seal.  Within the sealing zone, due to the activity of the 
membrane bound proton pumps, the pH becomes acidic which favors dissolution of bone 
mineral (Baron et al., 1985; Schlesinger et al., 1997).  In addition, osteoclasts also secrete 
enzymes such as tartrate resistant acid phosphatase (TRAP) and cathepsin K that are 
involved in the breakdown of the extracellular matrix (Boyle et al., 2003; Crockett et al., 
2011).  Various skeletal disorders such as osteopetrosis and Paget's disease are related to 
the defective regulation of osteoclast activity or function (Helfrich et al., 2007). 
 
1.2.3 Endochondral and intramembranous ossification 
Intramembranous ossification occurs during the formation of flat bones such as the skull, 
clavicles and the mandible.  In this ossification process, no cartilaginous intermediate is 
present.  Ossification sites appear within the fibrous connective tissue membrane.  During 
this stage, mesenchymal stromal cells (MSCs) proliferate and condense to form clusters 
which differentiate into osteoblasts.  Within the fibrous membrane, osteoblasts secrete 
type I collagen matrix and non-collagenous proteins to form the osteoid, which 
subsequently is mineralized.  The mineralized osteoid is laid down in a random fashion 
around the blood vessels to form a bone network that is woven in appearance.  At the 
same time, mesenchymal cells on the external surface of the woven bone also condense 
to become periosteum.  The periosteum is a thin non-calcified tissue on the exterior of 
bone.  The periosteum consists of an exterior layer of fibrous connective tissue and an 
internal osteogenic layer.  The exterior layer is primarily composed of collagen fibers and 
fibroblastic cells.  Whereas the inner layer contains the osteoprogenitor cells, which are 
critical for bone growth and repair.  As the osteoprogenitor cells along the inner surface 
of the periosteum differentiate into osteoblasts, they deposit osteoid matrix parallel to the 
existing woven bone.  These osteogenic cells are responsible for the appositional growth 
of woven bone, which eventually is replaced by lamellar bone that is organized in 
appearance.  As a result, flat bone will have a unique sandwich structure where the outer 
5 
 
layers are composed of dense cortical bone and the midsection is filled with trabecular 
bone (Cohen, 2000; Olsen et al., 2000). 
Endochondral ossification occurs during the formation of long bones and other bone 
types.  In this process, hyaline cartilage, which is formed first, becomes the platform that 
will be remodeled and replaced by bone.  Initially, periosteum and blood vessels form 
along the diaphysis of the hyaline cartilage.  Then periosteum-derived osteoprogenitor 
cells proliferate and differentiate into osteoblasts, which secrete osteoid matrix.  As the 
osteoid matrix mineralizes, bony collars are formed around the diaphysis of the hyaline 
cartilage.  Then mineralization of the cartilage matrix occurs at the diaphysis of the 
hyaline cartilage. The next step involves the formation of a primary ossification site at the 
center of the diaphysis.  At this stage, the periosteal bud begins to invade the primary 
ossification site carrying blood vessels and cells such as osteoblasts and osteoclasts.  
Over time, the remaining mineralized cartilage matrix will be broken down by osteoclasts 
and replaced by trabecular bone formed by the osteoblasts, which in turn will be 
remodeled into mature lamellar bone.  In addition, as blood vessels and cells invade the 
center of the bone, the diaphysis also starts to elongate.  The osteoclasts help to form the 
medullar cavity by breaking down the newly formed woven bone.   
In addition, the blood vessels also penetrate the hyaline cartilage at the epiphysis of the 
long bones to form the secondary ossification centers.  The process of secondary 
ossification is similar to the primary ossification, except instead of forming lamellar 
bone, trabecular bone is maintained.  At the end of the process, cartilage that remains at 
the ends of the bones is called articular cartilage.  In addition, the diaphysis and both 
epiphyses of the long bone are separated by epiphyseal plates, the sites responsible for 
bone elongation (Cohen, 2000; Olsen et al., 2000; Provot and Schipani, 2005).  
 
1.2.4 Bone repair 
Normal bone repair goes through a sequence of stages including inflammation, callus 
formation, and remodeling.  Damage to bone will result in fairly rapid inflammatory 
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response involving coagulation of blood and invasion of hematopoietic cells, which is the 
start of the tissue repair process.  For example during a repair of non-critical sized long 
bone fracture, within days, progenitor cells from the periosteum and bone marrow around 
the fracture site differentiate into chondroblasts, which generate new cartilage at the 
wound site.  At the same time, distal from the fracture site, other progenitor cells 
differentiate into osteoblasts, which generate the organic matrix of new osteoid.  The two 
tissues grow separately and eventually unite to create a bridge composed of a 
combination of cartilage and woven bone, which is known as the callus.  Eventually, at 
the remodeling stage, the callus is resorbed by osteoclasts and replaced with cortical bone 
by osteoblasts.  The remodeled bone will have a similar shape and strength as the original 
bone (Claes et al., 2012; Einhorn and Gerstenfeld, 2015; Marsell and Einhorn, 2011). 
However, in severe bone injury such as tumour excision, non-union trauma and critical-
sized defect fractures, normal repair is impaired.  In this condition, it may require years 
for complete healing; in some cases it may never heal completely without intervention.  
Therefore, various natural or synthetic biomaterials are used in conjunction with growth 
factors or other bioactive proteins to enhance regeneration and improve the functional 
state of the damaged tissues. 
Various animal models have been used to address the clinical challenge in repairing bone 
defects.  For our study, the rodent calvarial defect model was chosen since this model 
allows for reproducible defects that can be generated quickly.  In addition, the calvarial 
defect model is more economical compared to the femoral defect models, which require 
additional fixation procedures to stabilize the long bone.  For calvarial defect model, an 8 
mm defect is generally accepted as a critical size defect (Spicer et al., 2012).  Critical size 
defects are the smallest size defects that will not completely heal, without intervention, 
over the lifetime of the animal.  Various studies have also used smaller 5 mm defects, 
with 2 defects per animal, in order to allow for reduced animal usage for a given study.  
However, these non-critical size defects can heal even without intervention. Nevertheless, 
this is a good model to determine whether the addition of a specific osteoinductive or 
osteoconductive agent can enhance the healing process. 
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1.2.5 Mouse tooth development 
Mouse tooth development goes through three well-defined stages - the bud, cap, and bell 
stages as shown in Figure 1.1 (Caton and Tucker, 2009).  Around embryonic day 11.5 
(E11.5), at the tooth development site, formation of the dental lamina is observed, 
marked by the start of epithelial cell proliferation and thickening of the oral epithelium.  
By E12.5, invagination of the dental epithelium becomes apparent.  The invagination will 
continue further into the underlying neural crest-derived mesenchyme and start to form a 
bud.  At around E13.5, these underlying neural crest mesenchymal cells start to condense 
around the formed bud.   By E14.5, tooth development has reached the cap stage, where 
the epithelium is further folded and the enamel knot becomes visible.  The enamel knot is 
a transient structure, which will disappear by the end of the cap stage through apoptosis.  
The cells in the enamel knot are regulated by BMP-4 (Jernvall et al., 1998) and the 
enamel knot cells have a low proliferation rate.  Other studies have shown that these 
enamel knot cells act like an anchor constricting the movement of cells in the developing 
tooth (Jernvall et al., 1994; Vaahtokari et al., 1996).  During the cap stage, the epithelial 
cells become the enamel organ and the condensed mesenchyme forms the dental papilla.  
As for the surrounding tissue, it will become the dental follicle.   
By E16.5, these tissues developed further and form the bell stage.  During this stage, cells 
begin to differentiate into their respective lineages.  The cells in the enamel organ 
differentiate into two types of cells - 1) outer enamel cells, which cover the enamel organ 
and organize a network for the transport of nutrition, and 2) inner enamel cells, which 
become the ameloblasts that form the enamel.  The cells in the periphery of the dental 
papilla differentiate into odontoblasts that form pre-dentin, the precursor to dentin, which 
is mineralized.  The central region of the dental papilla, which contains undifferentiated 
mesenchymal cells, will become the dental pulp.  As for the dental follicle, this tissue 
contains progenitor cells that will differentiate into cementoblasts, periodontal ligament 
fibroblasts, and osteoblasts to form the cementum-periodontal ligament-alveolar bone 
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structure, respectively as shown in a representative diagram of the tooth anatomy in 
Figure 1.2.   
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Figure 1.1.  Schematic of mouse tooth development. 
(A) At embryonic day 12.5 (E12.5), thickening and invagination of the dental epithelium 
(dark pink) becomes apparent.  (B) At around E13.5, the neural crest mesenchymal cells 
(black dots) within the underlying mesenchyme (light pink) start to condense around the 
formed bud.  (C) By E14.5, the epithelium is further folded and the enamel knot becomes 
visible (blue oval).  During this cap stage, the condensed mesenchyme forms the dental 
papilla.  (D) At E16.5, the tissue development reaches the early bell stage and cells in the 
dental papilla begin to differentiate into their respective lineages.  By E20, the 
ameloblasts and odontoblasts have started to form enamel (blue) and dentin (yellow)   
respectively.  The central region of the dental papilla, which contains undifferentiated 
mesenchymal cells, will turn into dental pulp (white).  Note: This figure is adapted from 
(Caton and Tucker, 2009). 
 10 
 
Figure 1.2.  A diagram of tooth anatomy. 
A cross section of tooth anatomy showing major components of the tooth. 
The figure is copied from https://www.nlm.nih.gov/medlineplus/ency/
imagepages/1121.htm 
(Permission to use the image was acquired from A.D.A.M. Education) 
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1.2.6 Tooth anatomy 
The tooth is made up of four major tissues: enamel, dentin, cementum, and dental pulp as 
shown in a representative cross section diagram of molar and incisor (Figure 1.2, 1.3  and 
1.4).  Among the three mineralized tissues, enamel is the hardest and most highly 
mineralized.  Approximately 96% of enamel by weight consists of hydroxyapatite (HA), 
with the remainder water and organic matrix (Deakins and Volker, 1941; LeFevre and 
Manly, 1938).  Different from dentin, cementum and bone, enamel does not contain 
collagen.  Enamel contains three major structural proteins called amelogenin, 
ameloblastin, and enamelin (Bartlett, 2013).   
Dentin, which is found between the pulp chamber and enamel or cementum, is a 
mineralized tissue that is formed by odontoblasts.  While lower in mineral density than 
enamel, dentin is composed of 70% HA, 10% water, and 20% organic matrix.  Similar to 
bone, dentin's organic matrix is composed of collagen and a variety of non-collagenous 
proteins.  Within the mineralized matrix of dentin, there are dentinal tubules, which are 
microscopic channels that radiate outward from the pulp chamber to either the enamel or 
cementum border (Goldberg et al., 2011).   
Cementum is a mineralized tissue found adjacent to the dentin and covers the tooth root.  
Similar to osteoblasts for bone, cementoblasts are responsible for the formation of the 
organic matrix of the cementum, and its subsequent mineralization process.  Cementum 
consists primarily of 45% HA, 20% water, and 35% organic matrix (Gonçalves et al., 
2005).  The main role of the cementum is to act as a medium for the attachment of the 
periodontal ligament, which stabilizes and anchors the tooth root to the bone.  There are 
two types of cementum - acellular and cellular cementum.  The acellular extrinsic fiber 
cementum is found in the top 40 to 70% of the root surface.  This matrix consists of a 
dense fringe of short collagenous fibers that are oriented perpendicular to the root surface 
(Gonçalves et al., 2005).  As the fibers become elongated and become continuous with 
the principal PDL fibers, they are called Sharpey's fibers.  In addition, two major non-
collagenous proteins, bone sialoprotein (BSP) and osteopontin (OPN), are prominently 
expressed in acellular cementum.  BSP is believed to play a role in cell adhesion, 
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progenitor cell differentiation into cementoblasts, and initiating mineralization (Saygin et 
al., 2000; Somerman et al., 1990).   
The cellular intrinsic fiber cementum contains embedded cementocytes in the mineralized 
collagenous matrix.  This tissue is found at the apical root portion and it maintains the 
root in its proper position.  The collagen fibers in the matrix are oriented mostly parallel 
to the root surface (Gonçalves et al., 2005).  Studies have shown that it also participates 
in the repair process, however, there is no direct evidence that it plays a role in tooth 
attachment (Bosshardt and Selvig, 1997).   
The dental pulp is a soft connective tissue containing blood and nerve supplies to the 
tooth, which enters at the apex of the tooth root.  Along the boundary of the pulp and 
dentin, in the pre-dentin layer, odontoblasts are found.  Other cells such as pre-
odontoblasts and fibroblasts are also present in the pulp chamber. 
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Figure 1.3.  Schematic of a molar tooth cross section. 
The image represents a cross section (coronal) of the mice tooth, which are emphasized 
by color codes: enamel (blue), dentin (yellow), cementum (green for both acellular and 
cellular cementum), alveolar bone (brown), and gingiva (pink).  The pulp chamber is 
located in the core of the tooth.  Whereas the periodontal ligament (PDL) is located   
between the alveolar bone and cementum.  Note: This figure is adapted from (Foster, 
2012). 
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Figure 1.4.  Schematic of an incisor cross section.   
The image represents a cross section (sagittal) of the mice tooth, which are emphasized 
by color codes: enamel (blue), dentin (yellow), cementum (green for both acellular and 
cellular cementum), alveolar bone (brown), and gingiva (pink).  The pulp chamber is 
located in the core of the incisor.  Whereas the periodontal ligament (PDL) is located 
between the alveolar bone and cementum.   
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1.3 BONE SIALOPROTEIN (BSP) 
1.3.1 BSP structure and function 
Bone sialoprotein (BSP), an acidic phosphoprotein, is a member of the Small Integrin-
Binding Ligand N-Linked Glycoprotein (SIBLING) family of proteins and a major 
component of non-collagenous proteins in bone.  BSP is highly conserved and found in 
all vertebrate species with mineralized tissue.  BSP has been isolated from a wide range 
of animals such as bovine (Fisher et al., 1983; Franzen and Heinegard, 1985), pig (Zhang 
et al., 1990), rat (Gorski and Shimizu, 1988), rabbit (Kinne and Fisher, 1987), chicken 
(Yang et al., 1995), frogs (Shintani et al., 2008), and humans (Fisher et al., 1987).  The 
calculated molecular weight of human BSP based on mass spectroscopy was determined 
to be approximately 49 kDa (Wuttke et al., 2001) and 52.5 kDa (Zaia et al., 2001).  The 
variability in the average mass of BSP is likely due to its heterogeneous post-translational 
modifications.  Furthermore, BSP has a flexible structure which is intrinsically disordered 
with no secondary or tertiary structure (Fisher et al., 2001; Wuttke et al., 2001).  The 
flexible nature of BSP is likely important since it may allow for simultaneous interaction 
with other proteins, cells and minerals as previously discussed by Fisher et al (Fisher et 
al., 2001).  On average, BSP contains around 327 amino acid residues including the 16 
residue signal sequence and within it, a high concentration of acidic amino acid residues, 
glutamic acid and aspartic acid, as well as the negatively charged sialic acid residues 
(Zaia et al., 2001), which contributes to the overall negative charge of BSP [isoelectric 
point (pI) of 3.9].   
BSP has been determined to have three main functional regions: 1) collagen-binding 
region, 2) two hydroxyapatite (HA)-nucleating regions, and 3) an integrin recognition 
region (Figure 1.5).  These functional regions are highly conserved and always found in 
BSP regardless of species (Goldberg and Hunter, 2012).  The collagen-binding region 
(spanning residues 18-45) is a hydrophobic region located near the N-terminus (Tye et 
al., 2005).  The two nucleating regions (spanning residues 42-100 and 133-205), each 
containing a contiguous glutamate sequence, were found to be critical for HA nucleation 
(Hunter and Goldberg, 1993) and binding (Goldberg et al., 2001; Stubbs et al., 1997).  Of 
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the two HA-nucleating regions, the second sequence in rat (BSP 133-205) has been 
determined to be more potent than the first one (Harris et al., 2000; Tye et al., 2003).  
Previous studies have shown that even the short BSP133-148 sequence containing a poly-
glutamate sequence and a phosphorylated serine residue, possesses HA-nucleation 
activity (Baht et al., 2010).  In addition, using a steady state collagen-gel system, it has 
been demonstrated that the HA nucleation potency of BSP is enhanced when it is bound 
to collagen (Baht et al., 2008).  The integrin recognition region (RGD; spanning residues 
273-275) is located near the C-terminus (Wuttke et al., 2001).  This RGD motif of BSP 
has been shown to mediate cell attachment and signaling that contributes to 
osteoprogenitor cell differentiation and migration (Gordon et al., 2007).  The RGD motif 
interacts with the αvβ3 integrin, which is a cell-surface receptor present in osteoblasts 
(Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992).  The overexpression of BSP 
in MC3T3-E1 osteogenic cells has been shown to increase the level of osteoblast 
differentiation signaling markers and formation of matrix mineralization nodules in vitro 
(Gordon et al., 2007).  However, when the RGD sequence is mutated to KAE, the cell-
integrin binding capabilities have been shown to be diminished or abolished in 
osteoblasts (Gordon et al., 2007), fibroblasts (Harris et al., 2000), chondrocytes (Gill et 
al., 2008) and endothelial cells (Bellahcène et al., 2000).  Furthermore, overexpression of 
the BSP in rat primary calvarial pre-osteoblasts containing the KAE mutation did not 
result in enhanced osteoblastic differentiation in vitro (Gordon et al., 2007). 
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Figure 1.5.  Linear schematic of BSP functional regions.   
BSP contains on average 327 amino acid residues and has three main functional regions. 
The first region is the collagen-binding region (red), which is located near the N-
terminus.  The second region consists of two hydroxyapatite (HA)-nucleating regions, 
which are rich in poly-glutamic acid sequences (yellow).  The last region is an integrin 
recognition region consisting of the RGD sequence that has been shown to promote cell 
adhesion and signaling.  
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1.3.2 BSP expression and role in biomineralization 
BSP appears to be expressed in all mineralized tissues.  For example, it is highly 
expressed in bone, cementum, and calcified cartilage (Ganss et al., 1999).  Other studies 
have also suggested that BSP is expressed in dentin at low level (Fujisawa et al., 1993; 
Qin et al., 2001).  BSP expression has been demonstrated in cells that produce a matrix 
that mineralizes such as osteoblasts, hypertrophic chondrocytes, cementoblasts, 
ameloblasts, and odontoblasts (Bianco et al., 1991; Chen et al., 1998).  This suggests that 
BSP may play an important role in osteogenic mineral formation.  In the osteoblasts, BSP 
is detected in the Golgi apparatus where it is post-translationally modified before being 
secreted (Bianco et al., 1993).  A potential reason for BSP being a potent nucleator for 
HA is likely due to its highly acidic sequences that attract and immobilize calcium ions in 
a specific orientation.  Therefore when phosphate ions bind, a template for mineral 
formation is established.  This concept is further supported by a previous study that 
demonstrated that the phosphorylation of the Serine-136 residue, but not other potential 
serine sites in BSP, enhances HA nucleation potency of the protein (Baht et al., 2010).  
Interestingly, the Ser-136 residue is adjacent to a poly-glutamic sequence in BSP.  Of 
relevance to the potential role of BSP in mineral formation, other studies have shown 
BSP is associated with pathological calcification such as the microcalcifications observed 
in breast cancer tissue (Bellahcene et al., 1994) and lung cancer tissue (Bellahcene et al., 
1997).  Furthermore, various cancer cells, including breast, lung and prostate, express 
high levels of BSP (Bellahcene et al., 2008).  
A number of in vivo studies have also shown the physiological importance of BSP 
including its functional relevance in skeletal development.  Mice with the Bsp gene 
ablated (Bsp
-/-
) have impaired bone growth and mineralization.  Bsp
-/-
 mice were reported 
to have shortened long bones, decreased bone mineral density, delayed mineral 
formation, thinner cortical bones, and greater trabecular bone volume as compared to 
wild type (WT) mice (Malaval et al., 2008).  In addition, studies also indicate that 
reduction in osteoclast formation and activities were observed in Bsp
-/-
 mice, which 
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resulted in low bone turnover (Boudiffa et al., 2010; Malaval et al., 2008).  In a long bone 
defect model, Bsp
-/-
 mice also displayed delayed bone repair compared to WT control 
(Malaval et al., 2009; Monfoulet et al., 2010).  These phenotypes observed in Bsp
-/-
 mice 
suggest that BSP plays a crucial role in bone development and mineralization.  In 
addition, BSP may also be important for maintaining the homeostasis of both osteoblasts 
and osteoclasts in number and activities.  Of relevance, studies have demonstrated that in 
the presence of BSP and RANKL, the differentiation of osteoclast from 
monocyte/macrophage cells is greater compared to that without BSP (Valverde et al., 
2005).  In addition, previous studies on transgenic mouse line with overexpression of 
BSP demonstrated increased osteoclast formation and activity level (Valverde et al., 
2008). 
Studies have shown the therapeutic potential for BSP to induce bone repair in vivo (Wang 
et al., 2006; Xu et al., 2007).  The authors used a bovine BSP treated-collagen scaffold 
which was implanted into rat calvarial defects.  At 4 days post-surgery, the BSP-collagen 
scaffold induced recruitment of osteoblasts and promoted early mineralization.  However, 
no bone repair was observed when denatured collagen was used as a scaffold (Xu et al., 
2007).  Other in vitro studies were also able to confirm that BSP binding affinity to 
denatured collagen is less than to native collagen (Baht et al., 2008).  The outcomes of 
these studies indicate that the collagen-binding region in BSP potentially has an 
important role in biomineralization.   
On the other hand, there are a couple of studies that indicate BSP was not effective in 
promoting bone repair.  For example, when recombinant human BSP- (rhBSP) coated  
polymeric scaffolds [porous -tricalcium phosphate scaffold (Skelite TM) and synthetic 
polymer (Polyactive 
TM
)] were used in an in vivo subcutaneous model in nude mice, the 
presence of BSP did not improve the efficiency of bone tissue formation compared to the 
control group (Schaeren et al., 2010).   
Studies on BSP also look at its potential role in enhancing osteointegration of implants 
into biological tissues.  BSP coating of a hydroxyapatite-based titanium implant (TICER 
®) with rough surface improved its osteoinductive properties and enhanced attachment of 
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bone marrow derived cells in vitro (Graf et al., 2008).  Another study on bovine BSP 
coating of titanium femoral implants demonstrated enhanced osteoinductive properties 
with evidence of abundant osteoid, elongated osteoblasts and neovascularisation around 
the implant-bone interface (O'Toole et al., 2004).  However, when subjected to 
mechanical pullout test, the BSP coating was unable to enhance the strength of the 
implant-bone integration. 
 
 
1.4 BONE MORPHOGENETIC PROTEIN (BMP) 
1.4.1 Role of BMP in bone regeneration 
Bone morphogenetic proteins (BMPs) are multifunctional cytokines that belong to the 
transforming growth factor (TGF)-β superfamily (Abe, 2006).  BMPs are potent growth 
factors that have been widely investigated for use in the clinical setting for bone repair.  
For example, BMP-2, -4, and -7 have been shown to have strong osteogenic properties 
(Chen et al., 2012).  These BMPs are currently the standard growth factor used in 
combination with various carriers for bone tissue regeneration.  The BMPs possess the 
ability to stimulate osteoblastic differentiation (Canalis et al., 2003; Schmitt et al., 1999).   
Previous studies have shown that the growth factors BMP-2,4 and 7 are expressed by the 
mesenchymal stromal cells (MSC), osteoprogenitors cells, osteoblasts, endothelial cells, 
fibroblasts and chondrocytes at fracture sites and during the inflammatory phase of bone 
repair (Bostrom et al., 1995; Canalis et al., 2003; Martinovic et al., 2004; Nakase et al., 
1994; Onishi et al., 1998; Zhang and Li, 2005).  After being secreted, the extracellular 
matrix temporarily stores the BMPs, which are then released during bone repair and 
remodeling.  BMPs bind to BMP receptors types I and II, which are important for signal 
transduction to activate the transcription factor Smad cytoplasmic proteins.  The binding 
of BMP catalyzes phosphorylation of Smads 1,5,8, which are also associated with the 
activation of Smad-4 which translocates into the cell nucleus.  Smad-4 regulates the 
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expression of Runx2 and Osx genes, which are gene markers of osteoblastic 
differentiation (Chen et al., 2012).  
Other studies have also suggested that BMPs play a role in promoting angiogenesis via 
the Wnt pathways (de Jesus Perez et al., 2009; Guo and Wang, 2009).  During 
intramembranous ossification, these BMPs are expressed by the proliferating osteoblasts.  
Whereas during chondrogenesis and endochondral ossification, these BMPs are 
expressed by both the proliferating chondrocytes and osteoblasts near the ossification 
front (Sfeir et al., 2005).   
The inactivation of the various BMP genes leads to a variety of phenotypes.  For 
example, BMP-2-null mice have an embryonic lethal phenotype prior to the formation of 
the skeleton.  This mutation also caused defects in amnion, chorion, and cardiac 
development (Zhang and Bradley, 1996).  Similarly, BMP-4-null mice have an early 
embryonic lethal phenotype with defects in mesoderm development (Winnier et al., 
1995).  As for the elimination of BMP-7 gene, null mice also revealed a lethal phenotype 
due to developmental abnormalities in the kidney, eye and skeletal structure (Jena et al., 
1997; Luo et al., 1995).  These studies confirmed the important role of BMPs in 
development of a variety of tissues, including skeletal tissue. 
In addition, the use of BMP as a therapeutic growth factor to enhance bone repair has 
been accepted clinically as a standard procedure.  Previous studies using various animal 
models, including rats (Sawyer et al., 2009), rabbits (Murakami et al., 2002), dogs 
(Asamura et al., 2010), sheep (Geiger et al., 2003), and non-human primates (Suh et al., 
2002), have been used to evaluate the addition of BMPs to heal bone defects.  All of 
these studies have shown that the presence of BMPs accelerates bone formation at the 
defect sites.   
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1.4.2 Potential side effects of using high dose of BMPs 
Currently, there are two FDA-approved recombinant human BMPs (rhBMPs) 2 and 7, 
which are obtained by molecular cloning of their respective cDNAs and expressed using 
the Chinese hamster ovary cell line, for clinical use in humans (Wozney, 2002).  For this 
study, we focused on the use of rhBMP-2 since it has been extensively evaluated in 
numerous studies for bone repair (Chen et al., 2004).  For example, commercialized 
rhBMP-2 is delivered with a bovine collagen sponge (INFUSE Bone Graft, Medtronic) 
for posterior-lateral spine, tibia and specific craniofacial applications.  
Recent studies have reported wound complications in the use of rhBMP-2 for anterior 
cervical fusion and non-union fractures (Cahill et al., 2009; Papakostidis et al., 2008; 
Williams et al., 2011).  These complications include superficial and deep wound 
infections, and epidural hematoma or seroma.  In addition, there have also been reports of 
intense inflammation and bone resorption in children patients treated with BMPs for cleft 
lip and palate repair (Neovius et al., 2013) and symptomatic ulnar nonunion repair 
(Ritting et al., 2012). However, there are no clear studies that indicate the observed 
complication is directly caused by usage of BMP as opposed to normal surgical 
complication.  Another potential problem is that the commercially available BMP-2 is 
also clinically used "off-label".   
For in vitro studies, the utilization of BMP-2 is generally at very low dosages (5-20 
ng/mL).  However, for in vivo or clinical treatments, commercially available rhBMP-2 
are usually packaged in large dosage (up to 40 mg), which depend on the size of the 
defect.  High doses of BMP-2 are usually needed to be clinically effective due to poor 
retention of the BMPs to its carrier.  In addition, the high cost of rhBMPs for clinical use 
is another factor to consider.  Of relevance, animals studies have shown that rhBMP-2 
has a short half-life of 7-16 minutes systemically (Poynton and Lane, 2002), however if 
bound to collagen scaffold, the residence time of rhBMP-2 was determined to be 
approximately 8 days; with a half-life of 5.6 days (Sellers et al., 2000).  Another main 
concern of using rhBMPs at large dosage is that it will pose risks to patients due to its 
potential for significant side effects including heterotopic bone formation, significant 
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immune responses and potential to be carcinogenic (Carragee et al., 2011; Epstein, 2013).  
In spite of all of these controversial results, the use of BMPs is still the best solution for 
promoting bone repair in defects that do not respond to normal therapies or procedures.  
In orthopedics, the challenge is to use a much lower dose of BMPs without 
compromising the overall effectiveness in promoting bone regeneration.  Therefore, there 
is a necessity of designing a biomaterial scaffold that can retain and systematically 
release BMPs over time.  Thus, the selection of the carrier for BMPs and the dose used 
should be studied carefully in animal models.   
 
 
1.5 BIOMATERIALS FOR TISSUE ENGINEERING 
Large bone defects due to tumour excision, non-union fracture and critical-sized defect 
fractures affect millions of people worldwide each year.  Normal bone remodeling 
requires a number of factors that involve cell migration, adhesion, proliferation, and 
differentiation as well as the extracellular matrix and growth factors.  In critical sized 
defects, normal repair is impeded where in the majority of cases successful healing does 
not occur without intervention.  Various biomaterials have been developed with the goal 
to regenerate and improve the functional state of damaged tissues.  
 
1.5.1 Introduction of biomaterials scaffolds 
The use of autogenous and allogenic bone grafts are among the most common clinical 
procedures to promote bone regeneration.  These bone grafts have their own advantages 
and disadvantages.  Autograft tissue is the safest and has the fastest healing potential 
without dealing with issues such as tissue rejection due to immune response.  Clinically, 
it is the "gold standard" treatment for bone defects.  The source of autograft tissue, 
usually from the iliac crest, has the potential to facilitate new bone formation due to the 
endogenous presence of growth factors, which can promote angiogenesis and 
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osteogenesis (Soucacos et al., 2008).  However, additional surgical procedures are 
required to harvest the autograft from a secondary site within the patient body, leading to 
extended recovery time and potential risk of infection (Younger and Chapman, 1989).  
The secondary site (for example iliac crest) could also be uncomfortable and painful for 
years after the surgical procedure (Lementowski et al., 2010; Palmer et al., 2008).  Lastly, 
there is a limited supply of autograft material since over-harvesting can cause 
destabilization of the secondary site.  In contrast, allografts are obtained from human 
donors (cadavers) and do not require additional surgical procedures to the receiving 
individuals.  However, proper screening for pathogens and risk factors for diseases are 
necessary for the use of allografts.  Limited supplies and tissue rejection are also 
additional concerns for using allografts.   
In tissue engineering, the best surgical procedures to treat non-union bone fractures and 
spinal fusion involve the use of bone graft substitutes.  In addition, these substitutes need 
to be osteoconductive, osteoinductive and have mechanical properties allowing them to 
withstand normal in vivo loads (Bauer and Muschler, 2000).  There has been an emphasis 
on the use of synthetic biomaterials that can replace autogeneous and allogenic bone 
grafts for large bone defects.  Below are brief descriptions of these synthetic biomaterials 
for bone grafts, which can be divided into 3 main categories: metals, ceramics, and 
polymers.   
Metals implants are widely used for load-bearing applications such as fracture fixation 
plates or screws.  However, in some cases they are required to be removed after the bone 
heals, which can be inconvenient and painful for patients.  Another potential concern is 
that metals can corrode, due to chemical reaction with enzymes and acids in the body, 
and the metals ions can be toxic to the body.  However, there are medical grade metals 
such as titanium, which are naturally resistant to corrosion. 
Ceramics are also used for bone implants, in particular those containing calcium 
phosphates, the primary inorganic phase of bone minerals.  Ceramics are chemically inert 
and have high compressive strength.  However, they are also brittle and lack the 
toughness needed to bear cyclic loading (Ducheyne, 1987; Yaszemski et al., 1996).  
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However, bioceramic scaffolds comprised of porous β-tricalcium phosphate matrix 
combined with hydroxyapatite (HA) nano particles show a compressive strength similar 
to that of cancellous bone (Lu et al., 2002; Metsger et al., 1993; Ramay and Zhang, 
2004).   
Various polymers are widely used as biomaterials and they can be easily manufactured 
and modified for any application.  There are two broad categories of polymers that are 
used for biomaterials: 1) natural and 2) synthetic.  Natural materials such as type I 
collagen are usually derived from animals, which is the main matrix component of many 
connective tissues including bone and skin.  Natural materials are generally not toxic to 
the body and biocompatible.  In addition, natural materials may carry specific protein 
binding sites and elicit biochemical signals that promote tissue regeneration.  However, 
occasionally, these materials can also be subject to tissue rejection due to immune 
response.  One potential problem with natural materials such as unmodified type I 
collagen is their limited mechanical stiffness and strength for load bearing applications; 
especially when the scaffold is in aqueous condition.   
A variety of synthetic polymers are used in tissue engineering, which include poly(lactic-
co-glycolic) acid (PLGA), poly(methyl methacrylate) (PMMA), and polyesters.  Some 
modification can often be done on these synthetic polymers so that they can be 
hydrolytically degraded.  Unfortunately, in some cases, the degraded particles potentially 
may lead to an inflammatory response (Bostman et al., 1990; Vert et al., 1994).  Overall, 
some advantages of both natural and synthetic polymer scaffolds are the ability of them 
to be easily modified, adsorb proteins and retain solutions quite well. 
In general, synthetic biomaterials do not possess the three required properties for tissue 
engineering applications in bone repair, which includes being osteoconductive, 
osteoinductive and load-bearing.  Therefore, additional modifications to the synthetic 
biomaterials are required to achieve this goal.  To improve the osteoinductive property 
the most common technique is to combine the biomaterials with growth factors and other 
bioactive proteins that are able to promote angiogenesis and osteogenesis (Itoh et al., 
2001; Li et al., 2009; Schliephake et al., 2008).  In general the goal is to use the scaffold 
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as a carrier for slow release of the growth factors at the defect site.  For improvement in 
load-bearing properties, composites are used for tissue engineering application.  These 
composites are usually made up of a combination of polymers and bioceramics.  For 
example, studies were able to create scaffolds made up of collagen and HA that have the 
strength and stiffness comparable to trabecular bone (Itoh et al., 2002; Kikuchi et al., 
2001).  
 
1.5.2 Potential use of nanohydroxyapatite/poly(ester-urethane) 
scaffold as a carrier for growth factors and bioactive proteins 
Over the years, polyurethane has been shown to be safe, and easily molded into various 
shapes.  However, for most applications, pure polyurethane is a poor candidate for use in 
drug delivery due to its resistance to degradation.  The introduction of ester bonds into 
the polymer backbone resolves the resistance to degradation issue (Ulery et al., 2011).   
In general, polyurethane is composed of hard and soft copolymer segments that can 
undergo microphase separation, which allows these polymers to handle physical stress 
very well and improves its mechanical strength.  Typically, biodegradable poly(ester-
urethanes) (PU) are synthesized by polycondensation of diisocyanates with polyester diol 
or triols, which are composed of either glycilide, lactide or caprolactone, to create the soft 
segment of the polymer.  For the hard segment, the typical copolymers are composed of 
polypeptides or diols or triols of 3-hydroxybutyrate (Guelcher, 2008; Henry et al., 2007).  
In the literature, different forms of PU-based scaffolds have been used extensively in 
tissue engineering applications such as regeneration of bone (Hofmann et al., 2008; 
Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al., 2014; Lee et al., 2005), and 
other soft tissues (Gogolewski et al., 2008; Guan et al., 2005; Guelcher, 2008; Guelcher 
et al., 2008).  For bone tissue engineering, another important aspect for a successful 
biomaterial is its capability to bind growth factors, such as rhBMP-2, to promote bone 
repair.  Of relevance, previous in vitro studies have shown that rhBMP-2 binds well to 
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PU-based scaffolds (Li et al., 2009).  Based on this study, we postulate that the novel PU 
scaffolds used in the study may also be an effective carrier for rhBMP-2. 
Previous studies have demonstrated that the novel PU scaffolds have porous 
interconnected three-dimensional environment for cell and blood vessel infiltration 
(Laschke et al., 2009; Laschke et al., 2013).  These PU scaffolds are biocompatible and 
have viscoelastic properties, which are important for load bearing applications (Hofmann 
et al., 2008; Laschke et al., 2009; Laschke et al., 2013; Lee et al., 2005; Pirvu et al., 
2015).  In addition, the PU scaffolds were shown to have the capability of supporting the 
co-culture of primary human osteoblasts and human umbilical vein endothelial cells 
(HUVEC) (Hofmann et al., 2008).  Using  a novel in vivo subcutaneous model, the 
authors showed that the PU scaffolds are osteoconductive and also allow for blood 
vessels formation within its 3D matrix.   
For our study, modifications were made by incorporating nano-sized hydroxyapatite 
(nHA) particles into the PU matrix to make a novel scaffold (nHA/PU).  A 10% weight 
ratio of nHA to the PU was selected since it gave the best improvement in material 
stiffness, increased by 30%, compared to PU scaffold alone (Boissard et al., 2009).  The 
addition of nHA was also shown to increased the scaffold capacity to bind proteins such 
as serum albumin and fibrinogen (Laschke et al., 2010b).  The presence of nHA may 
potentially enhance binding affinity of growth factors and bioactive proteins to the 
nHA/PU scaffold.  The incorporation of nHA did not affect its biocompatibility or inhibit 
its ability to allow vascularization as previously shown by Laschke et al (Laschke et al., 
2009).   
 
1.6 PURPOSE OF THE THESIS 
 
The role of BSP in skeletal tissue development has been studied using in vitro culture and 
transgenic mouse models.  BSP has been suggested to promote osteoprogenitor cell 
differentiation leading to bone formation.  One study has also shown that the addition of 
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BSP-treated collagen scaffolds to critical sized defects promoted bone repair.  In addition, 
BSP is also present in mineralized periodontal tissues, especially in cementum, the 
mineralized tissue lining the tooth root.  However, the role of BSP in the periodontal 
tissues is unknown.   
The studies in this thesis are separated into two main objectives.  The first objective 
focused on the role of BSP in mineralized periodontal tissues.  The second objective 
focused on the potential use of BSP as a therapeutic agent, with a novel poly(ester) 
urethane (PU) scaffold, for bone repair.  
 
Hypothesis 1:  The absence of BSP in periodontal tissues, specifically acellular 
cementum, will result in a significant periodontal tissue phenotype. 
Rationale:  Previous studies have shown that the absence of BSP in mice results in 
abnormal bone phenotypes indicated by reduced bone growth, mineralization and repair 
(Malaval et al., 2008; Malaval et al., 2009; Monfoulet et al., 2010).  Other than bone, 
BSP has also been shown to be present in the mineralized tissues of the tooth, especially 
cementum (McKee et al., 1996; Somerman et al., 1990).  It has been postulated that BSP  
plays an important, though undefined, role in the formation and mineralization of the 
cementum (Somerman et al., 1990).   
In chapter 2 of the thesis, characterization of the Bsp
-/-
 mouse periodontium was 
conducted to determine whether there were periodontal tissue abnormalities.  In brief, the 
study confirmed that BSP is present in normal cementum and also demonstrated that the 
Bsp
-/-
 mouse has defective acellular cementum, which leads to periodontal tissue 
breakdown.  Histological, SEM, and microCT analyses were utilized to describe the 
observed phenotype.  
In chapter 3, the study focused in part on the additional characterization of the 
periodontal phenotype and the determination of the potential mechanisms that lead to the 
abnormalities observed in the Bsp
-/-
 mouse.  Substitution of hard-pellet diet to soft 
powdered diet was introduced to verify whether the reduction in occlusal force required 
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during mastication of the hard diet prevents or reduces the PDL detachment observed in 
the Bsp
-/-
 mouse, which is described in chapter 2.  MicroCT and histological analyses 
were performed.  In addition, detailed morphometric measurements were performed to 
characterize the periodontal tissue destabilization and breakdown. 
 
Hypothesis 2: BSP treated poly(ester-urethane) scaffolds promote bone repair. 
Rationale:  The implantation of BSP treated fibrillar type I collagen scaffolds has been 
previously shown to promote bone repair (Wang et al. 2006). Previous studies 
(Goldberg's group), however, were not able to reproduce these results using rat BSP and 
various types of collagen scaffolds.  Based on the efficacy of BSP in promoting 
biomineralization in a variety of in vitro studies as well as the published findings of the 
Glimcher group (Wang et al., 2006), it was believed that the delivery of BSP to the bone 
defect site may be the critical factor.     
In a collaborative study (Drs. David Eglin and Mauro Alini,  AO Foundation),  novel 
scaffolds composed of poly(ester) urethane mixed with nano-hydroxyapatite (nHA/PU) 
were prepared.  Previous studies by our collaborators demonstrated the effectiveness of 
the nHA/PU scaffold for tissue engineering applications because of its osteoconductive 
property and its ability to bind bioactive proteins (Boissard et al., 2009; Laschke et al., 
2009).  The applicability of the nHA/PU scaffold in conjunction with BSP for bone repair 
is the focus of our studies.    
There were  2 main objectives: 
The first goal (chapter 4) was to confirm that nHA/PU scaffolds can safely be used as a 
carrier of bioactive growth factors to promote bone repair.  The growth factor used was 
rhBMP-2, a clinically established therapeutic for bone repair.  In brief, using a rat 
calvarial defect model, this study indicated that the nHA/PU scaffolds bound rhBMP-2 
well, and the treated scaffolds enhanced bone formation.  MicroCT and histological 
analyses were used to monitor bone repair.  
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Based on the enhanced bone repair observed with rhBMP-2 treated nHA/PU scaffolds, 
our second goal was to determine the efficacy of BSP-treated nHA/PU scaffolds in 
promoting repair (chapter 5).  BSP was shown to bind to nHA/PU scaffolds, and the 
BSP-treated scaffolds apparently promoted osteoprogenitor cell adhesion, however bone 
repair in vivo was not enhanced.  MicroCT and histological analyses were used to 
monitor the bone repair. 
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CHAPTER 2  
 
 
 
2 Deficiency in acellular cementum and 
periodontal attachment in Bsp-null mice 
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2.1 INTRODUCTION 
Bone sialoprotein (BSP, or integrin binding sialoprotein) is an extracellular matrix 
protein in the Small Integrin Binding Ligand N-linked Glycoprotein (SIBLING) family, 
associated with mineralized tissues of the skeleton and dentition (Fisher and Fedarko, 
2003; Ganss et al., 1999).  Like other SIBLING proteins, BSP is multifunctional, with 
roles in cell attachment and migration (through the integrin-binding RGD motif), cell 
signaling, collagen binding, and hydroxyapatite nucleation.  The ability of BSP to act as a 
positive regulator for hydroxyapatite precipitation has been demonstrated in vitro (Hunter 
and Goldberg, 1993), and is of particular interest in terms of regulating mineralized tissue 
development.  Mice null for the Bsp gene (Bsp
-/-
) feature delayed bone growth and 
mineralization (Malaval et al., 2008).     
In addition to its inclusion in bone extracellular matrix, BSP is present in both acellular 
and cellular cementum (MacNeil et al., 1994; McKee et al., 1996).  Acellular cementum 
is the thin, mineralized tissue covering the cervical portion of the tooth root, important for 
attachment of the periodontal ligament (PDL) to the root surface (Bosshardt, 2005; Foster 
et al., 2007).  Cellular cementum is a more bone-like tissue covering apical portions of 
roots.  Developmental factors directing cementogenesis remain poorly defined, 
hampering progress towards more effective therapies for cementum regeneration.  The 
finding that BSP was present in cementum and strongly expressed by cementoblasts led 
to speculation that this protein might contribute to cementum formation and 
mineralization (MacNeil et al., 1995; Somerman et al., 1990), however this hypothesis 
has remained untested in the two decades since these findings.  Here, we analyzed the 
function of BSP in cementogenesis and periodontal stability by determining effects of 
lack of BSP on tooth formation.   
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2.2 MATERIALS & METHODS 
 
2.2.1 Animals 
Animal procedures were performed in accordance with guidelines of the Canadian 
Council on Animal Care and Animal Care and Veterinary Services, University of 
Western Ontario.  Preparation and genotyping procedures of Bsp
-/-
 and wild-type (WT) 
mice were described previously (Malaval et al., 2008).  All of the mice were maintained 
on a mixed 129/CD1 background and fed a standard mouse diet (2018 Tekland Global 
18% protein diet, Harlan Laboratories, USA).  Three to six animals were analyzed per 
genotype at ages 14, 26, 30, and 60 days postnatal (dpn) to determine abnormal 
phenotypes.  Serum biochemistry was analyzed using standard assays by NIH Veterinary 
Services Clinical Chemistry (Bethesda, MD).  For this study, all comparison were made 
between Bsp
-/-
 and WT littermate pairs. 
 
2.2.2 Micro-computed tomography (microCT) and scanning 
electron microscopy (SEM)  
MicroCT of formalin-fixed hemi-mandibles was performed using eXplore Locus SP (GE 
Healthcare, Canada).  2D images were acquired at 80 kVp and 80 A, using an 
integration time of 1600 ms/frame, 4 frames/view, and a total of 900 views at an 
increment of 0.4 degrees.  Images were constructed at a spatial resolution of 13 m and 
calibrated with a cortical bone phantom (SB3; Gamex RMI, Wisconsin, USA) having a 
hydroxyapatite equivalent of 1,100 mg/cc (White, 1978).  Data were analyzed using 
MicroView ABA version 2.2 (GE Healthcare). 
For SEM analysis, extracted and cleansed molars were osmium coated.  For fracture 
analysis, an ultra-fine diamond burr (Brassfler DET6UF-31) was used to drill through 
crowns, and teeth were fractured longitudinally.  SEM images were analyzed in 
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secondary electron mode at 1-10 kV on a Leo 1540 XB FIB/SEM (Carl Zeiss, Western 
Nanofabrication Facility). 
 
2.2.3 Histological procedures 
Procedures for histology, in situ hybridization (ISH), and immunohistochemistry (IHC) 
were previously described on Bouin’s fixed, decalcified, paraffin-embedded samples 
(Foster, 2012; Foster et al., 2012).  Histomorphometry was used to quantify cementum, 
root-lining cells (cementoblasts) (D'Errico et al., 1997), and epithelial attachment, and 
statistical analysis was performed by independent samples t-test.   
For the ISH of Bsp mRNA, digoxigenin (DIG)-labeled cRNA probe (Marian Young, 
NIDCR, Bethesda, MD) with NBT/BCIP substrate were utilized.  As for the IHC, 
biotinylated secondary antibodies and peroxidase substrate were utilized.  A variety of 
primary antibodies were used in the study, which included rabbit anti-BSP (1:200; Renny 
Franceschi, University of Michigan, Ann Arbor), rat anti-alkaline phosphatase 
(TNAP/ALPL, 1:200; R&D Systems, Minneapolis, MN), LF-175 rabbit anti-osteopontin 
(OPN; 1:200) (Larry Fisher, NIDCR), rabbit anti-cytokeratin (Abcam, Cambridge, MA), 
goat anti-RANKL (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), and rat anti-
neutrophil antibody (1:200; NIMP-R14; Abcam).   
As for undecalcifed, glutaraldehyde/formalin fixed tissues, they were either LR white-
embedded for ultramicrotome sectioning (1 m) for von Kossa staining (Everts et al., 
2012), or processed and methylmethacrylate-embedded for microtome sectioning (6 m) 
for Goldner’s trichrome staining (Kacena et al., 2004).  For all ISH and IHC sections, 
negative and positive controls were always stained to verify no background staining. 
The histology sections stained with alcian blue were used to measure the thickness of the 
acellular cementum (dark blue in appearance).  All of the measurement were done within 
the top 2/3 of the root.  Three random measurements were conducted and then the 
average values were calculated for each mouse. 
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2.3 RESULTS 
 
2.3.1 Bsp-/- mice exhibit defective acellular cementum formation 
Bsp mRNA is highly expressed by cementoblasts during tooth root formation, as well as 
osteoblasts of the alveolar bone (Figure 2.1A).  BSP protein is localized to alveolar bone, 
and acellular and cellular cementum covering the cervical and apical portions of the 
molar, respectively (Figure 2.1B-C).  Absence of BSP immunostaining was confirmed in 
Bsp
-/-
 mice (Figure 2.1D-E). 
Over the course of root development, Bsp
-/-
 mouse molar teeth displayed deficiency in 
acellular cementum formation.  At 14 days postnatal (dpn), a basophilic layer of acellular 
cementum covered the root dentin in WT mice (Figure 2.1F-G), while in Bsp
-/-
 molars, 
this layer was thinner (Figure 2.1H-I).  At 26 dpn, WT acellular cementum had grown 
thicker and inserted PDL fibers radiated from the surface of the cervical root (Figure 
2.1J-K).  Conversely, Bsp
-/-
 acellular cementum showed no additional growth (Figure 
2.1L-M).  It was common to find PDL disorganization in Bsp
-/-
 molars, and a structural 
defect in the cementum-PDL interface was indicated by detachment in all Bsp
-/-
 samples 
(possibly partly due to tissue processing, but not present in WT samples).  By 60 dpn, 
acellular cementum remained stunted in Bsp
-/-
 mice, and PDL detachment was present in 
all Bsp
-/-
, but not WT, samples (Figure 2.1N vs. P).  Histomorphometry confirmed that 
the apparent acellular cementum thickness was significantly reduced in Bsp
-/- 
compared 
to WT molars (Figure 2.1R).  Alcian blue staining supported diminished acellular 
cementum and Goldner’s trichrome staining indicated a lack of mineralized cementum 
matrix on Bsp
-/-
 molar surfaces (Figure 2.2).  The continuously erupting mouse incisor 
features acellular cementum on the lingual root analog, and Bsp
-/-
 incisors featured 
reduced cementum thickness and PDL disorganization (Figure 2.3), contributing to a high 
rate of incisor malocclusion observed in Bsp
-/-
 mice.  The quantity of cellular cementum 
covering the apical molar root was unaffected at 60 dpn in Bsp
-/-
 compared to WT molars 
(Figure 2.1O vs. Q), though at 26 dpn mineralization was delayed in this layer (Figure 
2.4).    
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Figure 2.1.  Bone sialoprotein is required for proper acellular cementum formation.   
(A) Bsp mRNA is expressed by cementoblasts (cb) and osteoblasts (ob) during molar 
tooth root development at 14 dpn.  (B, C) BSP protein is localized to alveolar bone (b), 
acellular cementum (ac), and cellular cementum (cc) at 26 dpn.  White box in B is shown 
at higher magnification in C to highlight acellular cementum.  BSP immunolabeling in 
(D) WT alveolar bone is absent in (E) Bsp
-/-
 mice.  (F, G) Newly formed acellular 
cementum anchors periodontal ligament (pdl) attachment in WT molars.  (H, I) Acellular 
cementum in Bsp
-/-
 molars is thin compared WT.  In contrast to the thickened acellular 
cementum in (J, K) WT at 26 dpn, (L, M) Bsp
-/-
 molars feature stunted acellular 
cementum, and regions of PDL detachment from the tooth (*) were common, indicating 
defects in cementum-PDL interface.  PDL detachment is observed in all of the Bsp
-/-
 
mice, whereas in all of the WT mice the PDL attachment appeared normal.  The well 
organized attachment of the acellular cementum, PDL, and bone in (N) WT molars at 60 
dpn is severely degraded in (P) Bsp
-/-
 molars, where stunted acellular cementum is 
associated with PDL disorganization.  In contrast, cellular cementum in (O) WT and (Q) 
Bsp
-/-
 at 60 dpn is not different in size.  (R) Both buccal and lingual acellular cementum 
are significantly reduced in thickness in Bsp
-/-
 mice compared to WT counterparts (* 
indicated significant difference, p < 0.05).  Scale bar is 200 µm in panels A, B, F, H, O, 
and Q (original 100X), 50 µm in panels C, D, E, G, I, K, M, N, and P (original 400X), 
and 400 µm in panels J and L (original 50X). n=6 
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Figure 2.2.  Decreased thickness and mineralization of acellular cementum in the 
Bsp
-/-
 mouse molar.   
(A-F) Alcian blue and nuclear fast red (AB-NFR) staining was used to visualize acellular 
cementum in WT and Bsp
-/-
 first molars at 14, 26, and 60 dpn because we found it to be a 
sensitive stain for cementum (Methods are described in detail in: Foster, 2012).  Briefly, 
Bouin’s fixed, demineralized, and paraffin-embedded sections were stained with Alcian 
blue stain, followed by counter-staining with nuclear fast red, rendering acellular 
cementum bright blue.  (A, C, E) Compared to the steady appositional growth of 
acellular cementum (ac) in the WT from 14 to 60 dpn, (B, D, F) Bsp
-/-
 molars feature thin 
cementum that does not increase in size over this time.  (G-H) Goldner’s trichrome 
(GTC) staining was used to indicate the relative mineralization of dental tissues, where 
mineralized tissues (e.g. bone, dentin) stain green and unmineralized fibrous-collagenous 
tissues (e.g. osteoid) stain pink to red.  Briefly, undecalcified 
glutaraldehyde/formaldehyde fixed tissues were methylmethacrylate-embedded, and 
sections stained by a standard protocol for Goldner’s  trichrome.  (G) Whereas WT 
mouse molars at 26 dpn feature a mineralized acellular cementum layer (light green, 
flanked by white arrows), (H) Bsp
-/-
 molar teeth exhibit no visible layer between root 
dentin (d) and periodontal ligament (pdl), suggesting the thin cementum layer identified 
by histology is unmineralized.  Tears that appear in the tissue are artifacts from 
undecalcified sectioning.  Scale bar is 20 µm in panels A-H (original 630X). n=6 
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Figure 2.3.  Loss of BSP compromises mouse incisor cementum development.   
(A, B, E, F)  Mouse continually erupting incisors feature a layer of acellular cementum 
(ac) on the lingual root analogue.  (C, D, G, H) In Bsp
-/-
 mice, incisors display a thin 
cementum layer, PDL fiber disorganization (#), and PDL detachment from the root 
surface (*) indicating cementum-PDL structural defects.  PDL detachment is observed in 
all of the Bsp
-/-
 mice, whereas in all of the WT mice the PDL attachment appeared 
normal.  Scale bar is 200 µm in panels A, C, E, and G (original 100X), and 50 µm in 
panels B, D, F, and H (original 400X). n=6 
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Figure 2.4.  Delayed mineralization in Bsp
-/-
 mouse cellular cementum.   
Mineralization of the apical cellular cementum (cc) appeared delayed in Bsp
-/- 
compared 
to WT at 26 dpn as evaluated by (A, B) H&E stain and (C, D) Alcian blue stain with 
nuclear fast red (AB-NFR) stain (see Figure 2.2 caption for description of methods).  
(E,F) Goldner’s trichrome (GTC) staining of undecalcified sections at 30 dpn confirmed 
increased cementoid (red layer) at the cellular cementum surface in Bsp
-/- 
compared to 
WT molars.  Tears that appear in the tissue are artifacts from undecalcified sectioning.  
Abbreviations: d=dentin; pdl=periodontal ligament.  Scale bar is 100 µm for panels E-F 
(original 200X) and 50 µm for panels E-F (original 400X).  n=6 
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2.3.2 Failure of acellular cementum mineralization in Bsp-/- mice 
SEM analysis supported histochemical observations that the thin layer of acellular 
cementum on Bsp
-/-
 molar roots was not mineralized, as no mineralized cementum 
ultrastructure could be identified on the cervical root surfaces of Bsp
-/-
 molars at 60 dpn, 
in contrast to the mineralized cementum layer on age-matched WT molars (Figure 2.5). 
We considered developmental possibilities predisposing to inhibition of cementum 
formation in Bsp
-/-
 mice.  Dentin, required as a foundation for cementum deposition, 
appeared sound and well-mineralized in Bsp
-/-
 mice by histology (Figure 2.1) and von 
Kossa staining (Figure 2.6A-B).  Acellular cementum formation requires migration of 
dental follicle/cementoblast precursors to the nascent root surface.  Root lining cells were 
present in similar numbers in Bsp
-/-
 versus WT first molar roots at 14 dpn (Figure 2.6C).  
PDL fringe fibers at the root surface suggested that the proper acellular cementum matrix 
was present for cementogenesis (Figure 2.6D-E).  Immunostaining revealed deposition of 
osteopontin (OPN) on the root surface, confirming functional cementoblasts in Bsp
-/-
 
mice (Figure 2.6F-I).  Markers of local and systemic mineral metabolism were assayed.  
TNAP immunolabeling in Bsp
-/-
 versus WT molars (Figure 2.6J-M), and serum alkaline 
phosphatase, calcium, and phosphorus, were undiminished in Bsp
-/-
 mice (Table 2.1), 
ruling out systemic mineral ion disturbance as an underlying cause of the cementum 
defect.       
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Figure 2.5.  Lack of mineralized acellular cementum ultrastructure on Bsp
-/- 
mouse 
molar teeth.   
Secondary electron SEM analysis on fractured first molars at 60 dpn indicates that,  
compared to the mineralized acellular cementum layer visible in WT molars at various 
magnifications (A, C, E), no mineralized cementum ultrastructure can be identified on 
the roots of Bsp-/- molars (B, D, F).  Some cracking is evident as an artifact of sample 
preparation.  Abbreviations: enam=enamel; ac=acellular cementum; pdl=periodontal 
ligament.  Scale bar is 50 µm in panels A and B (original 500X), 10 µm in panels C and 
D (original 2,000X), and 2 µm in panels C and D (original 10,000X). n=3 
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Figure 2.6.  Exploration of potential causative factors for lack of acellular cementum 
formation in Bsp
-/-
 mice.   
Comparison of dentin mineralization, cementoblast number, collagen fringe fiber 
distribution, and tissue nonspecific alkaline phosphatase (TNAP) activity were 
performed.  Von Kossa staining on undecalcified (A) WT and (B) Bsp
-/-
 molars at 14 dpn 
indicated Bsp
-/-
 dentin mineralization (black-stained regions) was comparable to WT.  (C) 
Cell counts for putative cementoblast root-lining cells performed at 14 dpn revealed no 
difference in cell numbers of Bsp
-/-
 vs. WT first molar teeth.  Picrosirius red staining 
under polarized light indicated that fringe fibers (ff) of the PDL (high intensity yellowish 
fibers; indicated by white arrows) were similar in density and distribution in (D) WT vs. 
(E) Bsp
-/-
 mouse molars.  OPN localized to the acellular cementum (ac) of (F, G) WT and 
(H, I) Bsp
-/-
 molars at 14 dpn.  TNAP was not altered in the periodontia of (J, K) WT vs. 
(L, M) Bsp
-/-
 mouse molars at 14 dpn.  Abbreviations: pd=predentin; d=dentin; 
pdl=periodontal ligament; ac=acellular cementum.  Scale bar is 200 µm in panels F, H, J, 
and L (original 100X), and 50 µm in panels A, B, G, I, K, and M (original 400X). 
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Table 2.1.  Serum biochemistry for Bsp
-/-
 and WT mice.   
Below are serum calcium, inorganic phosphorus, and alkaline phosphatase activity in 
male mice at 3, 4, and 8 weeks postnatal. 
 
Age Genotype Sample 
size 
Calcium, 
mmol/L 
Phosphorus, 
mmol/L 
Alkaline 
phosphatase, U/L 
3 wks WT 
Bsp
-/-
 
4 
5 
2.62 ± 0.09 
2.64 ± 0.12 
3.50 ±0.41 
3.53 ± 0.19 
257.25 ± 45.09 
358.20 ± 65.95 
4 wks WT 
Bsp
-/-
 
3 
3 
2.79 ± 0.60 
2.57 ± 0.33 
4.50 ± 1.05 
4.37 ± 0.96 
290.00 ± 61.02 
294.67 ± 93.94  
8 wks WT 
Bsp
-/-
 
6 
6 
2.38 ± 0.04 
2.37 ± 0.06 
2.52 ± 0.19 
2.49 ± 0.27 
119.00 ± 7.21 
     163.67 ± 12.68 * 
* indicates p < 0.01 by independent samples (Student’s) t-test 
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2.3.3 Periodontal breakdown in Bsp-/- mice 
Defective acellular cementum in Bsp
-/-
 mice preceded a progressive breakdown of 
periodontal organization at later ages.  WT molars at 26 dpn displayed dense and highly 
organized collagen fiber insertions in the cervical root, visualized by picrosirius red 
staining under polarized light (Figure 2.7A-B).  Conversely, Bsp
-/-
 molars lost PDL 
organization in the cervical root by this age (Figure 2.7C-D), a condition that degenerated 
further over time (Figure 2.8).  Defective cementum-PDL attachment in Bsp
-/-
 molars 
allowed for significant down-growth of gingival epithelial tissues into the periodontal 
region, initiating a long junctional epithelium (Figure 2.7E-F; Figure 2.9).  Periodontal 
disarray in Bsp
-/-
 mice was accompanied by increased incidence of root resorption by 60 
dpn (Figure 2.7G-J), and appearance of osteoclast-like cells, RANKL immunostaining, 
and bone resorption in alveolar bone (Figure 2.7K-N).  There was no indication that 
inflammation played a significant role in the periodontal breakdown, based on histology 
and lack of neutrophil infiltration into the periodontia (Figure 2.10). 
Tooth and bone resorption were documented further by SEM and microCT.  SEM 
revealed extensive pitting in Bsp
-/-
 versus WT molars, concentrated in the cervical roots 
(Figure 2.11A-F).  Lack of acellular cementum was indicated by clearly visible dentinal 
tubules on the external surface of Bsp
-/-
 molar roots.  MicroCT analysis revealed 
extensive reduction in alveolar bone height in Bsp
-/-
 vs. WT mandibles, particularly along 
the lingual aspect (Figure 2.11G-J).      
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Figure 2.7.  Periodontal breakdown in Bsp
-/- 
mice.   
(A, B) Picrosirius red stained sections viewed under polarized light reveal a high degree 
of organization and directionality (indicated by high intensity yellowish fibers) of 
periodontal ligament (pdl) collagen fibrils between acellular cementum (ac) and bone (b) 
in WT molars at 26 dpn.  The dark space represents either empty space or disorganized 
collagen fiber. (C, D) Bsp
-/-
 molars at 26 dpn feature loss of organization of collagen 
fibers in cervical PDL region (#) where detachment (*) is also present.  (E) Pan-keratin 
immunohistochemistry (red-brown color) indicates a well maintained junctional 
epithelium (je) in WT molars at 60 dpn, whereas (F) Bsp
-/-
 molars feature down-growth 
and establishment of a long junctional epithelium in association with loss of PDL 
attachment.  Compared to (G, H) WT molars at 60 dpn, (I, J) Bsp
-/-
 molar teeth feature 
extensive root resorption (chevrons).  Compared to (K, L) WT molars, Bsp
-/-
 molars at 60 
dpn showed (M) localization of receptor activator of nuclear factor kappa-B ligand 
(RANKL) near tooth and bone surfaces, and (N) numerous osteoclast-like cells (arrow 
heads; large, multinucleated, tartrate resistant acid phosphatase (TRAP) positive) on 
alveolar bone surfaces.  Scale bar is 200 µm in panels A and C (original 100X), 50 µm in 
panels B, D, H, J, L, and N (original 400X), 100 µm in panels G, I, K, and M (original 
200X), and 100 µm in panels E and F (original 100X). n=3 
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Figure 2.8.  Progressive loss of PDL organization in Bsp
-/- 
mice.   
Picrosirius red staining viewed under polarized light was used to reveal organization and 
directionality (indicated by high intensity yellowish fibers) of periodontal ligament (pdl) 
collagen fibrils over the course of root development.  The same sections photographed 
under non-polarized light are shown to illustrate presence of collagen (pink-red) 
regardless of organization.  At 14 dpn, a similar level of PDL organization is present in 
the nascent roots of (A-C) WT and (D-F) Bsp
-/-
 mouse molars.  At 26 dpn, cervical PDL 
of (G-I) WT molars is highly organized, with directional collagen fibers radiating from 
the root surface.  The cervical-most PDL of (J-L) Bsp
-/-
 molars at this age is disorganized 
and features periodontal detachment (*).  At the advanced age of 60 dpn, (M-O) WT 
molar PDL is very highly organized, while (P-R) Bsp
-/-
 PDL has become increasingly 
disorganized over the cervical portion.  Scale bar is 200 µm in panels A, D, G, J, M, and 
P (original 100X), and 50 µm in panels B, C, E, F, H, I, K, L, N, O, Q, and R (original 
400X). n=6 
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Figure 2.9.  Progressive epithelial in-growth in Bsp
-/-
 mouse molars and incisors. 
Pan-keratin immunohistochemistry was employed to visualize the dental epithelium 
(reddish-brown color) over the course of root development.   In the (A) unerupted molar 
and (B) incisor of WT mice at 14 dpn, ameloblasts (am) of the enamel organ are 
positively labeled by pan-keratin antibodies.  (C, D) Junctions of epithelium and the 
nascent root of Bsp
-/-
 teeth are well maintained at this early time point.  Junctional 
epithelium (je) is established in erupted (E) WT molars by 26 dpn, and (F) incisors 
feature a well maintained labial-lingual epithelial junction.  (G) Bsp
-/-
 molars display 
abnormal thickening of the junctional epithelium at 26 dpn, in association with 
detachment (*) of periodontal ligament (pdl).  (H) Bsp
-/-
 incisors at this age display 
epithelial in-growth to the periodontal region of the lingual root analogue, in association 
with periodontal detachment (*).  While WT (I) molars and (J) incisors display well 
maintained epithelial junctions at 60 dpn, Bsp
-/-
 (K) molars feature dramatic epithelial 
down-growth into regions of periodontal detachment (*), and (L) incisors also display 
extensive detachment (*) and epithelial invasion into the periodontal compartment.  
Measurement of epithelial attachment at (M) 26 and (N) 60 dpn indicated a significant 
and progressive increase in epithelial down growth in Bsp
-/-
 versus WT molars (p<0.05 
by ANOVA and post-hoc Tukey test).  Abbreviations: d=dentin; b=bone.  Scale bar is 
200 µm for all panels A-L (original 100X). n=6 
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Figure 2.10.  Lack of inflammation during periodontal breakdown in Bsp
-/-
 mice.    
Immunohistochemistry was used to localize neutrophils (reddish color) in periodontal 
tissues.  Despite severe bone and tooth resorption (See Figures 2.7 and 2.11), Bsp
-/- 
mice 
did not feature greater presence of neutrophils in the periodontal compartment, compared 
to WT at ages 26 dpn (B vs. A) and 60 dpn (D vs. C).  (E) Neutrophil staining around a 
first molar root in a ligature-induced murine model for peridontitis is included as a 
positive control for increased neutrophil infiltration associated with bone destruction.  
One month old mouse first mandibular molars were tied with a cotton ligature until tissue 
harvest 15 days later.   Abbreviations: je=junctional epithelium; d=dentin; b=bone.  Scale 
bar is 200 µm for all panels A-E (original 100X). 
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Figure 2.11.  Increased tooth root and alveolar bone resorption in Bsp
-/-
 mice.   
Compared to the smooth surface of (A, C) 10-week old WT molars viewed by 
backscattered SEM, (B, E) Bsp
-/-
 teeth exhibit abundant pitting (white arrows in B and E) 
of the root surface consistent with external root resorption, concentrated on the cervical 
portion of the root surface.  White boxes in A and B indicate regions shown at higher 
magnification in C and E, respectively.  Compared to the (D) WT molar root surface at 
high magnification, (F) Bsp
-/-
 molar roots display exposed dentinal tubules, indicating 
absence of cementum in regions of root resorption.  MicroCT revealed that compared to 
(G, I) WT mandibles, (H, J) Bsp
-/-
 mandibles display extensive reduction in alveolar 
bone height, especially on the lingual aspect (black arrows in H and J).  Abbreviations: 
M1=first molar; M2=second molar; M3=third molar.  Scale bar is 100 µm in panels A 
and B (original 50X), 20 µm in panels C and E (original 2,00X), and 1 µm in panels D 
and F (original 5,000X). n=3 
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2.4 DISCUSSION 
BSP is an extracellular matrix protein present in bone and cementum.  Here we 
demonstrate for the first time that lack of BSP inhibited formation and mineralization of 
acellular cementum.  Further, reduction and loss-of-function of the acellular cementum in 
Bsp
-/-
 mice led to structural defects in the cementum-PDL interface, PDL disorganization, 
down-growth of epithelium, and increased tooth and bone resorption.  Results collected 
here demonstrated that BSP plays a non-redundant role in acellular cementum formation, 
likely involved in initiating mineralization and/or promoting appositional cementum 
growth.  Because of its importance to cementum formation, BSP is essential for 
formation of a functional periodontium. 
 
2.4.1 Acellular cementum as a mineralization-sensitive tissue  
Lack of BSP led to a severe developmental inhibition of acellular cementum formation, 
shown here by histology, histochemistry, immunohistochemistry, and SEM.  As a late 
stage in odontogenesis, cementum formation depends on a number of prior 
developmental stages.  Our results suggested that the defect did not result from defective 
dentin, lack of migration/position of precursor cells, or root surface collagen fringe fibers 
[considered the extracellular matrix proper for acellular cementum  (Bosshardt and 
Schroeder, 1996)].  Local TNAP deficiency (by IHC), hypophosphatemia, and 
hypocalcemia were ruled out as causes of cementum inhibition in Bsp
-/-
 mice.  It is 
notable that acellular cementum formation is similarly inhibited in the Alpl
-/- 
mouse 
model featuring loss of TNAP function (Beertsen et al., 1999; Foster et al., 2012; McKee 
et al., 2011).  Alpl
-/- 
mice harbor increased levels of the mineral inhibitor pyrophosphate 
(PPi) and serve as a model of hypophosphatasia (HPP), where lack of acellular cementum 
predisposes to tooth loss (van den Bos et al., 2005).  We have demonstrated that 
reduction of PPi, in turn, promotes increased acellular cementum formation (Foster et al., 
2011; Foster et al., 2012), and hypothesized that acellular cementum represents a tissue 
strongly regulated at the physicochemical level of mineralization, i.e. hydroxyapatite 
nucleation and growth.  Cellular cementum size was undiminished by loss of BSP, 
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though mineralization was delayed at earlier ages; functional consequences of this are 
under study.  Cellular cementum was unaffected in Alpl
-/- 
mice (Beertsen et al., 1999) and 
in mice where acellular cementum increased via decreased PPi (Foster et al., 2012), 
supporting the view that these tissues are subject to different developmental influences.     
Acellular cementum forms as a progressive mineralization of the PDL collagen fiber 
bundles inserting into the root surface.  We have previously shown BSP binds collagen 
with high affinity (Tye et al., 2005), mediates hydroxyapatite formation (Harris et al., 
2000; Hunter and Goldberg, 1993), and that hydroxyapatite nucleation potency is 
increased 10-fold when BSP is incubated with collagen (Baht et al., 2010).  Considering 
BSP is localized across the width of the acellular cementum (Bosshardt et al., 1998; 
McKee et al., 1996), and based on our past and present findings, it is likely that BSP is 
critical for proper cementum formation and function.   
Another SIBLING protein, OPN, was present at Bsp
-/-
 root surfaces, as in WT controls.  
OPN functions as an inhibitor of hydroxyapatite crystal growth in vitro and in vivo 
(Boskey et al., 2002; Hunter et al., 1994).  Presence of OPN in the absence of BSP may 
additionally tip the balance toward inhibition of cementum mineralization.  It is also 
possible that another function of BSP (e.g. cell adhesion, signaling, etc.) may contribute 
to the cementum phenotype of the Bsp
-/-
 mouse, and this is currently under study. 
 
2.4.2 Absence of BSP leads to periodontal breakdown 
A functional periodontal complex depends on stable insertion of PDL collagen fibers into 
the acellular cementum, as well as ability for remodeling on the bone surface of the PDL 
space.  We propose that lack of acellular cementum in Bsp
-/-
 mice led to a progressive 
degradation of periodontal integrity over time.  Lack of PDL-tooth anchorage was 
followed by PDL disorganization, epithelial down-growth, and tooth and alveolar bone 
resorption.  These are hallmarks of periodontal breakdown associated with periodontal 
disease, however this phenotype developed without an apparent inflammatory response in 
the periodontal compartment, suggesting failure of function/adaptation of the 
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periodontium.  Similar examples of periodontal degradation have resulted in transgenic 
mouse models with compromised periodontal function, e.g. Dmp1 null (Ye et al., 2008) 
and periostin null (Rios et al., 2008) mice.  Substitution of a soft diet for pelletized chow 
is currently being studied to determine the contribution of occlusal stress to incidence of 
periodontal breakdown and incisor malocclusion.  
An unexpected finding was the increased incidence of tooth and alveolar bone resorption 
in Bsp
-/-
 mice.  Previous studies employing Bsp
-/-
 mice showed that BSP deficiency 
impairs osteoclastogenesis and bone resorption in vivo and in vitro (Boudiffa et al., 2010; 
Malaval et al., 2008).  Conversely, BSP over-expression increased osteoclastic activity 
(Valverde et al., 2008).  We propose that increased resorption in the periodontal 
compartment of Bsp
-/-
 mice is the result of local loss of integrity and function in a tissue 
that functions under high mechanical stress and depends on rapid remodeling for proper 
maintenance.  While increased presence of RANKL and TRAP-positive osteoclast-like 
cells was noted in periodontia of Bsp
-/-
 mice, the cause for increased tooth and bone 
resorption is being explored further in this model.       
In summary, results from these studies show for the first time that BSP is critical for 
acellular cementum formation and periodontal attachment.  The role of BSP in acellular 
cementogenesis is likely to be in promoting mineralization at the root surface, to anchor 
PDL fibers and provide strong attachment of the tooth to the alveolar bone.  Loss-of-
function of BSP may predispose to periodontal disease through defective cementum-PDL 
attachment.  Ongoing studies will further elucidate potential roles of BSP in cementum 
formation and regeneration, and in wider periodontal biology. 
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CHAPTER 3  
 
 
 
3 Mechanical Forces Exacerbate Periodontal 
Defects in Bsp-null Mice 
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3.1 INTRODUCTION  
Bone sialoprotein (BSP) is a multifunctional phosphoprotein belonging to the Small 
Integrin Binding Ligand N-Linked Glycoprotein (SIBLING) family (Fisher and Fedarko, 
2003).  BSP localizes primarily to mineralized tissues, including bone, calcified cartilage, 
dentin and cementum, where its expression is up-regulated at the onset of mineralization 
(Macneil et al., 1994; McKee et al., 1996).  In vitro studies have demonstrated that the 
integrin-binding RGD sequence in BSP promotes cell attachment, signaling, and 
migration (Ganss et al., 1999; Goldberg and Hunter, 2012).  In addition, BSP binds 
collagen (Baht et al., 2008; Tye et al., 2005) and hydroxyapatite with high affinity 
(Goldberg et al., 2001) and promotes mineral formation (Hunter and Goldberg, 1993).  
Analysis of the Bsp
-/-
 mouse, during development and repair, revealed decreased growth 
and mineralization of long-bones (Holm et al., 2015; Malaval et al., 2008; Malaval et al., 
2009).  Lack of BSP also affected osteoclast formation and recruitment negatively, 
leading to reduced long-bone turnover (Boudiffa et al., 2010; Malaval et al., 2008). 
Previously, we reported that loss of BSP causes inhibition of functional acellular 
cementum on molar and incisor tooth roots, hypomineralization of cellular cementum, 
and detachment and disorganization of the periodontal ligament (PDL) (Foster et al., 
2013b).  In contrast to reduced bone turnover reported in femurs and tibias (Malaval et 
al., 2008), we reported increased osteoclastic resorption in alveolar bone of Bsp
-/-
 mice, 
associated with increased presence of receptor activator of nuclear factor kappa-B ligand 
(RANKL) in the periodontium, increased numbers of TRAP-positive osteoclast-like cells, 
cervical resorption of molars, substantial alveolar bone loss, and increased incidence of 
incisor malocclusion (Foster et al., 2013b).  Collectively, these data support the 
interpretation that lack of acellular cementum is the primary defect, leading to PDL 
detachment, epithelial downgrowth, and alveolar bone destruction.  We hypothesized that 
defective periodontal attachment due to lack of acellular cementum played a central role 
in the periodontal breakdown observed in Bsp
-/-
 mice, and forces generated by occlusion 
contributed to these pathological changes in dentoalveolar tissues.  In this study, we 
aimed to determine whether reducing masticatory forces through use of soft diet would 
ameliorate periodontal dysfunction and malocclusion in Bsp
-/-
 mice.  To elucidate the 
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pathological mechanisms involved, changes in molar and incisor teeth were analyzed by 
micro-computed tomography (microCT) and histology over time. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Animal care followed guidelines of the Canadian Council on Animal Care and Veterinary 
Services at the University of Western Ontario.  Preparation and genotyping of Bsp
-/- 
and 
wild-type (WT) mice, maintained on a mixed 129/CD1 background, were performed as 
described previously (Malaval et al., 2008).  At 3 weeks of age, Bsp
-/- 
and WT littermates, 
offspring from heterozygous mice mating, were randomly assigned to groups fed a diet 
(2018 Tekland Global 18% protein, Harlan Laboratories, Indianapolis, IN) either in the 
form of hard pellets (hard diet; HD) or soft powder (soft diet; SD) and had access to 
water ad libitum.  Mice were weighed weekly (3-9 weeks).  Experimental endpoints for 
histological and radiographic analysis were 4, 8, and 20 weeks.  
The mice were observed on a weekly basis to determine onset of malocclusion.  Any 
form of incisor misalignment was considered  a malocclusion.  For classification of a 
severe malocclusion phenotype, both incisor misalignment and overgrowth need to be 
present. 
 
3.2.2 Blood chemistry 
Animals were anesthetized with isoflurane gas and whole blood collected by cardiac 
puncture.  Blood samples were transferred to BD Vacutainer® SST™ tubes and allowed 
to coagulate at room temperature for 20 min.  After centrifugation at 3,000g for 10 min at 
4°C, sera supernatants were collected and stored at -20°C.  Serum biochemistry was 
analyzed at the NIH Veterinary Services Clinical Chemistry (Bethesda, MD). 
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3.2.3 Histology 
Long-bones and mandibles used for microCT were harvested, fixed in 10% neutral-
buffered formalin solution overnight and stored in calcium-free Hanks' buffered saline 
solution.  Procedures for histology and analysis of hemi-mandibles were previously 
described (Foster, 2012).   
 
3.2.4 Micro-computed tomography  
MicroCT analysis of hemi-mandibles was performed using eXplore Locus SP at 80 kVp, 
80 µA, with 0.508mm Al filter and exposure time of 1600 msec/frame at 4 frames/view 
to obtain 900 views.  These images were reconstructed at 13 μm spatial resolution with 
calibration and data analysis as described previously (Foster et al., 2013b).  Long-bone 
images were acquired with eXplore Locus Ultra to obtain 1000 views at 120 kVp, 20 µA, 
and 16 msec/view exposure time.  Data were reconstructed at 154 μm spatial resolution.  
Long-bone lengths were measured between the tips of the medial condyle and greater 
trochanter (femurs) or medial malleolus (tibias).  
For analysis of hemi-mandibles, regions of interest (ROIs) were identified at three 
anatomical positions along the length incisor:  alveolar crest, first molar (mesial root), 
and third molar.  These anatomical positions are relative position of the mandible to the 
length of the incisor as shown in Figure 3.3A.  Coronal sections at these positions were 
used to measure the mineral density, thickness, and areas of incisor enamel, labial dentin 
and lingual dentin.  For the first molar analysis, ROIs were determined at three positions: 
crown enamel and dentin, and root dentin.  For all mineral density measurements, 3D 
cubical volumes of interest (VOIs; 10 isotropic voxel size) were defined within the ROIs.  
Three separate measurements were obtained and averaged for each ROI.  The 2D area of 
interest was defined by manually drawn contours along the boundaries of the incisors.   
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For mandibular molars, mesial root exposure was determined by comparing the distance 
between buccal/lingual alveolar ridge crest and cemento-enamel junction to the total root 
length.  All measurements were performed at the midline of mesial root of first and 
second molars.  As an indicator of bone loss, the PDL width in the furcation region of 
first and second molars was measured. 
 
3.2.5 Measurement of incisor eruption rate 
At 8 weeks, WT and Bsp
-/-
 mice (3 mice per group) were anesthetized by isoflurane gas.  
Lingual surfaces of mandibular incisors were etched with phosphoric acid gel etchant 
(Kerr Corporation, Orange, CA) for 30 sec, then cleaned by wiping with moist gauze.  
Incisors were dried completely using gauze, then bonding agent (OptiBond Solo Plus; 
Kerr Corporation) was applied to the etched surface and light cured for 20 sec.  Dental 
composite resin (Premise Flowable; Kerr Corporation) was applied to the incisors and a 
small (1-2 mm) piece of stainless steel wire was fixed to the incisors near the socket 
margin.  Composite was polymerized by UV light.  The affixed stainless steel wires are 
monitored for 9 days to determine the incisor eruption rate; based on the change in 
distance from the fixed wire to the socket margin.  A cabinet X-ray (Faxitron X-ray 
Corp., Chicago, IL, USA) was used for radiographic analysis of skulls, and a dissecting 
stereomicroscope (StereoDiscovery.V8) and digital camera (MRc5, Carl Zeiss 
Microscopy Gmbh, Jena, Germany) were used to capture images and make 
measurements.  
 
3.2.6 Statistical analyses 
Quantitative data are expressed as mean ± standard error.  Statistical analyses between 
experimental groups were performed using two-way analysis of variance and Bonferroni 
post-tests with Prism 5 version 5.03 (GraphPad, La Jolla, CA).   
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3.3 RESULTS 
3.3.1 Soft diet normalized body weight, long-bone length, and 
incisor malocclusion of Bsp
-/-
 mice 
In order to analyze the role of masticatory forces on the periodontal phenotype of Bsp
-/-
 
mice, WT and Bsp
-/-
 mice were assigned to hard (HD) or soft (SD) diet groups.  From 3-9 
weeks of age, Bsp
-/-
(HD) mice weighed significantly less than WT(HD) (Figure 3.1A), 
consistent with studies on 8-week-old (Bouleftour et al., 2014) and 4-month-old mice 
(Malaval et al., 2008).  However, WT(SD) and Bsp
-/-
(SD) groups were not statistically 
different in weight.  While weight of WT mice fed either diet were not significantly 
different, weight of Bsp
-/-
(SD)
 
was significantly greater than Bsp
-/-
(HD)
 
at 3-5 weeks, but 
not in older mice, suggesting differences become less pronounced with age.  These data 
suggest that soft diet, at least partially, rescues the reduced body weight phenotype of 
Bsp
-/- 
mice.  Bsp
-/-
 mice did not exhibit any abnormalities in behavior, fertility, breeding, 
and nursing capabilities.   
Bsp
-/- 
mandibular incisors featured chalky white enamel, in contrast to the normal yellow-
brown coloration in WT and heterozygous mice (Figure 3.1C).  Regardless of diet, Bsp
-/-
 
mice developed malocclusion, with mandibular incisors rotated in a lingual-to-labial 
direction compared to WT (Figure 3.1C insets).  Over the course of 8 weeks, ~30% of 
Bsp
-/-
(HD) but only ~3% of Bsp
-/-
(SD) developed severe malocclusion affecting maxillary 
and mandibular incisors, causing overgrowth and resulting in dysfunction (Figure 
3.1C,D).  The onset of these severe malocclusion occurs within the first 5 weeks post 
weaning (Table 3.1).  WT and heterozygous mice fed either diet did not develop 
malocclusion (data not shown).  Bsp
-/-
(HD) mice with severe incisor malocclusion 
weighed significantly less than Bsp
-/-
(HD) with milder incisor malocclusion (Figure 
3.1B), suggesting that severe malocclusion, with corresponding malnutrition, may 
contribute to the observed bone phenotype.  
Previous studies reported shortening of long-bones in Bsp
-/-
 mice fed normal hard pellet 
diet at 4 and 16 months of age (Malaval et al., 2008), consistent with our findings at 8 
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weeks (Figure 3.1E).  However, when fed SD, femur and tibia lengths of Bsp
-/- 
and WT 
mice were not significantly different.  Further, increased serum alkaline phosphatase 
(ALP) activity, a marker of skeletal activity, in Bsp
-/-
 mice (Foster et al., 2013b), was also 
normalized with SD (Figure 3.1F).  Other blood-chemistry markers, including calcium, 
phosphorus, magnesium, sodium, chloride, glucose, albumin, and protein triglycerides 
were similar for all groups (Table 3.2).  Thus, SD normalized body weight, long-bone 
length, serum ALP, and reduced severe malocclusion in Bsp
-/- 
mice.   
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Figure 3.1.  Soft diet normalizes body weight, bone length, and incisor malocclusion 
in Bsp
-/-
 mice.    
(A) Between 3 and 9 weeks, Bsp
-/- 
mice fed with hard diet (Bsp
-/-
(HD)) weigh 
significantly less (*) than the WT counterpart (WT(HD)) (n=35-58 for week 3-8; n=27 at 
week 9).  However, WT and Bsp
-/- 
mice fed soft diet (WT(SD) and Bsp
-/-
(SD)) are not 
statistically different in weight.  Between 3 and 5 weeks, Bsp
-/-
(SD) weigh significantly 
greater (#) than Bsp
-/-
(HD), but not in older mice. (B) Bsp
-/-
(HD) with severe 
malocclusion weigh significantly less (‡) than Bsp-/-(HD) with milder malocclusion, 
suggesting this phenotype might be caused by dental dysfunction and malnutrition.   (C) 
Bsp
-/- 
mice, regardless of diet, developed some degree of malocclusion that is associated 
with labial rotation of the incisors, observed by altered location of the cemento-enamel 
junction (black arrow in insets).  Severe malocclusion of maxillary and mandibular 
incisors is  prominent in Bsp
-/-
 mice fed hard diet.  (D) Over 8 weeks, 10 out of 35 
(~30%) Bsp
-/-
(HD) mice develop severe incisor malocclusion, a feature evident in only 1 
out of 35 (~3%) Bsp
-/-
(SD) mice.  (E) In the HD groups, femurs and tibias are 
significantly shorter in 8-week old Bsp
-/- 
mice compared to WT, however no differences 
were apparent between the two SD groups (n=6).  (F) The increased serum alkaline 
phosphatase (ALP) activity in Bsp
-/-
 vs. WT is normalized in the SD groups (n=5).  For 
A, B, E and F, values shown represent means ± SEM; *p < 0.05, **p<0.01, ***p<0.001.  
Note: (A) The average body mass for Bsp
-/-
(HD) mice includes all mice regardless of 
degree of malocclusion. 
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Table 3.1.  The effect of diet on the onset of severe malocclusion in Bsp
-/-
 mice. 
Bsp
-/-
 and wild type littermates were fed either a hard or soft diet from the time of 
weaning.  Each week animals were examined for evidence of severe malocclusion of the 
incisors.  The onset of malocclusion for Bsp
-/-
 mice were observed within 5 week post 
weaning.  For each Bsp
-/-
 mouse, the first observation of severe malocclusion was 
recorded.  No malocclusion was observed in any of the wild type mice. 
 
 
Number of mice that have first indication of  
malocclusion per week 
Bsp
-/-
Mice 
Diet 
N Week 4 Week 5 Week 6 Week 7 Week 8 Total 
Malocclusion 
Rate (%) 
Hard 
Diet 
35 0 7 2 1 0 10 28.6 
Soft 
Diet 
35 0 1 0 0 0 1 2.9 
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Table 3.2.  Serum biochemistry for Bsp
-/-
 and WT mice.   
Below are various chemical activity analysis of 8-week-old, which include calcium, 
phosphorus, magnesium, sodium, chloride, glucose, albumin, alkaline phosphatase, and 
protein triglycerides. n = 4 mice per group. 
 
Genotype 
and Diet 
Sodium, 
mmol/L 
Chloride, 
mmol/L 
Calcium, 
mmol/L 
Magnesium, 
mmol/L 
WT (HD) 
WT (SD) 
462.00 ± 4.24 
464.25 ± 1.50 
409.50 ± 5.20 
413.25 ± 2.87 
2.03 ± 0.14 
2.18 ± 0.08 
0.85 ± 0.04 
0.87 ± 0.05 
Bsp
-/- 
(HD) 
Bsp
-/- 
(SD) 
463.50 ± 5.20 
465.00 ± 4.90 
413.5 ± 4.50 
412.50 ± 1.73 
2.17 ± 0.07 
2.27 ± 0.15 
0.83 ± 0.11 
0.83 ± 0.09 
 
Genotype 
and Diet 
Phosphorous, 
mg/dL 
Glucose, 
mg/dL 
Blood Urea 
Nitrogen 
(BUN), mg/dL 
Uric acid, 
mg/dL 
WT (HD) 
WT (SD) 
7.88 ± 0.62 
7.95 ± 0.39 
253.50 ± 7.55 
212.25 ± 17.73 
2.03 ± 0.14 
2.18 ± 0.08 
1.20 ± 0.24 
1.28 ± 0.29 
Bsp
-/- 
(HD) 
Bsp
-/- 
(SD) 
8.10 ± 1.49 
8.18 ± 1.28 
240.75 ± 40.50 
237.75 ± 16.68 
2.17 ± 0.07 
2.27 ± 0.15 
1.13 ± 0.29 
1.73 ± 0.51 
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Genotype 
and Diet 
Albumin, 
g/dL 
Cholestrol, 
mg/dL 
Triglycerides, 
mg/dL 
Alkaline 
Phosphatase, 
U/L 
WT (HD) 
WT (SD) 
2.85 ± 0.39 
2.93 ± 0.15 
147.00 ± 11.75 
138.00 ± 9.49 
144.00 ± 61.73 
138.75 ± 23.03 
108.00 ± 5.48 
96.75 ± 7.89 
Bsp
-/- 
(HD) 
Bsp
-/- 
(SD) 
2.93 ± 0.15 
2.70 ± 0.24 
135.75 ± 19.81 
141.75 ± 17.56 
120.00 ± 57.60 
151.50 ± 41.10 
138.75 ± 17.73 * 
111.75 ± 18.87 
 
Genotype 
and Diet 
Aspartate 
Trans, U/L 
Amylase, U/L Total Protein, 
mg/dL 
WT (HD) 
WT (SD) 
63.00 ± 19.44 
60.75 ± 35.53 
2347.50 ± 223.41 
2415.75 ± 262.32 
4.65 ± 0.17 
4.58 ± 0.15 
Bsp
-/- 
(HD) 
Bsp
-/- 
(SD) 
45.00 ± 10.68 
57.00 ± 17.83 
2386.50 ± 255.60 
2680.50 ± 447.30 
4.65 ± 0.17 
4.58 ± 0.15 
* indicates p < 0.05 by two-way analysis of variance and Bonferroni post-tests. 
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3.3.2 Altered dentin and enamel formation in incisors of Bsp-/- mice 
At 4 weeks of age, Bsp
-/- 
incisors appeared similar to WT (Figure 3.2A).  However, by 8 
weeks, microCT and histology revealed increased dentin thickness and decreased pulp 
volume in Bsp
-/- 
mouse incisors compared to WT (Figure 3.2B,C,E,G,I, and Figure 
3.3A,B).  Incisor dentin thickness measured at the first and third molar increased by 85% 
in Bsp
-/- 
mice (Figure 3.3B), whereas enamel thickness was normal at all positions 
(Figure 3.4).  At first, the incisors appeared to have enhanced mineralization of both 
dentin and enamel in the unerupted portion compared to WT incisors (Figure 3.2B, 3.3C-
D).  At the site of eruption (at the alveolar crest), dentin and enamel mineral densities 
were equivalent in Bsp
-/- 
and WT.  Mineral density of Bsp
-/- 
molar crown and root dentin 
were comparable to WT, however, enamel mineral density was elevated by 12.4% 
(Figure 3.3E).   
Due to these alterations in dentinogenesis and enamel mineralization in Bsp
-/- 
mice, 
irrespective of diet type, we analyzed the incisor rate of eruption.  Bsp
-/-
 mouse incisors 
erupted at a significantly reduced rate compared to WT, 141 vs. 323 m/day, respectively 
(Figure 3.5).  Therefore, relative alterations in dentin and enamel mineral densities near 
incisor apices are likely due to reduced rate of eruption in Bsp
-/-
 mice. 
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Figure 3.2.  Altered incisor dentin and enamel formation in Bsp
-/-
 mice.   
For microCT analysis, 4 different landmarks were chosen: (1) alveolar crest, (2) mental 
foramen, (3) first molar, and (4) third molar.  The WT images in (A and B) are 
representative of both WT(HD) and WT(SD) since no apparent differences in phenotype 
were observed between these WT groups.  (A) At 4 weeks of age, microCT analysis 
indicates no striking difference in incisors of Bsp
-/- 
mice compared to WT.  (B) By 8 
weeks of age, microCT images reveal increased dentin thickness (red arrow) and 
decreased pulp volume towards the apical end of the incisors in Bsp
-/- 
mice compared to 
WT, regardless of diet.  In addition, regardless of diet, resorption of enamel and dentin 
(green arrow) and incisor-associated bone (white arrowhead) can be seen in Bsp
-/-
 mice.  
(C, E, G, I) Histology (H&E stain) confirms increased dentin (DE) thickness and 
decreased dental pulp (DP) space in Bsp
-/-
 mouse incisors compared to WT.  (D, F, H, J) 
Detachment (*) and disorganization of periodontal ligament (PDL) collagen-fiber 
bundles in Bsp
-/-
 mouse incisors with Picrosirius red (PR) staining under polarized light.  
Soft diet does not normalize dentinogenesis, or PDL attachment in Bsp
-/-
 mouse incisors.  
The histological tissues were sectioned at a position relative to the mental foramen 
(position 2). 
 
  
 93 
 
94 
 
 
 
 
Figure 3.3.  Increased incisor dentinogenesis and enamel mineralization in Bsp
-/-
 
mice.   
(A) Using microCT incisor dentin thickness, area, and mineral density were analyzed at: 
(1) alveolar crest, (2) mental foramen, (3) first molar and (4) third molar.  Linear 
measurements were also performed to determine thickness of incisor enamel, labial and 
lingual dentin, as well as cross-sectional area of the dentin and enamel. By 8 weeks of 
age, microCT analysis reveals significantly increased dentin thickness (B) and mineral 
density (C) in the apical end of the Bsp
-/- 
mouse incisors (incisor position 3 and 4) 
compared to WT, regardless of diet.  (D) Similar to dentin, the enamel mineral density is 
increased significantly at both incisor positions 3 and 4 of the Bsp
-/- 
mice, regardless of 
diet.  Interestingly, both enamel and dentin mineral density at position 3 and 4 are 
equivalent to the erupted incisor tissue densities (position 1) in both WT and Bsp
-/-
 mice, 
regardless of diet.  (E) First molar crown and root dentin densities are not different in 
Bsp
-/- 
compared to WT mice; however, the enamel mineral density is significantly 
increased in Bsp
-/- 
molars compared to WT, regardless of diet.  For B-E, values shown 
represent means ± SEM; n=5; *p < 0.05, **p<0.01, ***p<0.001.  Note: Measurements of 
thickness and mineral density determined at positions 1 and 2 were similar to each other, 
and showed no significant difference between WT and Bsp
-/- 
groups, thus only 
measurements at position 1 are shown. 
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Figure 3.4.  Similar enamel thickness was observed between experimental groups. 
Using microCT incisor dentin thickness, area, and mineral density were analyzed at: (1) 
alveolar crest, (2) mental foramen, (3) first molar and (4) third molar.  Linear 
measurements were also performed to determine thickness of incisor enamel.  No 
significant difference in enamel thickness were observed between the mice groups.  
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Figure 3.5.  Bsp
-/-
 mice feature reduced rates of incisor eruption.   
WT and Bsp
-/-
 mice at 8 weeks old were fixed with dental composite to affix a small 
length of stainless steel wire to the labial surface of the mandibular incisors near the 
socket margin.  (A-D) Radiographs of skulls taken after 9 days indicate the placement of 
the composite (COMP) on the incisors.  (E, F) Stereomicroscope images show the labial 
incisor (INC) surfaces, including the mass of composite, the embedded wire (outlined in 
red), and the socket margin (outlined in yellow).  Measurements made between the socket 
margin and middle of the wire were used to calculate incisor eruption distance and rate.  
(G) Bsp
-/-
 mice featured a significantly reduced incisor eruption distance over 9 days, (H) 
corresponding to a more than 2-fold significantly reduced rate of eruption, compared to 
WT incisors.  Graph in (G) shows mean ± SD and graph in (H) shows individual 
measurements and mean ± SD.  ** indicates p < 0.01 for unpaired t-test (n=3 for each 
group). 
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3.3.3 Soft diet does not rescue periodontal defects in Bsp-/- mice 
Defects noted in acellular cementum, PDL and alveolar bone in Bsp
-/- 
mice prompted us 
to determine the role of masticatory forces on these periodontal manifestations.  SD did 
not rescue PDL detachment and disorganization, and resorption of incisor enamel, dentin, 
or associated bone in Bsp
-/- 
mice (Figure 3.2C,E,G,I).  Furthermore, between 4 and 20 
weeks of age, Bsp
-/- 
mice in both diet groups exhibited similar dramatic loss of alveolar 
bone, extensive cervical root resorption (Figure 3.6A), PDL detachment, and epithelial 
downgrowth (Figure 3.6B-I).  The reduced periodontal structure contributed to premature 
loss of teeth, especially third molars, as the Bsp
-/- 
mice aged.   
Periodontal structures were analyzed quantitatively at 8 and 20 weeks, including 
exposure of molar roots (an indicator of alveolar bone reduction) and width of PDL in the 
interradicular region (Figure 3.7A).  MicroCT analysis confirmed increased root exposure 
for all Bsp
-/- 
molars compared to WT, regardless of diet type (Figure 3.7B).  At 20 weeks, 
additional loss of alveolar bone in Bsp
-/- 
mice was apparent, especially on the lingual side 
(Figure 3.8).  At both 8 and 20 weeks, Bsp
-/- 
mice exhibited significantly wider PDL in 
the interradicular regions of first and second molars (Figure 3.7C), reflecting bone loss in 
that region as well.  However, at 8 weeks, Bsp
-/-
(SD) featured significantly less of a width 
increase in PDL than Bsp
-/-
(HD), indicating diet-associated amelioration of bone loss in 
this region.  The altered periodontal structure, evidenced by reduced alveolar bone and 
wider PDL space (Figure 3.7D), is likely responsible for the observed molar 
malocclusion by 8 weeks of age (Figure 3.7E).      
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Figure 3.6.  Soft diet does not rescue periodontal phenotype in Bsp
-/-
 mice.   
(A) MicroCT images demonstrate progressive tooth root resorption (green arrow) and 
alveolar bone (AB) loss (red arrow) in both Bsp
-/- 
diet groups at 8 and 20 weeks.  (B, D, 
F, H) H&E stained first-molar sections in 8-week-old mice reveal that Bsp
-/- 
mice in both 
diet groups feature identical phenotypes marked by lack of acellular cementum (white 
arrowhead), PDL detachment (*), and epithelial (EP) downgrowth (yellow arrow).  (C, E, 
G, I) Picrosirius red (PR) stained sections under polarized light microscopy demonstrate 
loss of PDL collagen organization in both Bsp
-/- 
diet groups. 
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Figure 3.7.  Progressive periodontal breakdown in mandibles of Bsp
-/-
 mice.   
(A) MicroCT cross-sectional images reveal alveolar bone loss around molar roots (green 
arrows).  For all three molars (M1-M3), root exposure on buccal (blue arrow) and lingual 
(orange arrow) aspects, and PDL width in the interradicular region (yellow line) were 
determined.  (B) MicroCT analysis confirms significantly increased molar root exposure 
in all three molars in 8-week-old Bsp
-/- 
mice, with no difference in root exposure 
observed between both Bsp
-/- 
diet groups.  (C) At both 8 and 20 weeks, Bsp
-/- 
mice 
exhibited significantly wider PDL in the interradicular regions of first and second molars 
compared to WT, regardless of diet.  At 8 weeks, Bsp
-/-
 mice in the SD group exhibit 
significantly less increase in PDL width than the HD group, indicating diet-associated 
amelioration of bone loss in this region.  As expected, Bsp
-/-
(SD) showed further 
widening of PDL width at 20 weeks compared to 8 weeks due to progressive alveolar 
bone loss.   At 8 weeks, (D) extensive alveolar bone loss around the molar roots (green 
arrows) contributes to loss of periodontal support that lead to (E) molar malocclusion 
(red arrows).  For B and C, values represent means ± SEM; n=5; *p < 0.05.**p<0.01, 
***p<0.001.  Abbreviations: M1 = first molar; M2 = second molar; M3 = third molar. 
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Figure 3.8.  Further extensive alveolar bone resorption is seen in older Bsp
-/- 
mice. 
 
Quantitative microCT analysis of 20-week-old Bsp-/-(SD) mice revealed continuing pro-
gressive loss of alveolar bone, with more profound bone loss on the lingual aspects of 
M1-M3.  Values represent means ± SEM; n=5; *p<0.05, **p<0.01, *** p<0.001. 
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3.4 DISCUSSION 
We hypothesized that the periodontal manifestations in Bsp
-/-
 mice resulted from absence 
of acellular cementum, with the resulting loss of PDL attachment and associated 
abnormal mechanical forces leading to tooth dysfunction and periodontal tissue 
destruction.  We tested this hypothesis using a diet designed to reduce masticatory forces, 
thus reducing mechanical stress on the periodontal apparatus.  Soft diet was unable to 
diminish periodontal breakdown associated with Bsp
-/-
 mouse molars, including PDL 
detachment and disorganization, severe and progressive alveolar bone loss, and 
resorption of tooth root surfaces, indicating that masticatory forces are not primary 
factors in those pathological changes.  However, SD almost eliminated severe incisor 
malocclusion in Bsp
-/-
 mice, supporting the hypothesis that occlusal loading contributed 
to the malocclusion phenotype.  Surprisingly, SD normalized body weight, long-bone 
length, and serum ALP activity in Bsp
-/-
 mice, suggesting that tooth dysfunctions 
predispose Bsp
-/-
 mice to feeding problems and nutritional deficits that affect body and 
skeletal growth, and that provision of SD improves post-weaning nutrition.  Another 
surprising finding was Bsp
-/-
 incisor phenotype of enhanced dentinogenesis and enamel 
mineralization that is likely due to a slower eruption rate.  This study demonstrates the 
importance of BSP in maintaining proper periodontal function and alveolar bone 
remodeling, and points to dental dysfunction as causative factor of skeletal defects 
observed in Bsp
-/-
 mice.   
 
3.4.1 Role of altered mechanotransduction in Bsp-/- mice periodontal 
breakdown  
In this study, we demonstrated a progressive and severe alveolar bone loss in Bsp
-/-
 mice, 
in contrast to reduced long-bone turnover in vivo and reduced osteoclast activation in 
vitro reported previously (Malaval et al., 2008).  We propose two potential causal factors 
to account for the discrepancy in turnover between long-bone and alveolar bone in Bsp
-/-
 
107 
 
mice: (1) excessive traumatic forces, or (2) unloading of alveolar bone resulting in altered 
mechanotransduction.   
In normal function, alveolar bone undergoes frequent loading during mastication and is 
subject to continuous remodeling to accommodate tooth function (Sodek and McKee, 
2000).  The PDL is a mechanosensitive tissue that provides connection between tooth 
root and supportive alveolar bone acting as a pool of progenitor cells, a source of 
vascularity and innervation, and, importantly, as a shock-absorber helping to prevent 
tissue damage under the forces generated by tooth use (Beertsen et al., 1997).  Alveolar 
bone operates as a functional unit with the non-mineralized PDL, and proper mechanical 
and biological signals between PDL and alveolar bone are critical to maintain functional 
homeostasis of the periodontal apparatus (Ho et al., 2013; Wise and King, 2008).  
Masticatory forces are transmitted through the PDL generally in an occlusal-apical 
direction before being distributed to the surrounding alveolar bone (Meikle, 2006; Milne 
et al., 2009), including buccal and lingual alveolar ridges, interdental bone, and 
interradicular bone in multi-rooted teeth.       
Alveolar bone resorption can result from excessive compression forces or occlusal stress 
by stimulation of osteoclastogenesis through local up-regulation of RANKL, such as 
directed resorption on the compression side during orthodontic tooth movement (Kook et 
al., 2011; Sanuki et al., 2010; Walker et al., 2008; Wise and King, 2008).  Up-regulation 
of RANKL, often associated with inflammatory-mediated bone resorption (Yoshinaga et 
al., 2007), was evident in the PDL region of Bsp
-/-
 mice, although inflammatory cells 
were not observed (Foster et al., 2013b).  Furthermore, loss of PDL attachment and 
epithelial downgrowth in Bsp
-/-
 mice compromises the shock-absorbing function of the 
PDL, disturbing the stress-distribution function of the periodontium, and subjecting the 
bony socket to increased and possibly traumatic compression forces during mastication.  
Extensive resorption of alveolar bone in Bsp
-/- 
mice was most evident in the cervical root, 
where load-bearing horizontal and oblique PDL fibers enter bone as Sharpey’s fibers.  In 
contrast, traumatic hyperocclusion in mouse molars is more associated with bone and 
tooth resorption near the apex and in the interradicular bone (Walker et al., 2008). 
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 Secondly, alveolar bone resorption can also result from absence of mechanotransduction 
from the PDL.  Alveolar bone formation occurs as the tooth root forms and remodels in 
response to changes in tooth use (e.g. orthodontics), and disappears in the absence of 
teeth (e.g. edentulous ridges) (Hansson and Halldin, 2012; Wise and King, 2008).  These 
processes are regulated by the PDL, as both a mechanotransductor supplying mechanical 
stimuli to bone, and as cellular source of biological signals including regulators of bone 
homeostasis (e.g. RANKL and osteoprotegerin (OPG)).  The tooth-PDL-alveolar bone 
functional unit can be understood through application of the mechanostat theory 
introduced by Harold Frost (Frost, 1987), which proposes that proper functional loading 
is necessary to maintain structural integrity in bone through balanced resorption and 
formation.  Similar to edentulous ridges, where lack of mechanical stimuli leads to 
osteopenia and alveolar ridge resorption (Hansson and Halldin, 2012), Bsp
-/- 
mice may 
experience alveolar bone loss as a result of disturbance of tooth attachment and reduced 
functional loading.  
The inability of SD to ameliorate periodontal breakdown in Bsp
-/- 
mice supports the 
hypothesis that loss of PDL attachment and altered mechanotransduction are contributors 
to reduction in alveolar bone in Bsp
-/-
 mice.  Limitations of the study include inability to 
measure true mechanical forces in mouse periodontia, and inability to control chewing of 
other hard materials (e.g. cage wires, bedding) that could introduce unrecognized occlusal 
trauma into the SD group.   
 
3.4.2 Malocclusion and altered incisor formation in Bsp-/- mice 
While SD did not alter periodontal breakdown around molar teeth, it almost completely 
rescued the severe incisor malocclusion in Bsp
-/-
 mice.  This finding strongly supports 
non-physiological distribution of occlusal forces as a causative factor for incisor 
malocclusion. We also demonstrate, for the first time, evidence of molar misalignment 
and malocclusion in Bsp
-/-
 mice, likely due to PDL detachment coupled with occlusal 
stress, similar to the incisor.     
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These data favor dental dysfunction and malnutrition as factors contributing to low body 
weight, reduced long-bone length, and elevated serum ALP in Bsp
-/-
 mice.  Previous 
studies have demonstrated Bsp
-/-
 mice fed on normal hard pellet diet were smaller with 
shorter long-bones (Bouleftour et al., 2014; Malaval et al., 2008), and increased serum 
ALP (Foster et al., 2013b). These parameters were normalized with provision of SD to 
Bsp
-/-
 mice.  Studies on periostin-null mice, which exhibit a similar periodontal 
breakdown and incisor malocclusion, also report similar rescue with SD in body weight 
and long-bone length (Rios et al., 2005).  Additionally, pain associated with tooth 
dysfunction in enamelin-null mice resulted in malnutrition and reduced body weight, 
which was rescued by SD (Chan et al., 2013).  These parallel observations support the 
interpretation that post-weaning malnutrition from malocclusion contributes to the bone 
and weight phenotype in Bsp
-/-
 mice.  However, all bone changes in Bsp
-/-
 mice, do not 
necessarily stem from tooth dysfunction and malnutrition.  We and others have shown 
early delays in long-bone ossification in Bsp
-/-
 mice (Bouleftour et al., 2014; Holm et al., 
2015).  Serum ALP is a commonly used biomarker for bone formation and mineralization 
(Yadav et al., 2012).  In the Bsp
-/-
 mice, elevation of ALP activity may serve as a 
compensatory mechanism for the demonstrated skeletal hypomineralization described in 
(Bouleftour et al., 2014).  SD helps to reduce the severe malocclusion in Bsp
-/-
 mice, 
ameliorating the skeletal defect, which in turn is reflected by normalized serum ALP.  
Another surprising insight is related to the rapid incisor dentin and enamel mineralization 
in Bsp
-/-
 mice.  Dentin is reported to include BSP (Fujisawa et al., 1993; Qin et al., 2001), 
yet Bsp
-/-
 molar dentin appeared normal (Foster et al., 2013b), and confirmed by microCT 
analysis in this report.  Enamel is formed from dental epithelium and suspected to include 
BSP (Chen et al., 1998).  The question arises as to why the incisor is so dramatically 
affected by loss of BSP.  We determined that Bsp
-/-
 incisors erupt at a slower rate than 
WT, causing the appearance of enhanced or accelerated dentinogenesis and enamel 
mineralization towards the apex.  Alterations in Bsp
-/-
 incisor eruption could result from 
periodontal dysfunction due to lack of cementum and also, indirectly, chronic occlusal 
trauma.  Previous studies indicate that migration of PDL fibroblasts contributes to the 
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continuously erupting rodent incisor (Beertsen et al., 1997).  Several other mouse models 
have similar incisor enamel and/or dentin phenotype including periostin-null mice (Rios 
et al., 2005; Rios et al., 2008), OPG-null mice (Sheng et al., 2010), Vitamin D receptor-
null mice (Zhang et al., 2009), and integrin α11β1-null mice (Popova et al., 2007).  We 
propose that periodontal dysfunction and resulting lower rates of incisor eruption may 
underlie dentin and enamel changes in all of these models.   
 
3.4.3 Limiting factors of the studies 
The use of SD reduces the occlusal forces during mastication in comparison to hard diet.  
However, to address the role of occlusal forces on acellular cementum in the Bsp
-/-
 mice 
we can incorporate a similar strategy used in the periostin null mice.  This method 
requires weekly trimming of one side of the mandibular incisors using surgical clippers.  
The other side of the mandibular incisors will be used for comparison (Rios et al., 2008). 
Using this model they demonstrated that occlusal hypofunction was achieved.  In the 
study, the reduced incisors were able to rescue the enamel and dentin resorption observed 
in the incisors of periostin-null mice.  However, for our study, the surgical trimming of 
the incisors will introduces additional forces, which may have an effect on the integrity of 
the cementum-pdl interface of the Bsp
-/-
 incisor.   
 
3.5 CONCLUSION 
This study provides new insights into the role of BSP in the formation and maintenance 
of the periodontium, confirming the importance of BSP for acellular cementum formation 
that cannot be corrected by diet.   
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CHAPTER 4  
 
 
 
4 Healing of rat calvarial defects with nano-
hydroxyapatite/ poly(ester-urethane) scaffolds 
loaded with low dose rhBMP-2 
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4.1 INTRODUCTION 
Large bone defect repair generally requires surgical intervention and the use of 
biomaterials, combined with growth factors, as a temporary filler to promote de novo 
bone formation.  Various biomaterials such as autologous bone, allogeneic devitalized 
bone, resorbable ceramics, polymers, and ceramic/polymer composite have been used in 
clinical and research settings to enhance bone repair.  In general, biomaterials need to 
provide structure, rigidity, and a medium that enables cell and blood vessel infiltration. 
Due to the lack of osteoinductive property of most synthetic biomaterials, recombinant 
human bone morphogenetic protein-2 (rhBMP-2), which is one of the most prevalent 
growth factor used clinically due to its high potency to induce bone formation, are 
commonly added to scaffolds to promote tissue regeneration.  Of relevance, various 
studies have shown that the addition rhBMP-2 is effective in promoting the in-growth of 
cells and bone tissue regeneration (Brown et al., 2011; Fricain et al., 2013; Kim and 
Hollinger, 2012; Li et al., 2009).  Since rhBMP-2 has been shown to be primarily 
activated during fracture healing (Yu et al., 2010), it is important to maintain the presence 
of rhBMP-2 at the defect site during the bone repair process.  For clinical application, in 
2002, the Federal Drug Administration approved the InFUSE
TM
 bone graft, which is a 
porous collagen sponge that acts as a vehicle to deliver 12 mg of rhBMP-2.  However, 
this high dose of rhBMP-2 is required to be clinically effective due to the poor retention 
of the growth factor in the collagen sponge.  Not only is rhBMP-2 costly, but at high 
doses, patients would be at potential risks of adverse side effects that includes heterotopic 
bone formation, unnecessary immune response and even cancer (Carragee et al., 2011; 
Epstein, 2013).  Since retention and slow release from scaffolds would be optimum, it is 
important to develop a strategy that utilizes appropriate biomaterials with the right 
properties as a carrier of low dose rhBMP-2, without compromising its effectiveness.  
Here, for the first time, we investigate the effectiveness of a novel poly(ester-urethane) 
(PU) scaffolds incorporated with nano-sized hydroxyapatite (nHA) as the carrier of 
rhBMP-2, and mediator of bone repair. 
In recent years, PU-based scaffolds have been extensively developed and shown to have 
potential applications for the tissue regeneration.  Various studies have demonstrated 
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success using PU-based scaffold for tissue repairs in bone (Hofmann et al., 2008; 
Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al., 2014; Lee et al., 2005), and 
other soft tissues (Gogolewski et al., 2008; Guan et al., 2005; Guelcher, 2008; Guelcher 
et al., 2008).  The PU-based scaffolds used in this study were designed to have porous 
interconnected network that allows for cell and blood vessel infiltration (Laschke et al., 
2009; Laschke et al., 2013).  In addition, the scaffolds are biocompatible and have 
viscoelastic property for easy physical fitting into the bone defects, as shown in previous 
studies (Hofmann et al., 2008; Laschke et al., 2009; Laschke et al., 2013; Lee et al., 2005; 
Pirvu et al., 2015).  Furthermore, the incorporation of nHA particles into the PU matrix 
was able to improve its material stiffness (Boissard et al., 2009) and increased its capacity 
to bind proteins such as serum albumin and fibrinogen (Laschke et al., 2010b).  The 
incorporation of nHA particles did not appear to affect the scaffolds' biocompatibility and 
ability to allow for angiogenesis to proceed within its porous network (Laschke et al., 
2009).     
In this study, in vitro experiments were done on the novel nano-sized hydroxyapatite-
incorporated poly(ester-urethane) (nHA/PU) scaffolds to determine the ability of the 
biomaterial to support osteoblastic cell culture.  In addition, a well-established rat 
calvarial defect model (Cacciafesta et al., 2001; Kim et al., 2008; Mardas et al., 2008; 
Sawyer et al., 2009) was also utilized to validate the effectiveness of the nHA/PU 
scaffolds in delivering low-dose rhBMP-2 for guided bone regeneration.  The bone repair 
were assessed using micro-computed tomography (microCT), histology and mechanical 
testing.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Scaffold preparation 
The biodegradable PU solution was synthesized in a one-step solution polycondensation 
as previously described in detail (Laschke et al., 2010b).  The process involved the use of 
1,6-hexamethylene diisocyanate (Sigma-Aldrich, Milwaukee, WI), poly(-caprolactone) 
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diol (MW = 530 g mol
-1
, Sigma-Aldrich, Milwaukee, WI), and 1,4,3,6-dianhydro-D-
sorbitol as reactants.  Dibutyltin dilaurate (Fluka, Buchs, CH) was used a catalyst for the 
reaction and N,N-dimethylformaide (Fluka, Buchs, CH) was used as a solvent.  To create 
nHA/PU solution, nHA (Biomaterials US, Ltd., USA) particles, ranging in size from 50 
to 200 nm, were dispersed into a PU solution.  The nHA mass fraction added was 10 
wt.% of the PU solution.  Prior to usage, the nHA particles were washed with ethanol and 
dried at 100°C under vacuum (Laschke et al., 2010b).  The nHA/PU scaffolds were 
prepared using a salt leaching-phase inverse process as previously described (Boissard et 
al., 2009; Gorna and Gogolewski, 2006; Laschke et al., 2010b).  This method involved a 
vigorous mixing of nHA/PU solution with porogen (sodium phosphate heptahydrate 
dibasic salt; Fluka, Buchs, CH) until a homogeneous paste was obtained.  The paste was 
then poured into a cylindrical mould and left in air to allow for slow evaporation of the 
solvents.  The salt was leached out by extensive washing in water, which created porous 
nHA/PU sponges.  In order to produce scaffolds of consistent thickness, the sponges were 
cut using a water jet system.  In this study, the scaffolds were prepared with a circular 
dimension of 5.5 mm and 1 mm thickness with pore sizes ranging from 90 to 300 m.  
The scaffolds were washed in ethanol, dried under vacuum, and sterilized in ethylene 
oxide prior to use in the studies.   
 
4.2.2 In vitro rhBMP-2 release kinetics  
Three nHA/PU scaffolds were each incubated with 1 g of rhBMP-2 (R&D systems, 
Minneapolis, MN) diluted into 25 l of saline solution for 24 h at 4°C.  Control scaffolds 
were incubated in an equal volume of saline.  After 24 h incubation, each scaffold was 
immersed and agitated in 1 ml of phosphate buffered saline (PBS) to remove unbound 
rhBMP-2.  To determine the release kinetics of the bound rhBMP-2 from the nHA/PU 
scaffolds, the samples were further incubated at 37°C in 1 ml PBS in microcentrifuge 
tubes.  At 3, 24 and 72 h, the PBS solutions were replaced with fresh PBS and 100 l of 
the supernatant used to quantify the concentration of the rhBMP-2 using a Human BMP-
2 Quantikine ELISA kit (R&D systems, Minneapolis, MN) according to the 
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manufacturer's instructions.  The accumulated rhBMP-2 release kinetics were expressed 
as percentage of the rhBMP-2 bound to the nHA/PU scaffold. 
 
4.2.3 Cell isolation, culture conditions and cell viability 
Bone marrow was isolated from male Sprague-Dawley rats (Charles River Laboratories 
International, Wilmington, MA) aged 11-12 weeks (325-375 g) by flushing the tibia and 
femur marrow canal with culture medium consisting of Iscove's Modified Dulbecco's 
Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin and 1% L-glutamine (Life Technologies, Carlsbad, CA).  The recovered 
cells enriched in mesenchymal stromal cells (MSC) were cultured in culture medium in 
75 mm
2
 flasks (NUNC) at 37°C in 5% CO2 for 3 days, and then sub-cultured using 
0.05% Trypsin-EDTA solution. Cells at passage 2 were used for subsequent studies.  
Prior to cell seeding, the nHA/PU scaffolds (n=3 for each group; experiment conducted in 
triplicate) were incubated for 24 h at 4°C with either 25 l saline solution or 1 g of 
rhBMP-2 in 25 µl saline solution.  In addition, nHA/PU scaffolds that were pretreated 
with 1 µg rhBMP-2 and used in the 72 h rhBMP2 release kinetics study were also used in 
the studies outlined below.  Rat MSC were seeded onto the control and rhBMP2-
pretreated nHA/PU scaffolds at a density of 3.5 x 10
5
 cells/scaffold and incubated in 24-
well plates (NUNC).  After 1 h incubation, the MSC-seeded scaffolds were placed 
between a sandwich construct consisting of 2 Teflon-rings in a clean 24-well plate in 
order to fully immerse the scaffolds in culture medium.  The MSC-seeded scaffolds were 
then cultured in osteoblast differentiating medium consisting of culture medium 
supplemented with 50 µg/ml ascorbic acid and 2 mM -glycerophosphate.  The 
mineralizing medium was changed every 2 days for the duration of the culture.  For a 
control group, nHA/PU scaffolds with no cells were also incubated with differential 
media. 
After 4 weeks of culture, the scaffolds were washed with Hank's Balanced Salt Solution 
(HBSS) three times, fixed with 4% paraformaldehyde for 20 min, and processed for cryo-
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section.  In order to determine the relative level of matrix mineralization, the 
cryosectioned scaffolds were stained for calcium mineral deposition with Alizarin red 
staining solution (1% w/v, Ricca Chemical company, Arlington, TX) for 20 min at room 
temperature.  To remove excess dye, the sections were washed with deionized water three 
times (5 min incubation time for each wash). 
   
4.2.4 Scanning Electron Microscopy (SEM) analysis 
nHA/PU scaffolds cultured with MSC for up to 4 weeks were fixed with 4% 
glutaraldehyde solution (Sigma-Aldrich, Oakville, ON) for 15 min, after which the 
scaffolds were gently rinsed three times with Phosphate Buffered Saline (PBS) solution.  
Samples were dehydrated in a series of ethanol dilutions (25%, 50%, 75%, 90% and 
100%) for 5 min at each concentration and then air-dried.   The samples were osmium-
coated, and imaged with a Leo 1540 XB FIB/SEM using secondary electron mode at 1-
20 kV (Carl Zeiss, Western Nanofabrication Facility, University of Western Ontario, 
London, ON). 
 
4.2.5 Animals and surgery 
Male Sprague-Dawley rats aged 11-12 weeks (325-375 g) were maintained on a standard 
rat diet (5P00-Prolab RMH 3000; LabDiet, St. Louis, MO).  Animal experiments were 
conducted in accordance with guidelines of the Canadian Council on Animal Care 
(CCAC) and Animal Care and Veterinary Services (ACVS), University of Western 
Ontario.  
Animals were anaesthetized with isoflurane gas and the heads positioned in a stereotaxic 
frame.  The dorsal part of the cranium was shaved, aseptically prepared, and a midline 
incision of approximately 20 mm created.  The skin flaps were kept opened using a 
retractor and the underlying periosteum was removed.  A 5-mm stainless steel trephine 
drill (Salvin Dental Specialties, Charlotte, NC) was used to create circular defects on 
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each of the parietal bones, thus creating 2 defects in each rat.  The diameter of the wound 
is usually slightly larger at approximately between 5.1 to 5.3 mm.  Caution was exercised 
to prevent damage to the dura membrane by adding a custom-made stainless steel sleeve 
(1.5 mm depth shorter) around the trephine drill. In addition, in order to prevent heat 
damage of the host bone, irrigation with saline solution was done throughout the 
procedure.  The nHA/PU or rhBMP-2 (1 g) treated nHA/PU (nHA/PU/rhBMP-2) 
scaffolds without any cells were then implanted and secured in place by double crossing 
4-0 Vicryl suture attached to the temporalis muscles.  The amount of rhBMP-2 used per 
scaffold in the study was determined by previous studies that used low dose of rhBMP-2 
(La et al., 2010; Schofer et al., 2011b).  For the negative control group, the defect holes 
were left empty without any double crossing suture.  In order to prevent any 
contamination, both defects in each rat were implanted with scaffolds of the same 
treatment group.  The skin was closed using 4-0 Silk sutures.  Antibiotics and analgesic 
were administered to the animals and they were allowed to recover for up to 12 weeks 
post surgery, after which they were euthanized with CO2 gas inhalation according to 
CCAC and ACVS guidelines.  At 6 and 12 weeks post-op, the implants and surrounding 
bone were recovered, fixed with 10% buffered formalin overnight at 4°C and prepared 
for histology.  Samples for mechanical testing were not fixed but stored in HBSS 
containing 0.10% sodium azide.   
 
4.2.6 In vivo micro-computed tomography analysis 
At 0, 2, 6, 12 weeks post-op, animals were anaesthetized with isoflurane gas and placed 
in a microCT scanner (eXplore speCZT; GE Healthcare, London, ON).  The scans were 
performed using a standardized live-animal protocol (90 kVp, 40 µA, 900 views, 16 ms 
per view).  Images were reconstructed at a spatial resolution of 50 m and calibrated with 
a cortical bone phantom (SB3; Gammex RMI, Middleton, WI) having a hydroxyapatite 
equivalent of 1,100 mg/cc (White, 1978).  Data were analyzed with MicroView ABA 
version 2.2 (GE Healthcare).  
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In order to visually determine the new bone formation, the 2D Maximum Intensity 
Projection (MIP) and 3D isosurface images of the rat calvarial bones defect sites were 
constructed.  As for the quantification of the newly formed bone, a cylindrical region of 
interest (ROI, 5 mm x 1.5 mm) was positioned within the center of each defect site.  The 
bone mineral content (BMC) within the ROI was determined linearly by assigning a 
value threshold for air (-1000 Hounsfield unit (HU)), water (0 HU), soft tissues (below 
700 HU), trabecular bone (above 700 HU), cortical bone (above 1700 HU) and SB3 
phantom (2700 HU).  The total new bone volume (BV) formation was determined by 
adding all the voxels with HU value above 700 within the ROI.  Bone-to-total tissue 
volume ratio (BV/TV) was determined by calculating the ratio of total voxels with HU 
value above 700 over the total voxels of the ROI.  As for the cortical bone volume 
(CBV), only voxels with HU above 1700 were considered for calculation.  Twenty 
calvarial defects were measured at 2 and 6 weeks and twelve calvarial defects were 
measured at 12 weeks for each group (nHA/PU and nHA/PU/rhBMP-2 up to 12 weeks; 
empty control only up to 6 weeks). 
 
4.2.7 Histological Analysis 
The parietal bones were fixed with 10% formalin for 24 h and then decalcified in 0.65 M 
ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate, pH 7.4, at 37°C for 2 
weeks.  After dehydration, the samples were embedded in paraffin, and sectioned at 5 m 
thickness.  The sagittal sections were stained with hematoxylin and eosin (H&E) and 
Masson's Trichrome (MT).  The percentage of new bone area in the defect was quantified 
for each treatment group by comparing pixel quantities using image J.  Color threshold 
tools in Image J were used to differentiate pixels correspond to new bone or other non-
mineralized soft tissue.  
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4.2.8 Mechanical Testing 
The implants with surrounding parietal bones were recovered (undecalcified) , stored in 
HBSS containing 0.10% sodium azide overnight and then tested on an Instron machine 
(ElectroPuls E1000, Instron, Norwood, MA).  Native bone samples were also used for 
comparison.  For the mechanical testing, a custom-made stainless steel push-out test jig 
was made.  The base and cap had a 5.5-mm hole in the center to allow for the penetration 
of the cylindrical punch during testing.  Each specimen was then mounted with 
cyanoacrylate adhesive onto the base and adjusted to make sure that the center of the 
implant was aligned with the center of the hole.  The cap was then placed and tightened 
in order to prevent bowing of the specimen during testing. 
Indentation tests on the center of implants were performed using the Instron machine 
with a 100-N load cell and 1-mm diameter indenter in order to assess the quality of the 
newly formed bone within the defects.  The rate of indentation was 1 mm/min to a 
maximum load of 2N (± 0.003N).  The load and displacement data were recorded during 
the testing procedure and the elastic modulus was calculated with the following formula 
used in previous studies. (McKee et al., 2011a; McKoy et al., 1999): 
E = S(1 - v
2
)/d 
Where S is the indentation stiffness or the slope of the load-displacement in its linear 
region (N/mm) and d (mm) is the diameter of the indenter.  The Poisson's ratio (v) of 
bone was assumed to be 0.3 (Busa et al., 2005).  Five to eight specimens were used for 
each group. 
Push-out tests were conducted to evaluate the osteointegration of the implant with the 
surrounding host calvarial bone using the Instron machine with a 2-kN load cell and 1 
mm/min rate.  An indenter probe of 5-mm diameter with a flat polished end was 
fabricated for the test. Load and displacement data were recorded during the testing 
procedure and all specimens were tested to failure.  Five to seven specimens were used 
for each group.   
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For both mechanical test, intact native rat parietal bones of the same age were used as 
controls. 
 
4.2.9 Statistical Analyses 
Quantitative data were expressed as means ± standard error.  Statistical analyses among 
groups were performed using two-way analysis of variance (ANOVA) and Bonferroni 
post-tests with Prism 5 version 5.03 (GraphPad Software, La Jolla, CA). p<0.05 was 
considered to be statistically significant. 
 
4.3 RESULTS 
4.3.1 Cells adhesion and nHA/PU scaffold properties 
The sponge-like nHA/PU scaffolds are comprised of a network of multi inter-connected 
channels with pore sizes that varied from 90-300 m (Figure 4.1 A1-E1).  To determine 
whether cells attach, spread out and thrive in the scaffold, rat long bone MSC cells at 
passage 2 were seeded onto the scaffold and cultured for 2 or 4 weeks, fixed and 
observed by SEM.  The images demonstrate cells adhering to the wall of the internal 
pores in the scaffolds (Figure 4.1 C2 and C3).  In addition, collagen fibrils are also 
evident (Figure 4.1 E2 and E3).  These data showed that the nHA/PU scaffold is a 
biocompatible surface that permits MSC attachment and secretion of extracellular matrix.  
 
4.3.2 In vitro bioactivity of bound rhBMP-2 
In order to determine whether the nHA/PU scaffolds binds rhBMP-2 and releases it over 
time, the release profiles of rhBMP-2 from the scaffolds were determined (Figure 4.2).  
Of the 1 µg added to the scaffold, approximately 8.77 ± 1.25% of the rhBMP-2 was not 
bound.  After a 3 h incubation period, approximately 5% of the originally bound rhBMP-
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2 was released into the incubation medium.  At 24 and 72 h incubation period, only very 
low levels (a total of less than 2%) of the growth factor were released.  These results 
imply that the nHA/PU scaffolds were able to retain the bound rhBMP-2 very well.   
After the 72 h incubation period, no direct measurement of bound rhBMP-2 was 
attempted due to the harsh demineralizing and denaturing solutions that would be 
required to recover the rhBMP-2 from the scaffold.  However, to confirm the presence of 
bioactivity of the growth factor, these nHA/PU/rhBMP-2 scaffolds, after the 72 h 
incubation and buffer exchanges, were seeded with MSC and cultured in differentiation 
media for 4 weeks.  The control groups included untreated scaffolds and scaffolds treated 
with fresh 1 µg rhBMP-2 incubated overnight at 4°C without washing, prior to MSC 
seeding.  Both rhBMP-2 treated scaffold groups appeared to have enhanced 
mineralization based on Alizarin Red staining, compared to the control untreated scaffold 
group with or without cells (Figure 4.3 A and B).  Minimal red staining were observed in 
groups without any cells seeded after 4 weeks cultured with differential media.  These 
results suggest that even after incubation for 72 h, with buffer exchanges, the rhBMP-2 
treated scaffolds still retained activity consistent with the presence of rhBMP-2.   
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Figure 4.1.  SEM images of nHA/PU scaffolds incubated with mesenchymal stromal 
cells (MSC).   
Panels A1-3 are representative images of the surface and cross-sectional area of the 
nHA/PU scaffold with or without cell culture.  Panels B1-3 and D1-3 are 200X 
magnification of the area marked by white boxes as shown in panel A.  At higher 
magnification (C1, E1), inter-connected pores can be seen in the nHA/PU scaffolds.  
Macro (white star) and micro (white triangle) pores ranging from 90 to 300 µm and 
aggregates of hydroxyapatite nanoparticles (white circle) are evident in the nHA/PU 
scaffold.  By 2 weeks, extracellular matrix made by the cells can be observed covering 
the surface of the scaffold (B2,B3).  At 2 (C2, E2) and 4 weeks (C3, E3), cells (white 
arrow head) were seen adhering on the walls of the nHA/PU scaffolds.  Collagen fibrils 
(white arrow) secreted by the cells and aggregates of hydroxyapatite (red arrow head) 
were observed on the walls and across the pores of the nHA/PU scaffolds.  
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Figure 4.2.  In vitro cumulative release of rhBMP-2 from nHA/PU scaffolds. 
 
At 72 h, only approximately 7% of the originally bound rhBMP-2 was released from the 
scaffold.  n=3 
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Figure 4.3A.  Control nHA/PU scaffolds show minimal alizarin red staining. 
 
The images in panel A1-2 and B1-2 represent transverse and cross-sectional sections, 
respectively, of control nHA/PU scaffolds without cells stained with alizarin red.  The 
nHA/PU scaffolds were incubated with differential media for 0 day and 4 weeks.  At 
both time point, minimal red staining was observed. 
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Figure 4.3B.  The presence of rhBMP-2 in nHA/PU scaffold increased matrix 
mineralization when cultured with MSC cells.   
The images in panel A1-3 and B1-3 represent transverse and cross-sectional sections, 
respectively, of treated and control nHA/PU scaffolds stained with alizarin red.  The 
histology sections of nHA/PU/rhBMP-2_72h group appears to have similar quantity of 
alizarin red staining compared to nHA/PU/rhBMP-2 group, which confirms that a 
significant proportion of the rhBMP-2 remains associated with the nHA/PU scaffolds 
even after 72 h of incubation and 3 washes.  Both nHA/PU groups treated with rhBMP-2 
qualitatively appear to have elevated alizarin red staining compared to nHA/PU control 
group. 
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4.3.3 rhBMP-2 treated nHA/PU scaffolds promote bone repair  
An established rat calvarial defect model was used to determine whether the rhBMP-2 
treated nHA/PU scaffolds (nHA/PU/rhBMP-2) promotes in vivo bone repair.  At 2 weeks 
post-op, bone in-growth into the defects from host bone and some island-like bone 
spicules were observed in the nHA/PU/rhBMP-2 group, indicated by faint grey coloring 
in the MIP images that filled the defects (Figure 4.4).  This was not observed in the 
untreated nHA/PU control group.  At 6 weeks, the defect sites of the rhBMP-2 treated 
group were filled with apparent bone, whereas minimal bone formation was observed in 
the untreated nHA/PU control group.  Even after 6 weeks, for the group with empty hole, 
no new bone formation was observed in the middle of the defects (data not shown).  Most 
of the very limited bone in growth was from the periphery of the defects.  Therefore no 
further measurement was conducted for this group. 
The bone mineral content (BMC), new total bone volume (BV), percentage of bone-to-
tissue volume (BV/TV) and cortical bone volume (CBV) of the nHA/PU/rhBMP-2 group 
were significantly higher compared to nHA/PU group at all three time points (Figure 
4.5A to D).  Interestingly, between 6 and 12 weeks, no significant increase in new bone 
formation was observed in either group as shown in Figure 5B and C.  However, the 
BMC values at 12 weeks were significantly higher compared to values at 6 weeks, which 
was likely due to the continuous process of remodeling and densification of the newly 
formed bone.  This was confirmed by the observed significant increase in percentage of 
CBV between the three time points for both nHA/PU/rhBMP-2 and control groups 
(Figure 4.5D). 
Detailed histological analysis confirmed that rhBMP-2 treated nHA/PU scaffolds 
enhanced bone formation in vivo compared to the control scaffolds (Figure 4.6).  At 6 
weeks, compared to the control group, the nHA/PU/rhBMP-2 group demonstrated 
significantly more new bone formation.  This is indicated by union bone formation 
adjacent to the dura-membrane and island-like bone spicules throughout the defect sites.  
At higher resolution, fibrous tissue and individual island-like bone spicules, of which 
some appeared to contain osteons, can be seen forming in the defects of both groups.  
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However, the amount of fibrous tissue appears to be greater in the control group 
compared to the nHA/PU/rhBMP-2 group (Figure 4.6, panels C and D).  Quantitative 
measurements on histological sections were also done to determine the amount of new 
bone formed in the defects.  At both 6 and 12 weeks, nHA/PU/rhBMP-2 group showed 
significantly more new bone area compared to nHA/PU group (Figure 4.7).  However, 
similar to microCT analysis, the histological analysis demonstrated that similar amount of 
total bone formation was observed for both groups.  This result confirmed that, after 6 
weeks post-op, minimal increase of new bone formation was observed for both groups. 
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Figure 4.4.  MicroCT images of bone repair for nHA/PU and nHA/PU/rhBMP-2 
groups.   
Maximum Intensity Projection (MIP) and 3D isosurface images of rat calvarial defects 
indicate that the presence of rhBMP-2 enhanced bone formation in the calvarial defect 
sites.  By 6 weeks, new bone fills most of the defect site in the nHA/PU/rhBMP-2 
scaffold group and the radiodensity of the newly formed bones also appeared to be more 
dense over time, which is an indication of increasing mineral content.  The image on the 
left describes the cylindrical region of interest (ROI), coloured yellow to highlight area 
that was analyzed.  (n=12 for 2 and 6 weeks, n=20 for 12 weeks) 
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Figure 4.5.  Quantitative microCT analysis of bone repair.   
MicroCT analysis showed that (A) bone mineral content (BMC); (B) new bone volume 
(BV); (C) percentage of bone-to-tissue volume (BV/TV) and (D) percentage of cortical 
bone volume, were enhanced in nHA/PU/rhBMP-2 scaffold group compared to nHA/PU 
scaffold group at 6 and 12 weeks.  Data represents mean ± standard error (n=20 for 2 and 
6 weeks, n=12 for 12 weeks, *p<0.05, **p<0.01, ***p<0.001). 
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Figure 4.6.  Histology and microCT analysis of rat calvaria at 6 and 12 weeks.   
Both microCT and histology analyses confirmed that the presence of rhBMP-2 in 
nHA/PU scaffolds enhanced bone formation in vivo. (Panel A and B) Sagittal sections of 
nHA/PU/rhBMP-2 group showed extensive bone healing compared to nHA/PU group.  
Staining consists of H&E (Panel A and C; dark pink – mineralized bone) and Masson’s 
Trichrome (Panel B and D; teal – collagen and less mineralized bone, dark purple red – 
mature bone).  Arrows indicate edge of the bone defect adjacent to host bone (HB). 
Arrowheads indicate island-like new bone formation in the defect sites.  Triangle 
indicates continuous in-growth of new bone formation from the host bone adjacent to the 
dura membrane.  (Panel C and D) At a higher magnification, defects containing nHA/PU 
scaffolds are predominately filled with fibrous tissue (#); however, mineralized bone (*) 
can also be observed.  For the nHA/PU/rhBMP-2 scaffold group, island-like bone 
formation can be seen throughout the defect; especially at 12 weeks post-implantation.  
MicroCT images of coronal (Panel E) and sagittal (Panel F) sections confirm the 
demonstration of new bone formation indicated by histology. 
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Figure 4.7.  Quantitative histological analysis of explanted tissues at 6 and 12 week.   
For both time points, nHA/PU/rhBMP-2 group have significantly higher amount of new 
bone area within the original defect compared to nHA/PU group.  Data represents mean 
± standard error (n=8 for both 6 and 12 weeks, ***p<0.001). 
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4.3.4 Mechanical test analysis 
To test the mechanical property of the newly formed bone and degree of osteointegration 
of implant-host bone, push-out and indentation tests were performed on the bone repair 
sites.  Based on the indentation experiments, at 6 weeks, the elastic modulus was 
significantly higher (15-fold) for the nHA/PU/rhBMP-2 group compared to the untreated 
nHA/PU control group; however, the value was still significantly lower compared to 
native bone (Figure 4.8A).  By 12 weeks, the elastic modulus of the nHA/PU/rhBMP-2 
had doubled, and interestingly, the level was statistically similar to native bone modulus 
at 6 weeks but not at 12 weeks.  The modulus for the untreated nHA/PU group remained 
unchanged over time (Figure 8A).  The push-out tests indicates that at 6 weeks, 
approximately 50% more load was required to fracture the bone-implant osteointegration 
region of the nHA/PU/rhBMP-2 group compared to the untreated control and no scaffold 
groups (Figure 4.8B).  This suggests that the new bone in-growth from the host bone 
integrated well with the scaffold within the defect site.  Interestingly, the no scaffold 
group also registered similar fracture load compared to untreated control group, which 
was likely due to the in-growth of new bone from the host bone around the defect.  The 
similarity in fracture load for the nHA/PU control and no scaffold group indicates that the 
presence of the nHA/PU scaffold did not hinder the bone in-growth from the host tissue.  
This result suggests that the nHA/PU scaffold is biocompatible and well tolerated in vivo.  
Unexpectedly, at 12 weeks, the required load to fracture the bone of the untreated 
nHA/PU control and nHA/PU/rhBMP-2 groups were similar to those at 6 weeks, which 
indicates that the bone-implant osteointegration region strength had potentially peaked 
(Figure 4.8B).  This value was approximately 30% lower compared to native bone 
strength.  
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Figure 4.8.  Mechanical testing of rat calvarias at 6 and 12 weeks.   
(A) Micro-indentation tests indicated that the stiffness of newly formed bone in 
nHA/PU/rhBMP-2 group was significantly higher compared to nHA/PU group at both 
time points.  (B) Push-out tests showed a significant difference in load of fracture for 
nHA/PU/rhBMP-2 group compared to the nHA/PU group.  The bone-control was done 
on undamaged calvarial bone.  Data represents mean ± standard error (micro-indentation 
test: n = 6 for bone groups and n= 8 and 5 for all other groups at 6 and 12 weeks, 
respectively; push-out test: n = 5 for no scaffold group and n=7 for all other groups; 
*p<0.05, **p<0.01, ***p<0.001). 
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4.4 DISCUSSION 
In tissue engineering, biocompatibility, degradation rate, osteoconductive, and 
osteoinductive are important properties of effective biomaterials for bone repair.  
However, most biomaterials are not osteoinductive in nature; thus, the addition of various 
growth factors or bioactive proteins is a common practice.  Clinically, rhBMP-2 is the 
most prevalent growth factor for bone tissue regeneration due to its high potency in 
driving osteoprogenitor cell differentiation to osteoblastic cells, which leads to de novo 
bone formation.  A high dose of rhBMP-2 is usually required in the clinical setting to 
ensure the enhancement of bone repair.  Bone repair studies in small animals have also 
demonstrated that increasing the dose of rhBMP-2 enhances the rate and amount of bone 
formed (Angle et al., 2012; Ben-David et al., 2013; Murakami et al., 2002).  However, 
there are potential side effects due to the high levels of growth factor that include 
excessive bone formation, adverse immune responses, and cancer (Carragee et al., 2011; 
Epstein, 2013).  Therefore, delivery strategies that utilize low levels of rhBMP-2 and still 
achieve sufficient bone formation are required.  In this study, we demonstrate that the 
novel nHA/PU scaffold loaded with low-dose rhBMP-2 is effective in promoting bone 
regeneration.  In addition, rhBMP-2 appeared to bind well onto the nHA/PU scaffold as 
indicated by the low concentration of rhBMP-2 released from the scaffold after 72 hr 
incubation.  
 
4.4.1 nHA/PU scaffold supports cell attachment and binding of 
rhBMP-2 
Previous studies have shown that the inter-connective pore networks in PU scaffolds 
allow for the in-growth of cells and blood vessels (REF).  Furthermore, these scaffolds 
have an inherent mechanical stiffness and viscoelastic properties, which are important for 
bone tissue engineering applications (Boissard et al., 2009; Gogolewski et al., 2008).  In 
addition, the PU scaffolds have good angiogenic properties and are effective in 
supporting cell attachment, growth, and differentiation (Hofmann et al., 2008; Laschke et 
al., 2010a; Laschke et al., 2012; Laschke et al., 2013).  The addition of nHA to PU 
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scaffolds allow for improved mechanical stiffness and enhanced binding of proteins 
(Laschke et al., 2010b).  SEM images demonstrated that even though most of the mineral 
crystals appear to be embedded, some are found on the surface including the walls of the 
pores as shown in Figure 1.   
Hydroxyapatite has been shown to effectively bind proteins as demonstrated in its use as 
a chromatography resin (Matsumoto et al., 2004; Shen et al., 2008; Xie et al., 2010).  
Thus, this property of HA likely contributes to the binding of rhBMP-2 to the nHA/PU 
scaffold.  Of relevance, rhBMP-2 was shown to have higher binding to HA-coated 
ceramic surfaces than uncoated surfaces and, more importantly, be released at a slower 
rate (Autefage et al., 2009).  Our in vitro study indicates that approximately 7% of the 
initial bound rhBMP-2 to the HA/PU scaffold was released by 72 hrs, which is a similar 
release rate described in previous studies that utilized methods of rhBMP-2 entrapment 
within nano/micro-particle vehicles for controlled release (Li et al., 2009; Li et al., 2015; 
Xie et al., 2010).   
rhBMP-2 has been shown to promote differentiation of osteoprogenitor cells to 
osteoblastic cells which in turn leads to increased matrix formation with subsequent 
calcification.  This osteoinductive property of the rhBMP-2 is crucial for promoting bone 
repair, including the parietal bones which undergo intramembranous ossification.  
Previous studies have indicated that intramembranous ossification begins within the first 
few days of fracture and BMP expression is up-regulated in the proliferating 
osteoprogenitors during this process (Sfeir et al., 2005).  Therefore, the presence of 
rhBMP-2 within the interconnected porous network of the scaffold may promote 
osteogenic differentiation, which in turn will speed up the bone repair process.  
In order to confirm the bioactivity of the bound rhBMP-2, the treated nHA/PU scaffolds 
were seeded with MSC and cultured.  Based on alizarin red staining, the rhBMP-2 treated 
nHA/PU scaffolds qualitatively appeared to have higher amount of matrix mineralization 
compared to untreated nHA/PU scaffolds.  Interestingly, nHA/PU/rhBMP-2 that were 
incubated and washed in media for 72 h prior to the addition of the MSC, also appeared 
to have similar levels of mineralization compared to the nHA/PU scaffolds treated with 
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fresh rhBMP-2.  This result confirmed that rhBMP-2 was present and active even after 
the 72 h incubation period that included multiple washes.   
A limitation of our study was the difficulty to quantify certain metrics from the 3D cell 
cultures in the porous scaffolds.  Analysis using microscopic techniques quantifying cell 
numbers or mineral content require reproducible and representative sections of the 3D 
scaffolds with equivalent cell numbers spread evenly through the structure.  Staining of 
the polymers for cells, for example, showed an uneven distribution, with few cells found 
at or near the surface of the polymers.  Furthermore, histological sections through the 
scaffold show inconsistent pore sizes and distribution. 
In order to determine cell numbers in the scaffold, we tried to quantify DNA content.  
Unfortunately, no reliable data was obtained.  For example, using TRIzol reagent, 
inadequate levels of DNA was extracted from the scaffolds, whereas measureable levels 
were extracted from cultures in the absence of scaffolds.    
 
 
4.4.2 nHA/PU scaffold treated with low dose rhBMP-2 enhanced 
repair of calvarial bone defects 
MicroCT analyses have been reliably used to quantify level of mineralization with 
regards to the spatial distribution of new bone within the calvarial defects (Cowan et al., 
2007; Sawyer et al., 2009; Umoh et al., 2009).  In agreement with these studies, our CT 
bone volume measurements and histological analyses both demonstrated increased 
formation of new bone in the nHA/PU/rhBMP-2 scaffolds compared to untreated 
scaffolds.  A number of studies have shown that the addition of rhBMP-2 to various 
scaffold materials promotes bone repair.  In studies that used the rat calvarial defect 
model, large doses (5 µg or more) of rhBMP-2 were loaded into each scaffold of various 
compositions, which includes synthetic materials such as β-tricalcium phosphate,  
polylactic and polyglycolic acid gel, and poly ε-caprolactone/tricalcium phosphate, as 
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well as natural materials such as collagen and autogenous bone chips (Luvizuto et al., 
2011; Sawyer et al., 2009; Schwarz et al., 2009).  In comparison, our nHA/PU scaffold 
was only loaded with 1 µg of rhBMP-2 and was shown to be as good if not better in 
generating new bone.  In our study, the percentage of bone covering the defect volume 
(BV/TV) for the rhBMP-2 treated group was 75.48 ± 8.36 % at 12 weeks, which is 
greater than the findings reported by Sawyer et al and Luvizuto et al (Luvizuto et al., 
2011; Sawyer et al., 2009).  Of relevance, other studies using the calvarial defect model 
have also demonstrated that lower doses (174 - 500 ng) of rhBMP-2 per scaffold 
(polylactic acid based) can achieve relatively moderate bone formation covering 
approximately 20-45% of the defect volume (La et al., 2010; Schofer et al., 2011b).  The 
length of time in which rhBMP-2 is present in the scaffold during bone repair has been 
noted to be crucial for bone formation.  Previous studies have demonstrated that long-
term delivery of rhBMP-2 (1 µg or greater) promoted greater amount of bone formation 
compared to a short-term delivery method.  However at a very low dose of rhBMP-2 (500 
ng of less), both delivery methods resulted in the same amount of bone formation (La et 
al., 2010).  In our system, the effectiveness of nHA/PU/rhBMP-2 scaffold in bone repair 
is likely attributed to its porous interconnected network that allows for in-growth of cells 
and vascularization system, and also its ability to absorb and bind growth factors and 
other bioactive proteins.  The slow release of rhBMP-2 from nHA/PU scaffold 
contributed to the high percentage of new bone volume seen in this study.  Of relevance, 
most studies that used high dose of rhBMP-2 usually have a fast rhBMP-2 release profile 
from the scaffold.  For example, Sawyer et al. indicated that almost all of the bound 
rhBMP-2 was released from the poly ε-caprolactone/tricalcium phosphate/collagen 
scaffold within 10 hours of incubation (Sawyer et al., 2009).    
No adverse inflammatory response was observed in any of the treatment groups, 
supporting that the nHA/PU scaffold is biocompatible as previously shown (Dresing et 
al., 2014; Laschke et al., 2010b).  The mode of healing between the rhBMP-2 treated 
scaffolds appears to differ compared to the control scaffold group.  In the control group, 
containing only the untreated scaffold, minimal new bone formation was observed, with 
most observed at the edge of the defect and some island-like bone formation in the 
interior of the scaffold.  In contrast, use of the rhBMP-2 treated scaffold resulted in 
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widespread healing throughout the defect site.  This result also confirmed our in vitro 
study, which showed that the rhBMP-2 treated nHA/PU scaffold was effective in 
promoting cell migration and differentiation within the scaffold.   
At all three time points, we found that BMC, BV, BV/TV of rhBMP-2 treated nHA/PU 
scaffolds were significantly higher compared to those of the control scaffold group.  By 6 
weeks, the BV/TV analyses indicated that approximately 70% of the defects were filled 
with bone.  However, this BV/TV value was statistically similar to that at 12 weeks, 
which suggests that the rate of bone formation was significantly reduced after 6 weeks 
and likely approaching the limits of bone growth.  Other studies have also shown that 
new bone growth was significantly reduced after 8 weeks. (Schofer et al., 2011a).  In 
comparison, the average BMC and the percentage of cortical bone volume in the defect 
were significantly higher at 12 weeks compared to 6 weeks.  Together with the BV/TV 
values, these data indicate that bone remodeling was likely the main process during this 
post 6-week repair period.  Thus, this data highlights the importance of promoting and 
maximizing new bone growth at early stages of the bone repair.   
Of relevance, previous in vivo studies using a subcutaneous model demonstrated that 
BMPs induced both chondrogenesis and osteogenesis (Kuboki et al., 2001; Wang et al., 
1990).  Similarly, in vitro studies also have shown that BMP induces cartilage formation 
using muscle-derived cells (Sampath and Reddi, 1983; Sato and Urist, 1984).  However, 
it is possible that the type of ossification during bone repair depends on location and type 
of bone.  For example, the parietal bones are known to be formed via intramembranous 
ossification and during the bone repair, however in this study we did not analyze for 
markers of cartilage formation within the calvarial defects. 
Mechanical testing on the repaired bone defects was also performed in this study since it 
is another parameter that is crucial in evaluating the quality of new bone.  Two types of 
mechanical test models were utilized: micro-indentation and push-out test.  The micro-
indentation test has previously been shown to be useful in determining the elastic 
modulus of newly formed bone (Sawyer et al., 2009).  At both 6 and 12 weeks, the elastic 
modulus of the newly formed bone at the center of the defect were significantly higher 
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for the nHA/PU/rhBMP-2 group compared to the control scaffold group, though it is still 
lower than that of native bone.  The latter was expected since histological and microCT 
analyses suggest that the newly formed bone had not been fully remodeled even by 12 
weeks.  In order to determine the quality and strength of the osteointegration, the load of 
fracture at the implant-bone boundary was obtained using the push-out test.  The results 
indicate that significant higher load of fracture was required for the nHA/PU/rhBMP-2 
group compared to control group; but this value was still lower compared to that of native 
bone.  Interestingly, the control group has a similar load of fracture value compared to the 
no-scaffold group, which indicates that the mechanical strength at the osteointegration 
boundary is mainly due to the normal bone in-growth at the periphery of the defect.   
In conclusion, this study demonstrated that the nHA/PU scaffold has a high binding 
affinity with rhBMP-2.  Combined with low dose rhBMP-2, the nHA/PU scaffold was 
able to effectively promote bone repair by 6 weeks.  This data indicates that nHA/PU is 
an ideal scaffold for bone tissue engineering. 
 
  
  
152 
 
4.5 REFERENCES 
Angle SR, Sena K, Sumner DR, Virkus WW, Virdi AS (2012). Healing of rat femoral 
segmental defect with bone morphogenetic protein-2: a dose response study. J 
Musculoskelet Neuronal Interact 12(1):28-37. 
Autefage H, Briand-Mésange F, Cazalbou S, Drouet C, Fourmy D, Gonçalvès S et al. 
(2009). Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated 
hydroxyapatite/β-tricalcium phosphate porous ceramics. Journal of Biomedical Materials 
Research Part B: Applied Biomaterials 91B(2):706-715. 
Ben-David D, Srouji S, Shapira-Schweitzer K, Kossover O, Ivanir E, Kuhn G et al. 
(2013). Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen 
hydrogel matrix. Biomaterials 34(12):2902-2910. 
Boissard CIR, Bourban PE, Tami AE, Alini M, Eglin D (2009). 
Nanohydroxyapatite/poly(ester urethane) scaffold for bone tissue engineering. Acta 
Biomaterialia 5(9):3316-3327. 
Brown KV, Li B, Guda T, Perrien DS, Guelcher SA, Wenke JC (2011). Improving Bone 
Formation in a Rat Femur Segmental Defect by Controlling Bone Morphogenetic 
Protein-2 Release. Tissue Engineering Part A 17(13-14):1735-1746. 
Busa B, Miller LM, Rubin CT, Qin YX, Judex S (2005). Rapid Establishment of 
Chemical and Mechanical Properties during Lamellar Bone Formation. Calcif Tissue Int 
77(6):386-394. 
Cacciafesta V, Dalstra M, Carles, Melsen B, Andreassen TT (2001). Growth hormone 
treatment promotes guided bone regeneration in rat calvarial defects. The European 
Journal of Orthodontics 23(6):733-740. 
Carragee EJ, Hurwitz EL, Weiner BK (2011). A critical review of recombinant human 
bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and 
lessons learned. The Spine Journal 11(6):471-491. 
153 
 
Cowan CM, Aghaloo T, Chou Y, Walder B, Zhang T, Soo C et al. (2007). MicroCT 
Evaluation of Three-Dimensional Mineralization in Response to BMP-2 Doses In Vitro 
and in Critical Sized Rat Calvarial Defects. Tissue Engineering Part A 13(3):501-512. 
Dresing I, Zeiter S, Auer J, Alini M, Eglin D (2014). Evaluation of a press-fit 
osteochondral poly(ester-urethane) scaffold in a rabbit defect model. Journal of Materials 
Science: Materials in Medicine 25(7):1691-1700. 
Epstein NE (2013). Complications due to the use of BMP/INFUSE in spine surgery: The 
evidence continues to mount. Surgical Neurology International 4(Suppl 5):S343-S352. 
Fricain JC, Schlaubitz S, Le Visage C, Arnault I, Derkaoui SM, Siadous R et al. (2013). 
A nano-hydroxyapatite – Pullulan/dextran polysaccharide composite macroporous 
material for bone tissue engineering. Biomaterials 34(12):2947-2959. 
Gogolewski S, Gorna K, Zaczynska E, Czarny A (2008). Structure–property relations and 
cytotoxicity of isosorbide-based biodegradable polyurethane scaffolds for tissue repair 
and regeneration. Journal of Biomedical Materials Research Part A 85A(2):456-465. 
Gorna K, Gogolewski S (2006). Biodegradable porous polyurethane scaffolds for tissue 
repair and regeneration. Journal of Biomedical Materials Research Part A 79A(1):128-
138. 
Guan J, Fujimoto KL, Sacks MS, Wagner WR (2005). Preparation and characterization 
of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. 
Biomaterials 26(18):3961-3971. 
Guelcher SA (2008). Biodegradable polyurethanes: synthesis and applications in 
regenerative medicine. Tissue Eng Part B Rev 14(1):3-17. 
Guelcher SA, Srinivasan A, Dumas JE, Didier JE, McBride S, Hollinger JO (2008). 
Synthesis, mechanical properties, biocompatibility, and biodegradation of polyurethane 
networks from lysine polyisocyanates. Biomaterials 29(12):1762-1775. 
154 
 
Hofmann A, Ritz U, Verrier S, Eglin D, Alini M, Fuchs S et al. (2008). The effect of 
human osteoblasts on proliferation and neo-vessel formation of human umbilical vein 
endothelial cells in a long-term 3D co-culture on polyurethane scaffolds. Biomaterials 
29(31):4217-4226. 
Kavlock KD, Pechar TW, Hollinger JO, Guelcher SA, Goldstein AS (2007). Synthesis 
and characterization of segmented poly(esterurethane urea) elastomers for bone tissue 
engineering. Acta Biomater 3(4):475-484. 
Khadra M, Kasem N, Haanæs HR, Ellingsen JE, Lyngstadaas SP (2004). Enhancement of 
bone formation in rat calvarial bone defects using low-level laser therapy. Oral surgery, 
oral medicine, oral pathology, oral radiology, and endodontics 97(6):693-700. 
Kim J, Hollinger JO (2012). Recombinant human bone morphogenetic protein-2 released 
from polyurethane-based scaffolds promotes early osteogenic differentiation of human 
mesenchymal stem cells. Biomedical Materials 7(4):045008. 
Kim S-S, Gwak S-J, Kim B-S (2008). Orthotopic bone formation by implantation of 
apatite-coated poly(lactide-co-glycolide)/hydroxyapatite composite particulates and bone 
morphogenetic protein-2. Journal of Biomedical Materials Research Part A 87A(1):245-
253. 
La WG, Kang SW, Yang HS, Bhang SH, Lee SH, Park JH et al. (2010). The efficacy of 
bone morphogenetic protein-2 depends on its mode of delivery. Artif Organs 
34(12):1150-1153. 
Laschke MW, Strohe A, Scheuer C, Eglin D, Verrier S, Alini M et al. (2009). In vivo 
biocompatibility and vascularization of biodegradable porous polyurethane scaffolds for 
tissue engineering. Acta Biomaterialia 5(6):1991-2001. 
Laschke MW, Mussawy H, Schuler S, Eglin D, Alini M, Menger MD (2010a). Promoting 
external inosculation of prevascularised tissue constructs by pre-cultivation in an 
angiogenic extracellular matrix. European Cells & Materials 20(356-366. 
155 
 
Laschke MW, Strohe A, Menger MD, Alini M, Eglin D (2010b). In vitro and in vivo 
evaluation of a novel nanosize hydroxyapatite particles/poly(ester-urethane) composite 
scaffold for bone tissue engineering. Acta Biomaterialia 6(6):2020-2027. 
Laschke MW, Kleer S, Scheuer C, Schuler S, Garcia P, Eglin D et al. (2012). 
Vascularisation of porous scaffolds is improved by incorporation of adipose tissue-
derived microvascular fragments. European Cells & Materials 24(266-277. 
Laschke MW, Schank TE, Scheuer C, Kleer S, Schuler S, Metzger W et al. (2013). 
Three-dimensional spheroids of adipose-derived mesenchymal stem cells are potent 
initiators of blood vessel formation in porous polyurethane scaffolds. Acta Biomaterialia 
9(6):6876-6884. 
Lee C, Grad S, Gorna K, Gogolewski S, Goessl A, Alini M (2005). Fibrin–Polyurethane 
Composites for Articular Cartilage Tissue Engineering: A Preliminary Analysis. Tissue 
Engineering 11(9-10):1562-1573. 
Li B, Yoshii T, Hafeman AE, Nyman JS, Wenke JC, Guelcher SA (2009). The effects of 
rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on 
new bone formation in rat femora. Biomaterials 30(35):6768-6779. 
Li L, Zhou G, Wang Y, Yang G, Ding S, Zhou S (2015). Controlled dual delivery of 
BMP-2 and dexamethasone by nanoparticle-embedded electrospun nanofibers for the 
efficient repair of critical-sized rat calvarial defect. Biomaterials 37(0):218-229. 
Luvizuto ER, Tangl S, Zanoni G, Okamoto T, Sonoda CK, Gruber R et al. (2011). The 
effect of BMP-2 on the osteoconductive properties of β-tricalcium phosphate in rat 
calvaria defects. Biomaterials 32(15):3855-3861. 
Mardas N, Stavropoulos A, Karring T (2008). Calvarial bone regeneration by a 
combination of natural anorganic bovine-derived hydroxyapatite matrix coupled with a 
synthetic cell-binding peptide (PepGen™): an experimental study in rats. Clin Oral 
Implants Res 19(10):1010-1015. 
156 
 
Matsumoto T, Okazaki M, Inoue M, Yamaguchi S, Kusunose T, Toyonaga T et al. 
(2004). Hydroxyapatite particles as a controlled release carrier of protein. Biomaterials 
25(17):3807-3812. 
McKee CT, Last JA, Russell P, Murphy CJ (2011). Indentation versus tensile 
measurements of Young's modulus for soft biological tissues. Tissue Eng Part B Rev 
17(3):155-164. 
McKoy BE, Kang Q, An YH (1999). Indentation testing of bone. In: Mechanical testing 
of bone and the bone-implant interface. YH An and RA Draughn editors: CRC Press, pp. 
233-240. 
Murakami N, Saito N, Horiuchi H, Okada T, Nozaki K, Takaoka K (2002). Repair of 
segmental defects in rabbit humeri with titanium fiber mesh cylinders containing 
recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer. J 
Biomed Mater Res 62(2):169-174. 
Osathanon T, Linnes ML, Rajachar RM, Ratner BD, Somerman MJ, Giachelli CM 
(2008). Microporous nanofibrous fibrin-based scaffolds for bone tissue engineering. 
Biomaterials 29(30):4091-4099. 
Pirvu T, Blanquer SBG, Benneker LM, Grijpma DW, Richards RG, Alini M et al. 
(2015). A combined biomaterial and cellular approach for annulus fibrosus rupture repair. 
Biomaterials 42(0):11-19. 
Sawyer AA, Song SJ, Susanto E, Chuan P, Lam CXF, Woodruff MA et al. (2009). The 
stimulation of healing within a rat calvarial defect by mPCL–TCP/collagen scaffolds 
loaded with rhBMP-2. Biomaterials 30(13):2479-2488. 
Schofer MD, Roessler PP, Schaefer J, Theisen C, Schlimme S, Heverhagen JT et al. 
(2011a). Electrospun PLLA nanofiber scaffolds and their use in combination with BMP-2 
for reconstruction of bone defects. PLoS ONE 6(9):e25462. 
Schofer MD, Veltum A, Theisen C, Chen F, Agarwal S, Fuchs-Winkelmann S et al. 
(2011b). Functionalisation of PLLA nanofiber scaffolds using a possible cooperative 
157 
 
effect between collagen type I and BMP-2: impact on growth and osteogenic 
differentiation of human mesenchymal stem cells. J Mater Sci Mater Med 22(7):1753-
1762. 
Schwarz F, Ferrari D, Sager M, Herten M, Hartig B, Becker J (2009). Guided bone 
regeneration using rhGDF-5- and rhBMP-2-coated natural bone mineral in rat calvarial 
defects. Clin Oral Implants Res 20(11):1219-1230. 
Sfeir C, Ho L, Doll BA, Azari K, Hollinger JO (2005). Fracture Repair. In: Bone 
Regeneration and Repair: Biology and Clinical Applications. JR Lieberman and GE 
Friedlaender editors. Totowa, NJ: Humana Press Inc, pp. 21-44. 
Shen J-W, Wu T, Wang Q, Pan H-H (2008). Molecular simulation of protein adsorption 
and desorption on hydroxyapatite surfaces. Biomaterials 29(5):513-532. 
Umoh JU, Sampaio AV, Welch I, Pitelka V, Goldberg HA, Underhill TM et al. (2009). 
In vivo micro-CT analysis of bone remodeling in a rat calvarial defect model. Phys Med 
Biol 54(7):2147. 
Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick 
RM, Kerns KM, LaPan P et al. (1990). Recombinant human bone morphogenetic protein 
induces bone formation. Proc Natl Acad Sci U S A. 87(6):2220-2224. 
White D (1978). Tissue substitutes in experimental radiation physics. Med Phys 
5(6):467-479. 
Xie G, Sun J, Zhong G, Liu C, Wei J (2010). Hydroxyapatite nanoparticles as a 
controlled-release carrier of BMP-2: absorption and release kinetics in vitro. J Mater Sci 
Mater Med 21(6):1875-1880. 
Yu YY, Lieu S, Lu C, Miclau T, Marcucio RS, Colnot C (2010). Immunolocalization of 
BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone 46(3):841-
851. 
 
158 
 
 
 
CHAPTER 5 
 
 
 
5 Effect of bone sialoprotein treated nano-
hydroxyapatite/ poly(ester-urethane) scaffolds 
on bone formation 
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5.1 INTRODUCTION 
BSP is an acidic phosphoprotein highly expressed in mineralized tissues such as skeleton 
and dentition (Fisher and Fedarko, 2003; Ganss et al., 1999).  It is also a member of 
Small Integrin-Binding Ligand, N-Linked Glycoprotein (SIBLING) group and a major 
component of non-collagenous proteins in bone.  Similar to other SIBLING proteins, 
BSP contains several highly conserved functional domains.  These included a collagen-
binding domain, two hydroxyapatite nucleation regions and an integrin recognition site 
(RGD motif, which is involved in cell attachment, migration and signaling) (Goldberg 
and Hunter, 2012).  BSP has been previously shown to be a potent nucleator of 
hydroxyapatite (HA) (Hunter and Goldberg, 1993).  In addition, the attached phosphate 
has been demonstrated to be an important modification that regulates the HA nucleation 
potency, in particular at the Serine-136 position (Baht et al., 2010).  
Mice with Bsp gene ablated (Bsp
-/-
) have impaired bone growth and mineralization.  
Early studies by the Malaval group have shown Bsp
-/-
 mice to have shortened long bones, 
decreased bone mineral density, delayed mineral formation, thinner cortical bone 
thickness, and greater trabecular bone volume, as well as reduction in osteoclast 
formation and activity, which resulted in low bone turnover compared to wild type (WT) 
mice (Boudiffa et al., 2010; Malaval et al., 2008).  In femoral defect model, Bsp
-/-
 mice 
also displayed delayed bone repair compared to WT control (Malaval et al., 2009; 
Monfoulet et al., 2010).  All these defects seen in Bsp
-/-
 mice suggest that BSP plays a 
crucial role in bone development and mineralization.  Furthermore, studies reported by 
Wang and Glimcher indicate that BSP promoted new bone formation in vivo (Wang et 
al., 2006; Xu et al., 2007).  In these studies, the collagen-BSP scaffolds were able to 
induce some mineral formation along the dura membrane within 4 days of implantation 
in rat calvarial defect.  In addition, by day 7, cell proliferation, matrix mineralization, and 
angiogenesis were found within the BSP-treated implant.   
The physiological importance of BSP and its functional importance in skeletal 
development has been the main focus of research on BSP.  However, minimal research 
has been done testing BSP as a potential therapeutic reagent for promoting bone repair.  
In this study, we investigate the effectiveness of BSP-treated poly(ester-urethane) (PU) 
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scaffolds in promoting bone repair.  PU based scaffolds have been extensively studied 
and shown to have potential tissue engineering applications in tissues such as bone 
(Hofmann et al., 2008; Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al., 
2014; Lee et al., 2005), and other soft tissue (Gogolewski et al., 2008; Guan et al., 2005; 
Guelcher, 2008; Guelcher et al., 2008) regeneration.  The PU scaffolds are 
biocompatible, biodegradable and have viscoelastic properties for easy physical fitting 
into the bone defects (Hofmann et al., 2008; Laschke et al., 2009; Laschke et al., 2013; 
Lee et al., 2005; Pirvu et al., 2015).  For bone tissue engineering application, nano-sized 
hydroxyapatite (nHA) particles were incorporated into the PU-based (nHA/PU) scaffolds 
to improve the material stiffness (Boissard et al., 2009) and also to increase its capacity to 
bind proteins such as albumin and fibrinogen (Laschke et al., 2010b).     
In this study, in vitro experiments were conducted to determine the amount of BSP that 
can bind onto the nHA/PU scaffolds.  Furthermore, the BSP-treated nHA/PU scaffolds 
were cultured with MSC to validate whether the presence of BSP can improved cells 
attachment.  In addition, rat calvarial defect model will be utilized to validate the 
effectiveness of BSP-treated nHA/PU scaffolds in promoting bone repair.  Micro-
computed tomography (microCT) and histological analysis will be used to monitor the 
rate of bone repair.  
 
 
5.2 MATERIALS AND METHODS 
5.2.1 Scaffold preparation 
The biodegradable PU solution was synthesized in a one-step solution polycondensation 
as previously described in detail (Laschke et al., 2010b).  The process involved the use of 
1,6-hexamethylene diisocyanate (Sigma-Aldrich, Milwaukee, WI), poly(-caprolactone) 
diol (MW = 530 g mol
-1
, Sigma-Aldrich, Milwaukee, WI), and 1,4,3,6-dianhydro-D-
sorbitol as reactants.  Dibutyltin dilaurate (Fluka, Buchs, CH) was used a catalyst for the 
reaction and N,N-dimethylformaide (Fluka, Buchs, CH) was used as a solvent.  To create 
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nHA/PU solution, nHA (Biomaterials US, Ltd., USA) particles, ranging in size from 50 
to 200 nm, were dispersed into a PU solution.  The nHA mass fraction added was 20 
wt.% of the PU solution.  Prior to usage, the nHA particles were washed with ethanol and 
dried at 100°C under vacuum (Laschke et al., 2010b).  Both PU and nHA/PU scaffolds 
were prepared using a salt leaching-phase inverse process as previously described 
(Boissard et al., 2009; Gorna and Gogolewski, 2006; Laschke et al., 2010b).  This method 
involved a vigorous mixing of PU or nHA/PU solution with porogen (sodium phosphate 
heptahydrate dibasic salt; Fluka, Buchs, CH) until a homogeneous paste was obtained.  
The paste was then poured into a cylindrical mould and left exposed to air to allow for 
slow evaporation of the solvents.  The salt was leached out by extensive washing in 
water, which created porous PU or nHA/PU sponges.  In order to produce consistent 
thickness scaffolds, the sponges were cut using water jet system.  In this study, the 
scaffolds were prepared with a circular dimension of 5.5 mm and 1 mm thickness with 
pore sizes ranging from 90 to 300 m.  The scaffolds were washed in ethanol, dried 
under vacuum, and sterilized in ethylene oxide prior to use in the studies.   
 
5.2.2  BSP expression and purification 
Recombinant rat BSP (rBSP) was expressed in Escherichia coli strain BL21(DE3) cells 
and purified by fast protein liquid chromatography (FPLC) as described previously (Baht 
et al., 2010; Tye et al., 2003).  To phosphorylate the protein, rBSP was treated with 
casein kinase 2 (CK2) in reaction buffer [150 mM sodium chloride (NaCl), 10 mM 
magnesium chloride (MgCl2), 1 mM dithiothreitol (DTT), 0.1 mM adenosine 
triphosphate (ATP) and 50 mM tris(hydroxymethyl)aminomethane-hydrochloride (Tris-
HCl); pH 7.4] as described previously (Baht et al., 2010).  Phosphate content was 
determined by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry 
(Department of Biochemistry, UWO, London, ON).   
Native bovine BSP (bBSP) was purified from the long bones of a still-born calf.  The 
procedure followed methods previously described in detail for purification of native rat 
BSP (ratBSP) (Goldberg and Sodek, 1994).  In brief, bone chips were first washed 3 
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times with phosphate buffered saline (PBS) containing proteinase inhibitor (PI) [100 mM 
amino caproic acid, 5 mM benzamidine HCl, 5 mM N-ethyl maleimide, and 1 mM 
phenylmethylsulfonyl fluoride (PMSF)] solutions followed by a series (3-4 times) of 
freeze-thaw cycles for 24 h in order to fracture the bone to allow for removal of inner 
blood and cells from bone cavities.  Then the bone chips were incubated in chloroform-
methanol solution overnight in order to dissolve and remove fats and lipids.  The next 
step involved the extraction of the bone chips with 4.0 M guanidine hydrochloride/Tris-
HCl buffer containing PI (4 x 24 h incubations) to remove unwanted proteins not 
associated with bone mineral.  Finally, the mineral-associated proteins were extracted 
with 0.5M ethylenediaminetetraacetic acid (EDTA)/Tris-HCl buffer containing PI 
solutions (4 x 24 h incubations).  
The extracted protein solution was concentrated using an Amicon ultrafiltration cell and 
YM10 membranes (cut-off, 10 KDa) (EMD Millipore, Etobicoke, ON) with at least 2 
buffer exchanges with Q-buffer A (50 mM Tris-HCl, 7 M urea, pH7.4) chromatography 
solution.  The concentrated protein solution was diluted with Q-buffer A solution and 
then passed through Q Sepharose Fast Flow (Fast Q) column (1 x 10 cm; Pharmacia 
Biotech, GE Healthcare Life Sciences, Mississauga, ON) connected to an FPLC system 
to separate the proteins based on charge.  The proteins were eluted with a linear gradient 
of NaCl (0 - 1.2 M) at a flow rate of 2.5 ml/min.  The fractions containing the proteins of 
interest were then collected and pooled together.  Aliquots of the fractions were also run 
on 12.5% polyacrylamide gels using the Phastgel system (Amersham Biosciences, GE 
Healthcare Life Sciences, Mississauga, ON) to confirm the presence of the protein.  After 
electrophoresis, the gels were stained with Stains-All and silver nitrate (Goldberg and 
Warner, 1997).  The proteins were re-chromatographed on Fast Q column and then 
finally by gel filtration using a Superdex 200 PG column (1.6 x 60 cm; Pharmacia 
Biotech, GE Healthcare Life Sciences, Mississauga, ON) with S-buffer [50 mM 
Tris/HCl, 0.2 M NaCl, and 4 M urea; pH 7.4] to separate proteins based on molecular 
size, as described previously (Goldberg and Sodek, 1994).  The fractions enriched with 
BSP were pooled and dialyzed with 10 mM ammonium bicarbonate for 72 h at 4°C using 
Spectra/Por dialysis membrane (cut-off, 12-14 kDa) (Spectrum Laboratories, Rancho 
Dominguez, CA).  After dialysis, the final solutions were aliquoted and lyophilized.  The 
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purity and quantity of the protein samples were determined using Bicinchoninic acid 
(BCA) assay (ThermoFisher Scientific, Burlington, ON), amino acid analysis 
(Macromolecular Crystallography Facility, Department of Biochemistry, UWO, London, 
ON), and MALDI mass spectrometry (Bruker® Reflex IV MALDI TOF MS, MALDI 
Mass Spectrometry Facility, Department of Biochemistry, UWO, London, ON). 
 
5.2.3 In vitro prBSP binding experiment 
PU and nHA/PU scaffolds were first incubated in 500 l of phosphate buffered saline 
(PBS) solution for 1 h.  The scaffolds were then transferred and incubated with either 5, 
10 or 20 g of phosphorylated rBSP (prBSP) diluted into 60 l of PBS solution for 24 h 
at 4°C.  After 24 h of incubation, the scaffolds were centrifuged and the supernatants 
collected to determine (by sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
(SDS-PAGE) analysis) the amount of unbound prBSP.  The scaffolds were then washed 
with 60 l of PBS solution (4 times, 5 min each time) and 60 l of 0.5 M NaCl solution 
(for 5 min) to remove loosely bound prBSP.  Finally, the prBSP scaffolds were eluted 
from the scaffolds using 60 l of SDS loading buffer.  For SDS-PAGE analysis, 10 l of 
the 60 l supernatants from each step were collected and mixed with 10 l of 2 times 
concentrated SDS loading buffer.  The solutions were denatured at 95°C for 5 min prior 
to loading onto the gels.  The amount of bound prBSP (that were eluted with SDS-PAGE 
loading buffer) was estimated by comparing the relative pixel-to-intensity ratio of the 
stained protein bands with the total of unbound, washed, and eluted bands on the 
acrylamide gels after electrophoresis.   
 
5.2.4  Cell isolation, culture conditions and cell viability 
As previously mentioned, BSP has a RGD motif which plays a role in cell signaling and 
attachment.  In this study, we would like to verify that the presence of BSP on the 
nHA/PU scaffolds may increased the amount of cells bind onto the scaffolds.   
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Three in vitro experiments were done in the study.  In the first experiment, C3H10T1/2 
cells were used to determine the effect of prBSP on cell attachment.  Each nHA/PU 
scaffold was incubated for 24 h at 4°C with either 150 l of PBS solution or 150 µl of 
prBSP-PBS solution (containing 20 g of prBSP).  Approximately 1.2 x 106 of 
C3H10T1/2 cells were seeded onto the scaffold and incubated for 1 h  in culture media.  
The scaffolds were then fixed with 4% paraformaldehyde, sectioned (10 m) and imaged 
using confocal microscopy to determine the number of attached cells.  Three sections 
from each scaffold were assessed for cell numbers with the field of view being 
approximately 1.16 mm
2
.  The total surface area for the scaffold was estimated to be 
approximately 23.76 mm
2
.  Therefore, in order to determine the total numbers of cells, 
the average cells per section was multiplied with the number of sections (in this case 
equal to 100 since the thickness of the scaffold is 1 mm).  A limitation of the technique is 
that the polymer scaffolds are porous and have irregular pore size, which are factors that 
we are unable to include in our total surface area or volume calculation.
 
The second experiment involved the use of mesenchymal stromal cells (MSC).  Bone 
marrow was isolated from male Sprague-Dawley rats (Charles River Laboratories 
International, Wilmington, MA) aged 11-12 weeks (325-375 g) by flushing the tibia and 
femur marrow canal with culture medium consisting of Iscove's Modified Dulbecco's 
Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-
streptomycin and 1% L-glutamine (Life Technologies, Carlsbad, CA).  The MSC were 
cultured in culture medium in 75 mm
2
 (NUNC) flasks at 37°C in 5% CO2  for 3 days, and 
then sub-cultured using 0.05% trypsin-EDTA solution. Cells at passage 2 were used for 
subsequent studies.  
Prior to cell seeding, the nHA/PU scaffolds were incubated for 24 h at 4 °C with either 25 
l of saline solution or 25 µl of prBSP-saline solution (containing 20 g of prBSP).  Rat 
MSC were seeded onto the control and pretreated nHA/PU scaffolds at a density of 3.5 x 
10
5
 cells/scaffold and incubated in 24-well plates (NUNC).  After 1 h incubation, the 
MSC-seeded scaffolds were placed between a sandwich construct consisting of 2 Teflon-
rings in a clean 24-well plate in order to fully immerse the scaffolds in culture medium.  
The MSC-seeded scaffolds were then cultured in differentiating medium consisting of 
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culture medium supplemented with 50 µg/ml ascorbic acid and 2 mM -
glycerophosphate.  The mineralizing media were changed every 2 days for the duration of 
the culture.  
After 4 weeks of culture, the scaffolds were washed with Hank's Balanced Salt Solution 
(HBSS) three times, fixed with 4% paraformaldehyde for 20 min, and processed for 
cryosectioning.  In order to determine the relative level of matrix mineralization, the 
cryosectioned samples were stained for calcium mineral deposition with Alizarin red 
staining solution (1% w/v, Ricca Chemical company, Arlington, TX) for 20 min at room 
temperature.  To remove excess dye, the samples were washed with deionized water for 
three times (5 min incubation time for each wash). 
The third experiment used the same method as the second experiment; however, instead 
of prBSP, bBSP was used. 
   
5.2.5 Animals and surgery 
Male Sprague-Dawley rats (Charles River Laboratories International, Wilmington, MA) 
aged 11-12 weeks (325-375 g) were maintained on a standard rat diet (5P00-Prolab RMH 
3000; LabDiet, St. Louis, MO, USA).  Animal experiments were conducted in 
accordance with guidelines of the Canadian Council on Animal Care (CCAC) and 
Animal Care and Veterinary Services (ACVS), University of Western Ontario.  
Animals were anaesthetized with isoflurane gas and the heads positioned in a stereotaxic 
frame.  The dorsal part of the cranium was shaved, aseptically prepared, and a midline 
incision of approximately 20 mm created.  The skin flaps were kept opened using a 
retractor and the underlying periosteum was removed.  A 5-mm stainless steel trephine 
drill (Salvin Dental Specialties, Charlotte, NC) was used to create circular defects on 
each of the parietal bones, thus creating 2 defects in each rat.  Caution was exercised to 
prevent damage to the dura membrane by adding a custom-made stainless steel sleeve 
(1.5 mm depth shorter) around the trephine drill. In addition, in order to prevent heat 
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damage of the host bone, irrigation with saline solution was done throughout the 
procedure.  The nHA/PU or bBSP treated nHA/PU (nHA/PU/bBSP) scaffolds without 
cells were then implanted and secured in place by double crossing 4-0 Vicryl suture 
attached to the temporalis muscles.  In order to prevent any contamination, both defects 
in each rat were implanted with scaffolds of the same treatment group.  The skin was 
closed using 4-0 Silk suture.  Antibiotics and analgesic were administered to the animals 
and they were allowed to recover for up to 12 weeks post surgery, after which they were 
euthanized with CO2 gas inhalation according to CCAC and ACVS guidelines.  At 0, 2, 6 
and 12 weeks, in vivo microCT analysis was performed, as described below.  In addition, 
at 6 and 12 weeks, the rats were euthanized with CO2 and then the implants with 
surrounding bone were collected, fixed with 10% buffered formalin overnight at 4°C, and 
prepared for histology.   
 
5.2.6 In vivo micro-computed tomography analysis 
At intervals of 2 weeks, animals were anaesthetized with isoflurane gas and placed in a 
microCT scanner (eXplore speCZT; GE Healthcare, London, ON).  The scans were 
performed using a standardized live-animal protocol (90 kVp, 40 µA, 900 views, 16 ms 
per view).  Images were reconstructed at a spatial resolution of 50 m and calibrated with 
a cortical bone phantom (SB3; Gammex RMI, Middleton, WI) having a hydroxyapatite 
equivalent of 1,100 mg/cc (White, 1978).  Data were analyzed with MicroView ABA 
version 2.2 (GE Healthcare).  
In order to visually determine new bone formation, the 2D Maximum Intensity Projection 
(MIP) and 3D isosurface images of the rat calvarial bones defect sites were constructed.  
As for the quantification of the newly formed bone, a cylindrical region of interest (ROI, 
5 mm x 1.5 mm) was positioned within the center of each defect site.  The bone mineral 
content (BMC) within the ROI was determined linearly by assigning a value threshold for 
air (-1000 Hounsfield unit (HU)), water (0 HU), soft tissues (below 700 HU), trabecular 
bone (above 700 HU), cortical bone (above 1700 HU) and SB3 phantom (2700 HU).  The 
total new bone volume (BV) formation was determined by adding all the voxels with HU 
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value above 700 within the ROI.  Bone-to-total tissue volume ratio (BV/TV) was 
determined by calculating the ratio of total voxels with HU value above 700 over the total 
voxels of the ROI.  As for the cortical bone volume (CBV), only voxels with HU above 
1700 were considered for calculation.  Twenty calvarial defects were measured at 2 and 6 
weeks and twelve calvarial defects were measured at 12 weeks for each group. 
 
5.2.7 Histological Analysis 
The parietal bones were fixed with 10% formalin for 24 h and then decalcified in 0.65 M 
ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate, pH 7.4, at 37°C for 2 
weeks.  After dehydration, the samples were embedded in paraffin, and sectioned at 5 m 
thickness.  The sagittal sections were stained with hematoxylin and eosin (H&E). The 
amount of bone formation was quantified at the center sections of the implants.   
 
5.2.8 Statistical Analyses 
Quantitative data were expressed as mean ± standard error.  Statistical analyses among 
groups were performed using two-way analysis of variance (ANOVA) and Bonferroni 
post-tests with Prism 5 version 5.03 (GraphPad Software, La Jolla, CA).  p<0.05 was 
considered to be statistically significant. 
 
 
5.3 RESULTS 
5.3.1 bBSP expression and purification 
The extracted protein solution from the bovine bone was first passed through Fast Q 
column and eluted with a linear NaCl gradient in order to separate the proteins based on 
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charge.  At pH 7.0, bovine osteopontin (bOPN) and bBSP enriched fractions (proteins are 
eluted in overlapping peaks) were collected (Figure 5.1).  PhastGel electrophoresis was 
performed to confirm the presence of bOPN and bBSP in the fractions (data not shown).  
The collected fractions, with the highest concentration of bBSP, were pooled, 
concentrated, and re-chromatographed on Fast Q Sepharose column to further purify the 
protein (data not shown).  The bBSP enriched fractions were pooled, concentrated, and 
applied to a Superdex gel filtration column to separate proteins based on molecular size 
(Figure 5.2).  Based on the SDS-PAGE analysis, fractions (14-19) with the highest 
concentration of bBSP were pooled, concentrated and re-chromatographed on the 
Superdex 200 PG column to increase the purity of bBSP (Figure 5.3).  Fractions 14-18 
from the second Superdex run were combined, dialyzed and lyophilized.  Aliquots were 
analyzed by amino acid analysis to determine protein content, and relative purity.   
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Figure 5.1.  Separation of bone proteins by ion exchange chromatography. 
Extracted solution containing various bone proteins were passed through Q Sepharose 
Fast Flow column connected to the FPLC system.  The proteins were eluted with a    
linear gradient of NaCl (0-1.2M).  Fractions containing bBSP and bOPN were collected, 
pooled, and re-chromatographed on the Q-Sepharose column.  The bBSP and bOPN 
were eluted when the concentration of the NaCl at approximately 0.40-0.45M.           
Absorbance at 230 and 280 nm were determined.  
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Figure 5.2.  Separation of bBSP using Superdex 200 PG gel filtration column.   
The fractions from Q-Sepharose chromatography enriched in bBSP were pooled and run 
on a Superdex gel filtration column.  Fractions enriched in bBSP (Fractions 14-19; 
~75KDa) were pooled, concentrated and rechromatographed on the gel filtration column 
(Fig.2.3) Absorbances at 230 and 280 nm were measured.  
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Figure 5.3.  Re-purification of bBSP using Superdex 200 PG gel filtration column. 
The pooled fractions, which contain mainly bBSP were re-chromatographed on Superdex 
200 PG column, and samples analyzed by SDS-PAGE (inset).  Fractions 14-18             
representing the ‘cleanest’ fractions enriched in bBSP were pooled and used for future 
study.  
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5.3.2 Addition of nHA improved prBSP binding to the PU-based 
scaffold  
To be generally effective in tissue regeneration, scaffolds should demonstrate a 
propensity to bind and slowly release the added factors.  Our binding experiments 
demonstrated that prBSP are able to bind well to PU-based scaffolds.  The PU scaffolds 
were incubated with prBSP, followed by elution with 0.5 M NaCl which was unable to 
elute the bound prBSP (Figure 5.4).  Based on the relative intensity for both 5 and 10 µg 
prBSP loading onto scaffold, it was estimated that maximum binding to the PU scaffold 
was approximately 2.5 g of prBSP (Table 5.1 and Figure 5.4).  The addition of nHA to 
the PU scaffold was able to increase the binding capacity.  Approximately 7 g of bound 
prBSP appears to be the limit for nHA/PU scaffolds since loading 10 or 20 g of prBSP 
gave similar binding capacity (Table 5.1 and Figure 5.5). 
 
  
 173 
 
Figure 5.4.  SDS-PAGE analysis of prBSP binding to PU scaffold.   
The binding capacity of the prBSP on the PU scaffold was determined using a SDS-
PAGE based assay.  During the assay, a series of washes as indicated was done on the 
prBSP-treated PU scaffold to remove unbound or weakly bound prBSP.  Two concen-
trations of prBSP - 5 g (Left image) and 10 g (Right image) were used.  The amount 
of bound prBSP was estimated by comparing the relative pixel to intensity ratio of the 
SDS-eluted prBSP band with the total of unbound and from washes, and the intensity to 
the control 0.5µg of prBSP.  
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Figure 5.5.  SDS-PAGE analysis of prBSP binding to nHA/PU scaffold.   
The binding capacity of the prBSP on the nHA/PU scaffold was determined using a 
SDS-PAGE-based assay.  During the assay, a series of washes was done on the prBSP 
treated nHA/PU scaffold to remove unbound or weakly bound prBSP.  Two              
concentrations of prBSP - 5 g (Left image) and 10 g (Right image) were used.  The 
amount of bound prBSP was estimated by comparing the relative pixel to intensity ratio 
of the SDS-eluted prBSP band with the total of unbound and washes and the intensity to 
the control 0.167µg of prBSP. 
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Table 5.1.  Estimation of bound prBSP for each treatment group.   
The amount of bound prBSP was estimated by comparing the relative pixel to intensity 
ratio of the SDS eluted prBSP band with the total of unbound, washed, and the control 
prBSP sample.  The assumption was that the total amount of prBSP loaded equaled the 
combined pixels to intensity ratio of unbound, washed, and eluted prBSP.  
 
 
Number of pixels Intensity (Mean) 
Pixels to intensity 
ratio 
 
Sample 
Unbound 
prBSP 
Washed 
prBSP 
Eluted 
prBSP 
Unbound 
prBSP 
Washed 
prBSP 
Eluted 
prBSP 
Unbound 
prBSP 
Washed 
prBSP 
Eluted 
prBSP 
Bound 
prBSP 
(µg) 
PU + 5 µg 
prBSP 
4245 1731 4156 30.22 134.05 29.14 140.47 12.91 142.62 2.41 
PU + 10 µg 
prBSP 
5911 1451 3889 15.28 24.58 25.38 386.85 59.03 187.84 2.56 
nHA/PU + 
5 µg prBSP 
1535 - 5341 66.48 - 45.56 23.09 - 117.23 4.18 
nHA/PU + 
10 µg 
prBSP 
4914 - 8075 79.86 - 48.4 61.53 - 166.84 7.31 
nHA/PU + 
20 µg 
prBSP 
9775 4670 8389 105.54 154.28 117.95 92.62 30.27 71.12 7.33 
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5.3.3 The addition of BSP improved cell attachment and appeared to 
have increased mineral formation 
The C3H10T11/2 mouse cell line was used to study cell attachment and mineral 
formation in the HA/PU scaffolds.  After only 1 h of incubation, the presence of prBSP 
increased the number of cells attached to the scaffold by a factor of 5 (Figure 5.6, Table 
5.2).  Other in vitro studies have shown that the addition of recombinant human BSP 
(rhBSP) to MSC, in the presence of osteogenic media, drive osteogenic differentiation 
into osteoblasts (Xia et al., 2011).  Our experiments with MSC culture demonstrated that 
the presence of prBSP or bBSP on nHA/PU scaffold appeared to have enhanced mineral 
formation compared to their respective control groups (Figure 5.7 and 5.8).  In addition, 
these result also indicate that due to the highly conserved nature of BSP, its functional 
properties are similar regardless of the species source.  
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Figure 5.6.  The effect of prBSP treated nHA/PU scaffold cultured with C3H10T1/2 
cells. 
nHA/PU scaffolds were either untreated or treated with 150 μl of prBSP-PBS solution 
(containing 20 µg of prBSP).  Approximately, 1.2 x 106 C3H10T1/2 cells were seeded 
onto the scaffold and then incubated for 1 hr and fixed with 4% PFA.  Confocal image 
of the sectioned scaffold suggests that prBSP treated nHA/PU scaffolds had higher cell 
attachment compared to control group.  Blue is DAPI staining of cell nuclei. 
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Table 5.2.  The effect of BSP on cell attachment to the nHA/PU scaffold.   
The presence of BSP increased the number of attached cell to the nHA/PU scaffold. 
 
Treatment group 
Total number of cell in 
the polymer (10
5
) 
Percentage of cell 
attached (%) 
nHA/PU 0.70 5.80 
nHA/PU/prBSP 3.42 28.50 
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Figure 5.7.  Effect of prBSP on nHA/PU cultured with MSC for 4 weeks.   
After 4 weeks, the scaffolds were fixed, cryosectioned, and stained with alizarin red.  
Compared to the control group, the nHA/PU/prBSP group appeared to demonstrate more 
alizarin red staining, which suggest an increased in mineral formation. Note: The three 
images in each group are from different scaffolds. 
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Figure 5.8.  Effect of bBSP on nHA/PU cultured with MSC for 4 weeks. 
The images in panel A1-2 and B1-2 represent transverse and cross-sectional sections, 
respectively, of control and bBSP treated nHA/PU scaffolds stained with alizarin red.  
After 4 weeks, the scaffolds were fixed, cryosectioned, and stained with alizarin red.  
Compared to the control group, the nHA/PU/bBSP cryosections qualitatively appeared 
to have more alizarin red staining, which may be due to an increase in osteogenic     
mineralization.  
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5.3.4 bBSP treated nHA/PU scaffolds are not effective in promoting 
bone repair  
An established calvarial defect model was used to determine the effectiveness of the 
bBSP treated nHA/PU scaffolds in promoting in vivo bone repair.  At 2, 6, and 12 weeks 
after implantation, the nHA/PU/bBSP group showed similar bone mineral content 
(BMC), new total bone volume (BV), percentage of bone-to-tissue volume (BV/TV), and 
percentage of cortical bone volume compared to the control group (Figure 5.9).  In both 
groups, minimal bone in-growth into the defects from host bone and some island-like 
bone spicules were observed (Figure 5.10).  Occasionally, higher bone formation was 
observed in nHA/PU/bBSP group; however, this was also observed in the control group 
(Figure 5.11).  In agreement with the microCT data, the histological analysis of 
nHA/PU/bBSP groups also indicated a similar observation compared to control group 
(Figure 5.12).  In contrast, the rhBMP-2 treated nHA/PU group, which is the positive 
control group was able to promote bone repair as indicated in Chapter 4. 
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Figure 5.9.  Quantitative microCT analysis of bone repair.   
The microCT analysis of (A) bone mineral content (BMC); (B) new bone volume; (C) 
percentage of bone-to-tissue volume and (D) percentage of cortical bone volume were 
similar for both nHA/PU/bBSP group and nHA/PU group at 2, 6, and 12 weeks. The data 
suggest that bBSP are not effective in promoting bone repair.  Data represents mean ± 
standard error (n=20  for 2 and 6 weeks, n=12 for 12 weeks) 
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Figure 5.10.  MicroCT images of bone repair in rat calvarial defects from 0 to 12 
weeks post-op.   
Maximum intensity projection (MIP) images of both nHA/PU and nHA/PU/bBSP 
demonstrated a similar healing pattern.  Both groups often demonstrated variable results 
as presented in the two representative images for each group.  The white arrowheads 
referred to the island-like bone formation seen in the defect. 
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Figure 5.11.  MicroCT images of bone repair in rat calvarial defects after 12 weeks 
post-op. 
Maximum intensity projection images of both nHA/PU and nHA/PU/bBSP demonstrated 
a similar healing pattern.  These are additional images from 2 different pair of rats.  Both 
groups demonstrated variable results in bone formation.  
 188 
 
Figure 5.12.  Histological analysis of rat calvaria at 12 weeks. 
H&E stained sectioned of nHA/PU/bBSP and nHA/PU groups demonstrated similar 
bone repair response even after 12 weeks post-op. Minimal island-like new bone        
formation are observed in the defect site as marked by black arrows. No apparent major 
inflammation can be seen in any of the groups.  These results suggest that BSP is not a 
potent promoter of bone repair. 
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5.4 DISCUSSION 
In tissue engineering, prevalent strategies to enhance bone repair utilize osteoconductive 
biomaterials in combination with osteoinductive growth factors or bioactive proteins.  
This study was designed to evaluate the effectiveness of BSP-treated nHA/PU scaffolds 
for guided bone regeneration using a rat calvarial defect model.  BSP is an extracellular 
matrix protein present in mineralized tissue such as bone and dentition.  The expression 
of BSP in mineralized tissues is upregulated at the onset of mineralization.  Previous 
studies have shown that the presence of BSP enhances osteoblast differentiation and HA 
nucleation in vitro (Cooper et al., 1998; Zhou et al., 1995).  In addition, other studies 
have also provided evidence for the role of BSP in bone formation, in which the authors 
demonstrate that the presence of BSP enhanced bone repair in vivo (Wang et al., 2006; 
Xu et al., 2007).   
The presence of BSP in the PU based scaffold is able to promote cell attachment and 
differentiation, which in turn led to the improved overall osteogenic mineralization in 
vitro.  The addition of nHA was able to significantly improve the PU-based scaffold 
capability to bind BSP.  These results confirmed the effectiveness of nHA/PU scaffold as 
a carrier for bioactive proteins.  Unfortunately, in spite of the promising in vitro results, 
our data indicated that, in our model, the presence of BSP was not effective in promoting 
bone regeneration in vivo; suggesting that BSP is not a potent promoter of bone repair.  
 
5.4.1 The presence of BSP enhanced mineral formation in vitro; 
however, BSP is not effective for bone repair in our in vivo 
model. 
In the literature, there are few studies on the potential role of BSP as a therapeutic reagent 
to promote bone repair.  However, over the years, various in vitro studies have postulated 
for an important role of BSP in biomineralization and bone development.  Previous 
studies including from our group were able to identify the three functional regions of BSP 
[collagen binding, HA nucleation, and integrin recognition (RGD)] that play important 
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roles in biomineralization as described in (Goldberg and Hunter, 2012).  In addition, 
various in vitro studies were able to demonstrate that BSP promotes cell proliferation and 
differentiation to osteoblasts, which led to increase osteogenic mineralization in culture 
(Cooper et al., 1998; Gordon et al., 2007; Xia et al., 2011; Zhou et al., 1995).  In vivo 
studies demonstrated that Bsp
-/-
 mice have a bone phenotype, which include lower bone 
density, shorter long bone length, thinner femoral cortical bone (Malaval et al., 2008), 
and slower bone repair process (Malaval et al., 2009; Monfoulet et al., 2010).  
Furthermore, the use of BSP bound to native but not denatured collagen in an in vivo 
bone repair model was effective in promoting bone repair (Wang et al., 2006; Xu et al., 
2007).  These latter authors indicated that bovine BSP-treated collagen scaffold in rat 
calvarial defects was able to promote early mineral deposition within the first 4 days, 
followed by new bone formation over time.  These findings led us to believe that BSP 
can be a good therapeutic reagent for bone repair since it plays an important role in 
mineralization and maintains homeostasis during bone remodeling (Ganss et al., 1999; 
Goldberg and Hunter, 2012). 
In our study, we investigated the potential use of BSP-treated nHA/PU scaffolds in bone 
repair.  Previous studies indicated that long term delivery of growth factors such as bone 
morphogenetic-2 (BMP-2) has resulted in greater amount of bone formation compared to 
a shorter term delivery (La et al., 2010).  The authors showed the importance of 
continuous presence of the BMP-2 in the system during bone repair.  For this study, we 
believed that the presence of BSP throughout the bone repair was also crucial; therefore 
increasing the BSP binding capability of the PU scaffold was determined to be a 
necessity.  Previous studies had shown that the addition of nHA improved the adsorption 
of bovine serum albumin, fibrinogen, and other proteins derived from fetal calf serum to 
the scaffold (Laschke et al., 2010b).  Our results confirmed that the addition of nHA 
particles also increased the level of BSP bound to the nHA/PU scaffold.  Furthermore, 
our binding studies demonstrated that the elution step with high salt was unable to 
remove the additional BSP from the nHA modified PU scaffolds, suggesting that the BSP 
was tightly bound to the exposed hydroxyapatite.  Of relevance, hydroxyapatite is a well-
established material used in chromatographical purification since it has significant protein 
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binding properties (Matsumoto et al., 2004; Shen et al., 2008; Xie et al., 2010).  The data 
from the binding studies suggest that nHA/PU scaffold is an effective carrier for BSP.  
The addition of either prBSP or bBSP to the scaffolds was able to enhance cell 
attachment and mineral formation in our in vitro cultures compared to the control group.  
The integrin recognition region (RGD sequence) near the C-terminus of BSP likely 
contributed to the recruitment and attachment of cells onto the scaffold.  RGD motifs are 
known to mediate cell attachment and signaling for differentiation and migration since it 
interacts with the αvβ3 integrin, a cell-surface receptor present in both osteoblasts 
(Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992).  Furthermore, other in vitro 
studies also indicated that the addition of BSP was found to improve the overall 
osteoconductivity of implants made from various materials such as titanium, ceramic, and 
synthetic polymer and enhanced cell attachment (Graf et al., 2008; O'Toole et al., 2004).  
These in vitro results were promising and together with previous demonstration of BSP 
promoting in vivo bone repair (Wang et al., 2006), led us to perform in vivo experiments 
using rat calvarial defect model to monitor the effect of BSP in bone repair. 
Analysis of the implanted BSP-treated nHA/PU scaffolds in rat calvarial defects resulted 
in no significant differences in new bone formation compared to the control group.  The 
results of both prBSP and bBSP-treated scaffold were variable, in which moderate 
amount of island-like bone formation were observed on occasion in the defect site; 
however, most of the time only minimal bone formation were observed.  These surprising 
results prompted us to look at the use of collagen scaffold instead of nHA/PU scaffold to 
re-confirm the positive result from previous published studies (Wang et al., 2006; Xu et 
al., 2007).  However, similar to BSP-treated nHA/PU scaffold, BSP-treated collagen 
scaffold did not enhance bone formation compared to the respective control group (data 
not shown, n=4).  Of relevance, other in vivo studies also indicate that the presence of 
BSP did not significantly enhanced the efficiency of bone formation (Schaeren et al., 
2010) or improved the strength of implant-bone integration (O'Toole et al., 2004).  
Similar to our study, the authors demonstrated that in the in vitro setting the presence of 
BSP induced cell differentiation and osteogenic mineralization.  However, in their in vivo 
system, BSP was not effective in enhancing bone repair.   
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In order to understand how the Glimcher group (Wang et al., 2006; Xu et al., 2007) was 
able to show that BSP promoted bone repair in vivo, we contacted the authors responsible 
for the study (Glimcher is deceased).  In contrast to what was indicated in their 
manuscripts (Wang et al., 2006; Xu et al., 2007), succinimide was added to the BSP-
collagen incubation solution, which immobilized the BSP through covalent linkage to the 
collagen (E. Salih, personal communication).  The use of succinimide, which is a potent 
cross-linking agent was not indicated in the relevant manuscripts.  Confirmation of this 
knowledge, as well as additional information regarding the relatively poor potency of 
BSP and collagen mixtures to promote bone repair in vivo was also obtained (J. Wang, 
personal communication).  It has been documented that immobilization of anionic 
peptides or proteins to a surface promotes nucleation since the overall negative charges of 
the protein will attract and bind calcium, which will initiate mineral formation by itself.  
For example,  phosphorylated acidic peptides have been demonstrated to act as nucleators 
of HA when immobilized on a surface (Saito et al., 1997).  It is well known that the 
implantation of mineral in bone defects, either hydroxyapatite or calcium carbonate, is 
relatively effective in initiating bone repair (Fu et al., 2013; Parizi et al., 2013).  Thus the 
initiation of mineral deposition in the calvarial defects that was evident in the Wang et al. 
study, may have been the required prerequisite to initiate the remodeling sequence that 
would ultimately drive the bone repair that was observed in their study.  While BSP binds 
tightly to collagen, it is quite possible that the HA nucleating regions in BSP are less 
susceptible to blood derived enzymatic activity if crosslinked to collagen.  Enzymatic 
activity would normally be elevated during the initial stages of repair.  
Our recent studies have shown that some of the Bsp
-/-
 mice bone defects reported by the 
Malaval group are related to malnourishment (Soenjaya et al., 2015).  The absence of 
BSP resulted in defective acellular cementum formation (Foster et al., 2013b), which in 
turn destabilized the periodontium, causing periodontal breakdown and tooth 
malocclusion.  As a result the Bsp
-/-
 mice were not able to feed properly.  When given a 
soft food diet, many of the bone phenotypes were reversible.  These results suggested that 
Bsp
-/-
 mice do not have a major bone phenotype as described in the previous studies done 
by the Malaval's group.  In spite of the ineffectiveness of BSP in enhancing bone repair in 
our study, BSP has still been shown to be relevant for bone development since delayed 
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mineralization were observed in fetal or young long bones (Holm et al., 2015) and 
craniofacial bones (Foster et al., 2015) of Bsp
-/-
 mice.  In addition, absence of BSP was 
also shown to negatively affect the rate of bone repair and cause reduced osteoclast 
activity (Malaval et al., 2008; Monfoulet et al., 2010).  Therefore, there is a possibility 
that BSP may be more relevant in promoting osteoclast formation and maintaining 
osteoclast activity.  If this process is delayed, then bone turnover will also be delayed. 
In summary, this study showed that BSP can bind effectively onto the nHA/PU scaffold 
and the presence of BSP resulted in improved cell attachment and osteogenic 
mineralization in vitro.  These results confirmed that nHA/PU scaffold is an effective 
carrier for bioactive proteins.  However, in spite of the encouraging observation in the in 
vitro experiments, our in vivo studies using the calvarial defect model indicate that BSP 
by itself is not an effective therapeutic reagent for enhancing bone repair.   
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6 Discussion 
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6.1 DISCUSSION 
Development and repair of skeletal tissue and its subsequent mineralization involve 
complex processes and cell-cell interaction.  During the onset of mineralization, the 
expression of bone sialoprotein (BSP) is up-regulated in mineralized tissues such as the 
bones and teeth (Fisher and Fedarko, 2003; Ganss et al., 1999).  Our previous studies 
have been focused on determining the functional roles of BSP in biomineralization.  
These include the demonstration that BSP has three highly conserved functional regions: 
1) collagen-binding region, 2) two HA-nucleation regions, and 3) an integrin recognition 
region (Goldberg and Hunter, 2012).  However, we still have yet to determine which one 
or combination of the three functional regions is the most critical for biomineralization 
and bone formation.  The nucleating regions of BSP were found to not only contribute as 
HA nucleation sites (Hunter and Goldberg, 1993) but also allow for binding to HA  
(Goldberg et al., 2001; Stubbs et al., 1997).  The phosphorylation of BSP was verified to 
be a very important modification of BSP since this regulated the HA nucleation potency, 
especially at the Serine-136 position (Baht et al., 2010).  Additional studies demonstrated 
that the HA nucleation potency of BSP is further enhanced when it is bound to collagen 
(Baht et al., 2008).  This suggests that the combination of collagen binding and HA 
nucleation regions might potentially be important for bone formation.  The integrin 
binding region (RGD motif) of BSP has been previously shown to mediate cell 
attachment to the matrix and cell signaling as well as contributing to differentiation of 
osteoprogenitor cells to osteoblasts and their migration (Gordon et al., 2007).  The RGD 
motif is recognized by cell-surface receptors, in particular the αvβ3 integrin, which are 
present in both osteoblasts (Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992).   
In recent years, the physiological relevance of BSP in skeletal development has also been 
investigated by other research groups using the Bsp
-/-
 mouse model.  In various in vivo 
studies, Bsp
-/-
 mice were found to have impaired bone growth and mineralization.  The 
observed bone phenotype includes: shortened long bone, delayed mineral formation, 
reduced bone mineral density, and thinner cortical bone thickness compared to WT mice 
(Malaval et al., 2008).  The absence of BSP was also found to negatively affect osteoclast 
formation and activities (Boudiffa et al., 2010; Malaval et al., 2008), which in turn 
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reduced bone turnover.  As a result, Bsp
-/-
 mice also displayed delayed bone repair 
compared to WT mice (Malaval et al., 2009; Monfoulet et al., 2010).  Furthermore, 
previous studies had indicated that BSP is a promising therapeutic reagent for bone 
repair.  Using a rat calvarial model, the authors were able to induce osteoprogenitor cell 
recruitment and early mineralization at the defect site when it was implanted with BSP-
treated collagen scaffold (Wang et al., 2006; Xu et al., 2007).  All of these studies 
provided strong evidence for BSP playing an important role in bone development and 
mineralization.  
Bone is not the only mineralized tissue that expresses BSP.  Studies have shown that BSP 
is also present in both acellular and cellular cementum (Macneil et al., 1994; McKee et 
al., 1996), however the role of BSP in cementum development is undefined.  The 
acellular cementum is a thin layer of mineralized tissue that covers the cervical portion of 
the tooth root.  This tissue layer has been shown to be important in maintaining the 
attachment of the periodontal ligament (PDL) to the tooth root surface (Bosshardt, 2005; 
Foster et al., 2007).  In contrast, the cellular cementum is a bone-like tissue covering the 
apical portions of the tooth root.  During normal root formation, cementoblasts express 
and secrete BSP which led us to postulate that it likely contributes to cementum 
formation and mineralization (Macneil et al., 1995; Somerman et al., 1990).  
The purpose of this thesis project was to further understand the role of BSP in the 
periodontal development and its potential as a therapeutic reagent for bone repair.  The 
information gained from these studies will allow us to potentially design a new novel 
therapeutic peptide, based on BSP functional regions, for use in enhancing periodontal 
and bone repair. 
 
Role of BSP in mineralized tissue development 
In the absence of BSP, we demonstrated that acellular cementum formation is severely 
affected (chapters 2 and 3).  Bsp
-/-
 mice have severe periodontal tissue breakdown, 
marked by defective acellular cementum on both of the molar and incisor roots.  The 
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acellular cementum appeared hypomineralized and detachment was observed at the 
acellular cementum-PDL interface (Foster et al., 2013b).  The PDL detachment from the 
cementum likely contributed to the observed disorganization of PDL Sharpey's fibers, 
increased epithelial down-growth into the detached space, and tooth malocclusion.  The 
destabilization of the periodontium eventually resulted in extensive root and alveolar 
bone resorption (Foster et al., 2013b).  In comparison, under normal conditions, PDL 
fibers inserted into the cementum, anchor and stabilize the tooth.  Previously, our group 
demonstrated that BSP has a high binding affinity site to collagen (Tye et al., 2005), and 
its HA nucleation potency is significantly increased (10-fold) when bound to collagen 
(Baht et al., 2010).  Thus, BSP may function as a glue at the cementum-PDL interface 
while promoting proper mineralization of the tissue, which in turn, provides stabilization 
of the tissue.  Histological analyses indicated that the structural defect only occurs at the 
acellular cementum-PDL interface.  The alveolar bone-PDL interface appears to be 
unaffected by the absence of BSP (Foster et al., 2015); which may be due to the cellular 
nature of bone and presence of possible compensatory mechanisms in bone but not in 
acellular cementum.  Of relevance, the phenotype of the Alpl
-/-
 mouse was also that of 
deficient acellular cementum formation due to the loss of TNAP function that led to 
increased levels of pyrophosphate, which is a potent inhibitor of mineralization (Beertsen 
et al., 1999; Foster et al., 2013a; McKee et al., 2011b).  In addition, other studies have 
demonstrated that the reduction in the level of pyrophosphate promotes acellular 
formation (Foster et al., 2011; Foster et al., 2013a).  Similar to that in bone matrix, the 
presence of various growth factors such as transforming growth factor-β, bone 
morphogenetic proteins (BMPs), and fibroblast growth factor were also observed in the 
cementum matrix.  However, the acellular cementum, which lacks cementocytes, does 
not have a similar distribution of these growth factors compared to cellular cementum 
and bone (Bosshardt, 2005).  These findings suggest that the acellular cementum is 
strongly regulated by the physicochemical level of mineralization.  Thus, the absence of 
BSP, which binds well with collagen and is involved in hydroxyapatite nucleation and 
growth, likely has directly weakened the acellular cementum that led to PDL detachment 
observed in Bsp
-/-
 mice.  
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Periodontal tissue breakdown is usually associated with periodontal disease due to 
infection.  However, in the Bsp
-/-
 mice no apparent inflammatory response was observed 
in the periodontal ligament or adjacent tissues, suggesting that the defect was likely due 
to failure in the function of the periodontium.  These findings prompted us to investigate 
whether occlusal stress contributes to the periodontal breakdown and tooth malocclusion 
observed in Bsp
-/-
 mice.   
All of the mice in this study were fed either the standard hard diet (HD) or powdered soft 
diet (SD), which should reduce the stress applied to the periodontium during mastication.  
As expected, similar to previous study (chapter 2), Bsp
-/-
 mice fed with HD were found to 
have higher incident of tooth malocclusion, were smaller in size [long bone length and 
body weight], and had elevated serum alkaline phosphatase (ALP) activity compared to 
WT mice.  The substitution of SD was able to reduce the severe incisor malocclusion rate 
by a factor of 10-fold, suggesting that excessive occlusal loading contributed to the 
malocclusion phenotype of Bsp
-/-
 mice.  In addition, the Bsp
-/-
 mice fed with SD appeared 
to have normal body weight, long bone length, and serum ALP activity compared to WT 
mice.  These results indicated that Bsp
-/-
 mice do not have a major bone phenotype as 
previously described by Malaval's group.  These bone phenotypes are likely related to 
malnourishment due to difficulty of the mice to consume standard HD (Soenjaya et al., 
2015).  Another factor to consider is that litter mate controls were used in all of our 
studies; in contrast, Malaval's group did not, as indicated by different color mice 
(between groups) used in their recent study (Bouleftour et al., 2014), but also evident in 
their other publications.  Other studies have demonstrated that undernutrition negatively 
influences immune function (Chan et al., 1996), growth (Lifshitz, 2009) and offspring 
neurodevelopment  (Akitake et al., 2015), behavior and fertility (Rios et al., 2005), and 
intuitively breeding and nursing capabilities.  We did not observe any significant issues 
with these characteristics in our Bsp
-/- 
mouse colony.  However, in contrast, Malaval's 
group have reported uncharacteristic nesting behavior of their Bsp
-/-
 mice colony 
compared to WT mice (Bouleftour et al., 2014), presumably due to malnutrition.  
Changing the diet was not able to prevent PDL detachment, tooth malocclusion, and 
periodontal breakdown in Bsp
-/-
 mice.  Furthermore, regardless of diet group, Bsp
-/-
 mice 
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have lower rates of incisor eruption compared to WT mice, which is likely due to lack of 
acellular cementum formation and the associated periodontal detachment.  In addition, a 
small preliminary study on older Bsp
-/-
 mice (above 1 yr old), indicate that odontoma-like 
nodules are present at the apical end of the incisors (data not shown).  These unusual 
features are not yet fully understood, however, we postulate that it is caused by the 
inability of the mouse incisor to properly erupt due to the defects at the PDL-acellular 
cementum interface.  Over time, the cumulative occlusal stress from mastication possibly 
has caused the cementum-PDL interface to become progressively weaker, and thus less 
resistant to the forces.  This might have pushed the continually developing incisor inward 
or into the socket, which resulted in the continuously forming dentin and enamel to be 
deposited around the apical end of the incisor.  These results demonstrate the importance 
of BSP in maintaining proper periodontal structure and function and alveolar bone 
remodeling, and point to dental dysfunction as causative factor of skeletal defects 
observed in Bsp
-/-
 mice.   
 
Potential use of nHA/PU scaffold and BSP for bone regeneration therapy 
The second half of the thesis [Chapter 4 and 5] focused on the role of BSP as a 
therapeutic reagent to enhance bone repair.  As mentioned before, previous studies done 
by the Glimcher's group indicated that the addition of BSP in a collagen scaffold was able 
to promote early mineralization in rat calvarial defect model and promoted bone repair 
that was evident after a month (Wang et al., 2006; Xu et al., 2007).  For our study, a 
similar rat calvarial defect model was used.  However, novel PU and nHA/PU scaffolds 
developed by our collaborators, David Eglin and Mauro Alini (AO Foundation) were 
used instead of collagen scaffolds.  The first step of the study was to determine whether 
the scaffolds could be effective carriers for growth factor and bioactive proteins.  Both 
the PU and the nHA/PU scaffolds have previously been demonstrated to be 
biocompatible and effective for tissue regeneration (Hofmann et al., 2008; Laschke et al., 
2009; Laschke et al., 2010b).  The PU-based scaffold has been shown to be 
osteoconductive and also able to bind bioactive proteins.  The addition of nHA particles 
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was found to be have additional capacity to bind serum proteins (Boissard et al., 2009).  
Our in vitro experiments verified that nHA/PU scaffolds had a threefold higher binding 
capacity for BSP than PU scaffolds alone.  Of relevance, other studies have shown that 
during bone repair, long term delivery of growth factor resulted in a greater amount of 
bone formation than a scaffold that would release the factor over a shorter time period 
(La et al., 2010).  Thus, the use of a scaffold with higher binding capacity, and potentially 
with increased affinity, was relevant in our bone repair model.  Furthermore, previous 
studies have also demonstrated that the PU scaffolds were able to promote angiogenesis 
in vivo (Hofmann et al., 2008; Laschke et al., 2010b), which is critical in the normal bone 
remodeling sequence that occurs in bone repair. 
In this study, recombinant human morphogenetic protein-2 (rhBMP-2) was used as a 
positive control group.  rhBMP-2 is the most common growth factor used in the clinical 
setting due to its high potency to drive osteoprogenitor cell differentiation to osteoblasts 
which subsequently leads to increased new bone formation.  However, a main concern is 
that clinically high doses of rhBMP-2 are usually required to ensure successful bone 
repair.  Various studies have demonstrated that there are potential side effects when high 
levels of BMPs are used, including excessive bone formation, adverse immune responses, 
and increased risk in developing cancer (Carragee et al., 2011; Epstein, 2013).  Therefore, 
to avoid these complications, we decided to use a low-dose rhBMP-2 to determine 
whether this would achieve a similar positive outcome in regards to new bone formation.  
Our in vitro study showed that nHA/PU scaffold was able to bind well with both rhBMP-
2 and BSP.  Both rhBMP-2 and BSP treated nHA/PU scaffold in cell culture appeared to 
have elevated amount of mineral formation.  In our calvarial in vivo system, the presence 
of low dose rhBMP-2 was able to significantly enhance bone repair compared to the 
scaffold-only control group.  MicroCT analyses suggested that approximately 70% of the 
defects were filled with bone by 6 weeks.  This result was very promising since other 
studies that utilized larger dose of rhBMP-2 were shown to achieve either a lower or 
similar amount of new bone formation by 6-8 weeks post-op (Luvizuto et al., 2011; 
Sawyer et al., 2009; Schwarz et al., 2009).  Unfortunately, BSP-treated nHA/PU scaffold 
group was not able to significantly enhance in vivo bone repair even after 12 weeks.  In 
the BSP-treated group, moderate island-like bone formation were found in the defect sites 
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on occasion; however, most of the time only minimal bone formation was observed in the 
defect sites.  Similar observations were also found in the scaffold-only control group.   
In summary, this study showed that nHA/PU scaffold is able to bind both rhBMP-2 and 
BSP.  Even though on its own, BSP is not effective as a promoter of bone repair in our 
model, various mineralized tissue phenotypes observed in the Bsp
-/-
 mice provide strong 
support that BSP is still important for mineralized tissue development.   
 
6.2 FUTURE DIRECTION 
 
Role of BSP in mineralized tissue development 
To further understand which part of the functional regions of BSP is important for 
cementum development, a preliminary study was done by injecting BSP into Bsp
-/-
 mice 
in order to determine whether the acellular cementum phenotype could be rescued.  
Subcutaneous injections (daily for the first 3 time points, every 2 days for the next 4 time 
points, and every three days for the last 3 time points) of native and recombinant rat BSP 
were done beginning with 5 day old Bsp
-/-
 mice.  At 6 weeks, microCT images revealed a 
slight delay in periodontal breakdown (data not shown).  However, no significant 
conclusions could be derived using this method possibly due to the limited amounts of 
BSP that could be injected (10 µl or less; using a 1mg/ml BSP-PBS solution) into the 
young pups.  In addition, it is likely that only a small percentage of the injected BSP 
would be carried by the circulatory system to the periodontium.  Future studies should 
utilize an adeno-associated virus (AAV) linked to the Bsp gene (wild type full length, or 
full length with altered functional domains) to rescue the acellular cementum deficiency 
in the Bsp
-/-
 mice.  This method should be a more effective way to determine the potential 
use of BSP to repair or rescue the structural defects seen in cementum-PDL interface of 
Bsp
-/-
 mice. In addition, the use of functional mutants may provide critical new 
information on the roles of these domains in vivo, and insight into the mechanism of BSP 
action.  Of relevance, other studies have also used AAV-mediated systemic gene therapy 
208 
 
method in order to effectively treat a transgenic mouse model. The authors demonstrated 
that AAV-mediated gene therapy was able to successfully rescue the severe bone 
phenotype seen in hypophosphatasia mice (Matsumoto et al., 2011).   
As part of the Goldberg's group objective, as a side project, we also investigated the 
potential role of BSP in other mineralized tissue development.  Other than bone and 
dentition, mineralized tissues are also found within the enthesis, which is composed of 
four transitional zones, including tendon connective tissue, un-calcified fibrocartilage, 
calcified fibrocartilage (CF), and bone, that connects tendon to bone.  Using an anti-BSP 
antibody, our preliminary study demonstrated for the first time that BSP is present in the 
CF zone of the enthesis, which is found adjacent to the bone.  Therefore, it is postulated 
that BSP also plays an important role in the enthesis development and fibrocartilage 
mineralization.  All of the mice used for this study were fed with SD to reduce 
malocclusion and prevent malnourishment.  Initial mechanical tensile tests indicated that 
the Bsp
-/-
 mouse patellar tendon appeared to fail at a lower mechanical load compared to 
that of WT mice.  Based on these results, a more complete analysis of the quadriceps 
tendon (QCT) and supraspinatus tendon (SST) entheses of 15-week old Bsp
-/-
 mice were 
performed (Marinovich, Soenjaya et al., 2016).  In the QCT enthesis, the CF zone of the 
Bsp
-/-
 mice was 28% greater in length compared to WT mice.  This lengthening of the CF 
appeared to increase as the Bsp
-/-
 mice aged.  By 14 months of age, the length of the CF 
zone was determined to be 41% greater than that of WT mice.  However, no apparent 
difference in the lengths of CF zone were observed in the SST enthesis of Bsp
-/-
 and WT 
mice.  Other studies have indicated that the CF zone helps to anchor the tendons or 
ligaments to the bone and withstand tensile and shear loads under minimal movement 
(Benjamin and McGonagle, 2001).  The enthesis fibrocartilage is a dynamic tissue that 
responds to mechanical load.  Thus, the observed increased length of the CF zone is 
likely a compensation to strengthen the CF-bone interface and also restrict movement of 
the enthesis to prevent injury.  Further analysis revealed that the cross sectional area of 
Bsp
-/-
 patellar tendon is 7.5% larger compared to WT mice.  Both Bsp
-/-
 and WT patellar 
tendon failed at a similar load, which suggests that the increased cross sectional area of 
the Bsp
-/-
 patellar tendon likely act as a compensatory mechanism to allow for greater 
dissipation of stress along the enthesis to prevent failure.  In addition, the study also 
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indicated that no significant difference in mineral distribution and collagen organization 
were observed between Bsp
-/-
 and WT mice (Marinovich, Soenjaya et al., 2016).  As 
previously mentioned, Bsp
-/-
 mice fed with soft diet have normal bone phenotypes such as 
bone length and bone mineral density.  Other studies from our groups have also indicated 
that all of the bone phenotype occurred at the early stage of development.  For example, 
recent studies have indicate that the absence of BSP delayed the mineralization of the 
fetal long-bones (Holm et al., 2015) and craniofacial bones (Foster et al., 2015).    
However, these bone phenotypes become less apparent as the Bsp
-/-
 mice aged, which 
suggest that the role of BSP is likely being compensated by other related mechanisms. 
Thus, future studies should focus on the role of BSP in early enthesis development and 
mineralization.   
 
Potential use of BSP for bone regeneration therapy 
In terms for future studies, one potential suggestion is that BSP may be more effective if 
used in combination with a growth factor such as rhBMP-2.  In order to confirm this 
hypothesis, we performed a preliminary study (n=2) that used nHA/PU scaffold treated 
with a combination of 0.25 µg of rhBMP-2 and 20 µg of BSP in a rat calvaria defect 
model.  The initial results showed that the BSP-rhBMP-2 treated group appeared to have 
increased bone formation compared to 0.25µg rhBMP2 treated group.  Furthermore, the 
amount of bone formation in BSP-rhBMP-2 treated group appeared to be approaching of 
that observed in nHA/PU scaffold group treated with 1 µg of rhBMP-2 (data not shown).  
However, for the pilot study the animal sample size were too small for proper statistical 
analyses.  Therefore, a more complete study should be done to determine the best BSP-
rhBMP-2 cocktail concentration that will gives the optimal bone repair.  
Another potential study is the concept of permanently immobilizing BSP to the nHA/PU 
scaffold, which was a technique used by the Glimcher’s group to crosslink BSP to 
collagen scaffold.  It will be interesting to verify whether covalently cross-linked BSP to 
nHA/PU scaffold can promote bone repair. 
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As for in vitro studies, future directions, experiments with rhBMP-2 and BSP should be 
done to confirm any up-regulation of osteoblastic differentiation markers such as alkaline 
phosphatase, collagen I, osterix and osteocalcin.  The results will confirm whether the 
presence of rhBMP-2 or BSP in the nHA/PU scaffolds can promote osteogenic 
differentiation.  Another suggestion is to look at other markers related to bone repair such 
as angiogenesis.  It will also be interesting to verify whether the presence of BSP 
(covalently cross-linked) or rhBMP-2 treated nHA/PU scaffold can enhanced 
angiogenesis in our calvarial defect model. 
PicoGreen DNA quantification assay has been demonstrated to be a useful technique to 
determine total DNA from scaffolds cultured with cells (Ng et al., 2005).  This assay can 
potentially be used in our in vitro culture system to quantify the approximate amount of 
cells in the nHA/PU scaffold in the presence of BSP or rhBMP-2.  Previous studies have 
shown that DNA binds tightly to HA; the bound DNA are found to be more resistant to 
degradation compared to unbound DNA (Brundin et al., 2013).  Thus, after the cell lysis, 
an additional step would need to be considered for extraction of DNA from mineralized 
tissue using decalcification step with EDTA as previously described in previous studies 
(Malaver and Yunis, 2003).   
In conclusion, these future studies will further demonstrate the importance of BSP in 
mineralized tissue development and also verify BSP potential role in enhancing bone 
repair.   
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Appendix A:  Statement of permission for the use of animals for experimental 
research. 
All animal experimentation was conducted in compliance with the animal use protocol 
2008-092 and 2009-008 held by Dr. Harvey Goldberg, principal investigator at the 
Schulich School of Medicine and Dentistry and the department of Biochemistry at the 
University of Western Ontario in London, Ontario, Canada.  
 
Appendix B:  Appendix B:  Statement of permission to re-use Figure 1.2 from 
A.D.A.M. Education. 
The permission of re-use of Figure 1.2, which was copied from 
https://www.nlm.nih.gov/medlineplus/ency/imagepages/1121.htm, were acquired from 
A.D.A.M. Education. 
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